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SUMMARY 
Influenza A reassortant viruses contain the surface glycoproteins of specified epidemic strains 
and the internal genes of a high-yielding egg-adapted strain, usually A/PR/8/34 (H1N1). 
Reassortment of influenza B viruses for the preparation of seeds for inactivated vaccines is 
not usually undertaken due to the lack suitable donor strains, but such an approach could 
improve vaccine yields, lower costs and introduce a further element of predictability to 
vaccine manufacture. The use of stable cell lines for vaccine virus growth would largely 
overcome problems associated with the use of embryonated eggs as a substrate, such as egg-
adapted variants and the lack of flexibility in egg supply, if yield and safety issues could be 
successfully addressed. 
 
Potential donor strains were prepared from B/Lee/40 by two approaches involving the 
selection of stable cold- and high- temperature mutants. Initial passaging was undertaken in 
SPF CEK cultures and later passage in SPF embryonated chicken eggs. Both approaches were 
successful, although a smaller number of viable progeny could be isolated from plaques 
obtained at 38°C. Potential donor strains, isolated by selection at either 25 or 38°C and 
plaque-purified in SPF CEK cultures, were tested for HA titre, infectious titre compared with 
the original parental strain by three methods, and for differences in antigenicity by cross-HI 
tests. Potential donor strains selected at temperatures of 25°C (C25) and 38°C (H38) 
consistently produced HAs of 320 units/50µL and infectivities of 8.57 and 8.39 EID50, 
respectively, when grown in eggs at the permissive temperature (34°C). The haemagglutinin 
of parental and temperature-adapted strains were antigenically indistinguishable. Partial 
nucleotide sequencing studies showed that passage of B/Lee40 at 25°C in the preparation of 
C25 resulted in one residue change from Ile to Thr at position 48 in the HA2 protein. 
 
xvi 
The growth of a panel of epidemic viruses at restrictive temperatures (25 and 38°C) varied, 
with 4/28 being positive for growth at 25°C and 9/28 at 38°C. C. A set of PCR primers was 
designed and used in tests for gene identification using different restriction enzymes. 
Reassorting experiments using the B/Lee-derived potential donor strains C25 and H38 and the 
epidemic strain, B/Johannesburg/5/99 (B/Johannesburg), showed that the preparation of 
reassortant progeny with both epidemic strain HA and NA was difficult. In the first 
experiment with B/Johannesburg, all viral progeny contained the NA of the donor strain. The 
reassortant protocol was varied (Protocol 2) and in the next experiment, 1/24 of the resulting 
reassortants possessed both the HA and NA of the epidemic strain. Co-infection with 
B/Panama/45/90 (B/Panama) and either donor strain by Protocol 2 produced few reassortants, 
with 17/22 clones being identical to B/Panama. Further variations to Protocol 2 increased the 
proportion of reassortants but none possessed the desired 6:2 gene constellation (i.e. genes for 
the two surface antigens of the epidemic strain and the remainder from the donor strain). The 
infectious titre of selected progeny from the reassortment experiments were determined by 
three methods and compared with their respective epidemic parents. The infectious titre of 
CP2 was significantly lower than that of B/Panama; CJ4 was significantly higher than that of 
B/Johannesburg. 
 
Yields of several influenza B epidemic strains and potential donor strains were measured after 
growth in MDCK cells prepared in serum-free (SF) and animal- and human-derived protein-
free (AHPF) media. Attempts to condition MDCK cells by passage in a modified version of a 
previously published medium (SF1; Taub et al., 1979) or a commercial medium designed for 
Vero cells were unsuccessful. Two newly developed commercial medium formulations were 
also tested for their ability to support the growth of MDCK cultures. One (EX-CELL 
xvii 
MDCK) supported the growth of MDCK cells with or without conditioning, although cells 
that had been conditioned were more robust after resuscitation from LN2. 
 
Optimal multiplicities of infection (MOIs) were determined for B/Panama, B/Johannesburg 
and C25 in MDCK cultures grown in SC medium. Maximum yields for B/Panama and 
B/Johannesburg were obtained using an MOI of 0.01 (yields of 6.89 log10 pfu mL-1 at 24 h 
and 7.15 at 48h). The maximum yield for C25 was 6.91 at 24h using an MOI of 2.0 although, 
for 0.01, the yield at 48h was only slightly less (6.63). A series of experiments were then 
undertaken to determine the maximum virus yields in MDCK cells grown in SC medium, 
followed by a further experiment using C25, B/Panama, B/Johannesburg, CJ4, CP1 and HP1 
after preparation in AHPF medium. Cell culture yields from 5/6 viruses grown in MDCK 
cells prepared in AHPF medium were higher than in cells prepared in SC medium and 
approached those obtained in eggs. 
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1.1 GENERAL INTRODUCTION 
Influenza is a highly infectious, acute upper respiratory tract infection of humans and some 
animal species. Historical reports of acute respiratory disease clinically characteristic of 
influenza infections have been described for centuries and the constantly changing nature of 
the influenza genome has ensured that influenza infections remain a continuing major public 
health problem (Noble, 1982). Despite the protection which has been provided by vaccines 
over many years and from the likely future use of antiviral chemotherapy, the influenza 
disease burden remains significant, an issue which is particularly cogent with the possibility 
of a new influenza pandemic. The annual global attack rate of influenza infection has been 
estimated to be 5-10% in adults and 20-30% in children, resulting in total annual costs of 
influenza outbreaks estimates in the US and Europe of US$1–6 million per 100,000 
inhabitants (Anonymous, 2005b). 
 
1.1.1 Classification 
Influenza viruses were originally classified together with mumps and Newcastle disease 
viruses as myxoviruses (Andrewes, Bang, and Burnet, 1955). These viruses were later split 
into the families Orthomyxoviridae (influenza viruses) and Paramyxoviridae (mumps and 
Newcastle disease viruses) (Melnick, 1971). The Orthomyxoviridae currently consists of five 
genera: influenza A, B and C viruses, the tick-borne Thogotoviruses and Isaviruses found in 
salmon (Kawaoka, Y et al., 2005). 
 
The three types of influenza viruses are classified according to antigenic differences in the 
two major internal proteins, the matrix protein (MP) and the nucleoprotein (NP) (Wilson and 
Cox, 1990). Influenza A viruses were first isolated in 1933 (Smith, Andrewes, and Laidlaw, 
1933) and influenza B in 1940 (Francis, 1940). In 1949 Taylor isolated an influenza virus that 
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was antigenically different from Types A and B and was later classified as a Type C virus 
(Francis, Quilligan, and Minuse, 1950). Influenza A viruses can cause pandemics and large 
epidemics, influenza B smaller self-limiting epidemics and influenza C viruses can result in 
occasional cases that are usually confined to children, causing common-cold like symptoms 
(Potter, 1992). Influenza C viruses are quite distinct from influenza A and B, in that they 
possess a segmented genome consisting of seven RNA fragments, and a single glycoprotein - 
the haemagglutinin-esterase-fusion protein (HEF) (Lamb and Krug, 2001). Because of their 
distinct characteristics, influenza type C viruses will not be discussed in detail in this thesis. 
Influenza B infections are restricted to human hosts while influenza A viruses have been 
isolated from humans, lower mammals and birds (Webster et al., 1992). Influenza A has been 
further classified into subtypes based on changes in the two surface glycoproteins, the 
haemagglutinin (HA) and the neuraminidase (NA) (Wright and Webster, 2001). To date 16 
HA and 9 NA subtypes have been described (Fouchier et al., 2005). 
 
1.1.2 Structure 
Influenza viruses are enveloped and range in size from 80 to 120 nm. Virions vary and may 
be roughly spherical to rod-shaped or filamentous in shape (Laver, 1973; Wright and 
Webster, 2001). Long filamentous forms are usually found in freshly isolated specimens 
whereas virions are usually spherical after adaptation to growth in chick embryos or cell lines, 
indicating selection after passage in these hosts (Laver, 1973). The typical structure of a 
spherical influenza A virion is shown in Figure 1.1. Two major surface antigens project from 
the influenza virion, the haemagglutinin (HA) and neuraminadase (NA) glycoproteins. 
Another integral membrane protein is M2, also present in the viral envelope (Lamb, Zebedee, 
and Richardson, 1985). Electron microscopy has shown that the HA is a spike of 
approximately 140Å x 40 Å while the NA has a mushroom-like structure with a stem of 
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approximately 100Å and a cap 85Å wide (Laver and Valentine, 1969). Each HA spike is a 
trimer of non-covalently linked monomers and the HA:NA ratio is approximately 5:1 (Wiley 
and Skehel, 1977; Wilson and Cox, 1990; Wrigley, 1979). The matrix protein, the most 
abundant component of the virion, is located directly underneath the host-derived envelope 
and forms a shell that encloses the viral RNA (Ruigrok, Calder, and Wharton, 1989). The 
single-stranded RNA genome is negative-sense and linear and, for influenza A and B viruses, 
consists of eight segments (Lamb and Krug, 2001). Nucleoprotein molecules associate with 
the RNA, forming helical nucleocapsids (Heggeness et al., 1982). Three polymerase proteins 
(PB1, PB2 and PA) are bound to the viral RNA and are responsible for RNA replication and 
transcription (Perez and Donis, 2001) The influenza A genome codes for 10 proteins (Lamb 
and Krug, 2001). Six RNA segments code for a single protein (segments 1-6), while segments 
7 and 8 each code for two proteins (Table 1.1). The influenza B genome differs from 
influenza A, in that segment 6 also encodes for two proteins - NA and another small 
glycoprotein NB. 
 
Segments 1, 2 and 3 are the largest in size and code for the polymerase basic protein 2 (PB2), 
the polymerase basic protein 1 (PB1) and the polymerase acidic protein (PA), respectively. 
The three polymerase proteins together form the polymerase complex, which functions as an 
RNA-dependent RNA polymerase, initiating RNA transcription and replication within the 
nucleus (Detjen et al., 1987; Lamb and Krug, 2001). PB1 is the central unit of the polymerase 
complex, with interactions occurring between PB1-PB2 and PB1-PA but not PB2-PA 
(Toyoda et al., 1996). The interactions and functions of the polymerase proteins are complex 
and will be discussed in further detail in Section 1.1.4. 
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Figure 1.1 Diagram of a typical influenza A virion. Nucleoprotein (NP) and three polymerase 
proteins, PB1, PB2 and PA associate individually with each of the RNA genome segments 
forming the ribonucleoprotein (RNP) complex. The major structural protein M1 is found 
directly underneath the host-derived envelope, forming a shell that encloses the RNP. The 
NS2 protein associates with M1. HA and NA glycoproteins project from the virion surface, as 
does the M2 membrane protein. From (Wright and Webster, 2001). 
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Table 1.1 – Influenza A gene segments and their proteins (adapted from (Lamb and Krug, 
2001)) 
 
 
Segment Length 
(nucleotides) 
 
Encoded protein Protein functions 
1 2341 Basic protein 2 (PB2) Polymerase complex subunit 
2 2341 Basic protein 1 (PB1) Polymerase complex subunit 
3 2233 Acidic protein (PA) Polymerase complex subunit 
4 1778 Haemagglutinin (HA) Surface glycoprotein, involved in 
attachment and fusion 
5 1565 Nucleoprotein (NP) Encapsidates RNA complex, 
involved in replication 
6 1413 Neuraminidase (NA) Surface glycoprotein, involved in 
progeny release 
7 1027 Matrix protein 1 (M1) 
 
Matrix protein 2 (M2) 
Major structural protein 
 
Integral membrane protein with ion 
channel activity 
8 890 Non-structural protein 1 
(NS1) 
 
Non-structural protein 2 
(NS2) 
RNA binding protein involved in 
replication 
 
Associated with M1, involved in 
nuclear export of vRNPs. 
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Segment 4 codes for the 75kDa haemagglutinin precursor polypeptide HA0 (Skehel and 
Waterfield, 1975). Proteolytic cleavage of HA0 into two disulphide linked chains, HA1 and 
HA2, is required for virus infectivity (Klenk et al., 1975). Following cleavage of HA0, the 
HA1 chain gains a carboxy-terminus and HA2 an amino-terminus (Skehel and Wiley, 2002; 
Wilson and Cox, 1990). HA1 forms a globular head, containing the receptor-binding site and 
highly variable antigenic loop structures. A fibrous stem, consisting predominantly of HA2 
residues, extends down to the membrane. The fusion peptide, required for viral entry and 
membrane fusion, is located within the HA2 portion of the monomer (Wilson and Cox, 1990). 
 
Segment 5 encodes the nucleoprotein polypeptide. NP is the main structural protein that 
combines with viral RNA and the three polymerase proteins to form ribonucleoprotein (RNP) 
complexes (Lamb and Krug, 2001; Neumann, Castrucci, and Kawaoka, 1997). It has been 
estimated that there is one NP molecule for every 20 nucleotides (Murti, Webster, and Jones, 
1988). NP is also a type-specific antigen and a key target for cross-reactive cytotoxic T cells 
(Lamb and Krug, 2001). Whilst the main function of NP is to encapsidate the RNA 
complexes, it is also involved in a number of critical steps in virus replication (Portela and 
Digard, 2002). NP is required for RNA transcription, nuclear import and export of RNP’s and 
possibly the development of apoptosis late in infection (Hay et al., 1977b; Neumann, 
Castrucci, and Kawaoka, 1997; Ryan et al., 1986; Whittaker, Bui, and Helenius, 1996; 
Zhirnov et al., 1999). 
 
For influenza A viruses segment 6 codes for the NA glycoprotein. Influenza B segment 6 
codes for two different glycoproteins, NA and NB, which are encoded by overlapping reading 
frames. Two initiation codons (AUG) are separated by four nucleotides, with the translation 
of type B NA beginning at the second AUG codon from the 5’ end of the mRNA (Shaw et al., 
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1982). The first AUG codon is followed by an open reading frame (ORF) of 100 amino acids 
which overlaps the NA ORF by 292 nucleotides. The NB protein is translated from the ORF 
initiating at the first AUG codon (Shaw, Choppin, and Lamb, 1983). NA is a 220 kDa 
tetramer consisting of a large, enzymatically-active globular head with a stalk region that 
extends down to the membrane and ends with a cytoplasmic tail (Colman, Varghese, and 
Laver, 1983; Varghese, Laver, and Colman, 1983). The major function of NA is to remove 
sialic acid receptors on the virus envelope to prevent the aggregation of newly formed 
progeny (Palese et al., 1974). The small (18kDa) NB glycoprotein, a type III integral 
membrane, possesses one internal hydrophobic domain (Paragas et al., 2001; Richardson and 
Akkina, 1991; Yasuda et al., 1993). It is expressed at the cell surface with a free NH2 –
terminus and two exposed carbohydrate chains (Hatta and Kawaoka, 2003; Webster et al., 
1992). There is continuing debate as to the function of NB which may have a role in ion 
channel activity, although one report suggests that NB is not essential for influenza B 
replication (Hatta and Kawaoka, 2003). 
 
Segment 7 of influenza A codes for the matrix protein M1 and a second, smaller 
transmembrane protein (M2) that possesses ion channel activity. M1, a type-specific antigen, 
is the major component of the influenza virion and is involved in a number of stages of virus 
replication (Burleigh et al., 2005). M1 interactions include mediation of the nuclear import 
and export of vRNPs, reassociation with vRNPs during late infection for virus assembly, 
binding of RNA, inhibition of polymerase activity, virion assembly and release by budding 
(Bourmakina and Garcia-Sastre, 2003; Bui, Whittaker, and Helenius, 1996; Gomez-Puertas et 
al., 2000; Wakefield and Brownlee, 1989; Watanabe et al., 1996; Whittaker, Bui, and 
Helenius, 1996). The NS2 protein (coded for by segment 8) is associated with M1, with both 
proteins being involved in the process of vRNP export (O'Neill, Talon, and Palese, 1998; 
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Paragas et al., 2001; Yasuda et al., 1993). Viral growth and morphology can be modulated by 
sequences in M1 and also, to some extent, HA, NA and M2 genes (Elleman and Barclay, 
2004; Enami and Enami, 1996; Jin et al., 1997; Liu, Muller, and Ye, 2002; Mitnaul et al., 
1996; Roberts, Lamb, and Compans, 1998). M1 is greatly conserved among influenza A 
subgroups (Ito et al., 1991; Lamb and Lai, 1981). M1 mRNA is produced as a co-linear 
transcript from the first ORF at nt 26-28 (Allen et al., 1980; Hay et al., 1977b; Winter and 
Fields, 1980). A second ORF, beginning at nt 714, overlaps the M1 sequence by 68nt and 
codes for the spliced M2 mRNA (Lamb and Choppin, 1981). The M2 protein is a minor 
component of influenza A virions but is expressed in large numbers at the infected cell 
surface (Lamb, Zebedee, and Richardson, 1985; Zebedee and Lamb, 1988). The M2 protein 
forms a tetrameric channel, with two disulphide-linked dimers held together by non-covalent 
interactions (Sugrue and Hay, 1991). M2 acts as an ion channel, transporting protons across 
the viral membrane to reduce pH inside the virion (Pinto, Holsinger, and Lamb, 1992). The 
lowered pH is required for M1 dissociation from the VRNPs (Bukrinskaya et al., 1982; 
Whittaker, Bui, and Helenius, 1996). The M2 ion channel can also regulate the pH of the 
trans-Golgi network in the latter stages of infection (Ciampor et al., 1992). The cytoplasmic 
tail of M2 has been associated with co-ordination of efficient genome packaging (McCown 
and Pekosz, 2005). Another small, alternatively spliced mRNA (mRNA3) has been found on 
segment 7; mRNA3 may code for a potential protein of only 9 aa - identical to the COOH-
terminal region of M1, although there is no evidence that mRNA3 is translated (Lamb, Lai, 
and Choppin, 1981). Influenza B segment 7 codes for the M1 protein and an oligomeric 
integral membrane protein (BM2). There is significant homology between influenza A and B 
M1 proteins, although the BM2 protein of influenza B has little homology with the M2 
protein of influenza A (Briedis, Lamb, and Choppin, 1982). The BM2 protein is translated 
from bicistronic mRNA using an unusual strategy. The AUG initiation codon for BM2 
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overlaps the M1 protein termination codon in a stop-start pentanucleotide, requiring the 
initiation and termination of the M1 protein for expression of the BM2 protein (Horvath, 
Williams, and Lamb, 1990). BM2 proteins are synthesized during the latter stages infection 
and are incorporated into virions and expressed at the surface of virus-infected cells (Odagiri, 
Hong, and Ohara, 1999; Paterson et al., 2003). Although the exact functions of BM2 remain 
unclear, it has been shown to possess ion channel activity and plays an essential role in virus 
replication and assembly (Hatta, Goto, and Kawaoka, 2004; Imai et al., 2004; Mould et al., 
2003). 
 
Segment 8 codes for two proteins, NS1 and NS2. NS1 mRNA is produced as a co-linear 
transcript, while NS2 mRNA is a spliced product derived from NS1 mRNA (Briedis, Lamb, 
and Choppin, 1981; Inglis, Gething, and Brown, 1980; Lamb et al., 1980). NS1 is an RNA-
binding protein and has a number of functions at post-transcriptional stages during replication 
(Lu et al., 1995; Qiu and Krug, 1994; Wang and Krug, 1996). NS1 has also been shown to 
inhibit certain host cell antiviral responses, including a range of cellular interferons (IFN’s), 
IFN-regulatory factors, Jun N-terminal kinase and AP-1 transcription factors (Garcia-Sastre et 
al., 1998; Geiss et al., 2002; Lu et al., 1995; Ludwig et al., 2002). The NS2 protein, together 
with NS1, was formerly considered to be non-structural. However later studies demonstrated 
that NS2 is a virion structural component and is associated with the M1 protein (Richardson 
and Akkina, 1991; Yasuda et al., 1993). NS2 is now referred to as the nuclear export protein 
(NEP), being involved in the export of vRNP’s from the host cell nucleus to the cytoplasm 
(O'Neill, Talon, and Palese, 1998; Paragas et al., 2001). 
 
1.1.3 Virus attachment, entry & uncoating 
The HA of influenza viruses is responsible for the binding of virus to cell surface receptors 
specific for oligosaccharides with a terminal sialic acid (SA). The receptor-binding site is 
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located at the distal tip of the HA molecule (Weis et al., 1988). Cellular SAs consist of 9 
carbon acidic amino sugars with an amino group substitution, yielding either N-
acetylneuraminic (NeuAc) or N-glycolylneuraminic (NeuGc) acid. The distribution of SA 
types varies between species, with bovine, equine and swine tissue possessing both NeuAc 
and NeuGc while human tissues possess mainly NeuAc and only very low amounts of NeuGc 
(Suzuki et al., 2000). The binding specificity of influenza virus to cellular receptors also 
varies. Most avian and equine influenza viruses bind to receptors with SA-α2,3-galactose 
linkage (SAα2,3Gal), whereas human influenza viruses preferentially bind to receptors with a 
SA-α2,6-galactose (SAα2,6Gal) linkage. Swine influenza viruses can bind to either linkage 
(Ito et al., 1998; Rogers and Paulson, 1983; Suzuki et al., 2000; Wan and Perez, 2006). The 
anatomical distribution and concentration of receptors in human airways is considered to be a 
factor in avian influenza virus pathogenesis and transmission to humans. Receptors with 
SAα2,6Gal linkage are abundant in the human upper respiratory tract, while SAα2,3Gal 
receptors are absent in the upper airways but are present in cells lining the alveolar wall. It has 
been hypothesised that this distribution means that H5N1 viruses can only replicate efficiently 
on the human lower respiratory tract where many SAα2,3Gal receptors are present (Shinya et 
al., 2006). The spread of influenza viruses through coughing and sneezing efficiently 
transmits viruses to the upper airways but not to the lower respiratory tract where avian 
receptors predominate (Shinya et al., 2006). 
 
After the initial physical contact between cell surface and virus, the virus is internalised by 
endocytosis (Dales and Choppin, 1962). The low pH environment within the endosome (pH 
5–6) facilitates fusion of the viral membrane with the endosome membrane (Huang, Rott, and 
Klenk, 1981). Cleavage of the native HA0 into HA1 and HA2 is required to prime membrane 
fusion and is essential for virus infectivity (Klenk et al., 1975; Skehel et al., 1982). Fusion is 
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mediated by a pH-induced conformational change within the HA. This process rearranges and 
refolds HA1 and HA2, resulting in the exposure of the previously inaccessible HA2 fusion 
peptide (Skehel et al., 1982). The fusion peptide is moved approximately10 nm to the tip of a 
trimeric α-helical coiled coil, formed by rearrangements of the HA2 α-helices (Bullough et 
al., 1994; Wharton et al., 1995). 
 
After fusion, the low pH within the endosome induces M2 ion channel activity, facilitating 
transport of H+ ions to the interior of the virus and lowering its internal pH (Czabotar, Martin, 
and Hay, 2004; Pinto, Holsinger, and Lamb, 1992). The M2 protein forms a tetramer 
consisting of two di-sulphide-linked dimers oriented with the N-terminus external and 
forming a parallel array. This activity can be blocked with the antiviral drug amantadine (Hay 
et al., 1985; Sugrue and Hay, 1991). M2 activity assists the uncoating of the virus, allowing 
delivery of nucleocapsids into the cytosol and subsequent nucleocapsid disassembly 
(Lanzrein, Schlegel, and Kempf, 1994). Influenza BM2 protein is essential for influenza B 
replication and has a similar proton pump function, although its exact role is still unclear 
(Hatta, Goto, and Kawaoka, 2004; Imai et al., 2004; Pinto and Lamb, 2005). Disassembly 
involves the release of the M1 protein from the RNP complex, after which the vRNPs can be 
transported to the nucleus via nuclear pore complexes (Bui, Whittaker, and Helenius, 1996; 
Martin and Helenius, 1991). The uptake of vRNP’s to the nucleus is an ATP-dependant 
process (Kemler, Whittaker, and Helenius, 1994). 
 
1.1.4 Transcription & replication 
Once in the nucleus, viral transcription and replication can take place under the control of the 
polymerase complex (Gambaryan, Tuzikov, and al, 1997; Gastaminza et al., 2003; Hay et al., 
1977b). Viral mRNA is transcribed from the vRNA using capped RNAs derived from host 
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cell mRNA (Plotch et al., 1981). PB2 recognises the 5’ end cap structure of cellular mRNAs 
and specifically cleaves them into 10-13nt capped primers by a process referred to as cap 
snatching (Shih and Krug, 1996; Ulmanen, Broni, and Krug, 1983). The polymerase complex 
also functions to protect viral mRNA from its own cap snatching activity by selectively 
binding to a common viral mRNA sequence adjacent the 5’ snatching sequence (Shih and 
Krug, 1996). PB1 then uses the capped primers to initiate mRNA synthesis and to continue 
chain elongation using vRNA as the template (Beaton and Krug, 1984; Biswas and Nayak, 
1994; Ulmanen, Broni, and Krug, 1981). Termination of transcription occurs when the 
polymerase moves to a terminal panhandle structure located on the 5’ end of the template 
vRNAs, close to a stretch of uridines (Hsu et al., 1987; Luo et al., 1991). At this point the 
polymerase also adds poly(A) to the viral mRNA by a stuttering mechanism, in which the 
polymerase pauses at the uridine stretch which it copies reiteratively. (Luo et al., 1991; Poon 
et al., 1999; Robertson, Schubert, and Lazzarini, 1981). The polyadenylated mRNA 
transcripts are incomplete copies of the vRNAs (Hay et al., 1977a). 
 
Replication of viral RNA requires a switch from vRNP synthesis of mRNA to the generation 
of positive-sense full-length complementary RNA (cRNA) from the vRNA template. Unlike 
mRNA synthesis, the cRNA transcripts do not require primer initiation and are not 
polyadenylated (Hay et al., 1977a; Hay et al., 1977b; Hay, Skehel, and McCauley, 1982). The 
mechanism for the switch to cRNA synthesis is not fully understood, although NP has been 
implicated as a major factor (Portela and Digard, 2002). However, simply increasing the 
intracellular concentration of NP does not appear to bring about the switch and there is some 
evidence that a specific switch mechanism does not exist (Mullin et al., 2004). According to 
this hypothesis, mRNA and cRNA may both be synthesised early in infection, with cRNAs 
being degraded by host cell nucleases unless they can be stabilised with newly synthesised 
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PB1, PB2, PA and NP (Vreede, Jung, and Brownlee, 2004). Once generated, the cRNA is 
then copied to produce negative-sense vRNAs, a process which does not use primers but does 
require the presence of free NP (Shapiro and Krug, 1988). The use of NP for chain extension 
causes encapsidation of the vRNAs, resulting in the formation of vRNPs (Lamb and Krug, 
2001). Export of vRNPs from the nucleus requires binding to protein(s) containing a nuclear 
export signal (NES). A functional domain of the NEP (NS2) protein has been described and 
shown to act as an adaptor molecule, facilitating the binding of vRNPs to the nuclear pore 
complexes (O'Neill, Talon, and Palese, 1998). The M1 protein also has a role in the export 
process and the extent to which NEP is required is a matter of contention (Whittaker, Bui, and 
Helenius, 1996). However, it has also been proposed that vRNP nuclear export is mediated by 
NEP through interactions with vRNPs, possibly involving M1 and a cellular export factor – 
chromosome region maintenance 1 protein (CRM1) (Neumann, Hughes, and Kawaoka, 
2000). Interactions between exported vRNPs and cytoplasmic M1 prevent re-entry to the 
nucleus (Whittaker, Bui, and Helenius, 1996). 
 
1.1.5 Packaging, budding & release 
Influenza viruses assemble and bud from the plasma membrane of infected cells. vRNP-M1 
complexes are transported to the assembly site by association with host-cell microfilaments in 
the cytoskeleton (Avalos, Yu, and Nayak, 1997). The envelope proteins HA, NA and M2 are 
transported to the plasma membrane by the exocytic pathway and the trans-Golgi network 
(Nayak, Hui, and Barman, 2004). Lipid rafts (lipid microdomains, rich in sphingolipids and 
cholesterol are involved with the transport of HA and NA and also provide a platform for the 
budding of new virus particles (Nayak and Barman, 2002).  
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Packaging the viral genome into virions involves recognition by the viral components of cis-
acting sequences (packaging signals) in the viral nucleic acid (Watanabe et al., 2003b). 
Initially, packaging signals were thought to be located in the 3’ and 5’ non-coding regions of 
each RNA segment (Luytjes et al., 1989). Further work has shown that both ends of the NA, 
HA, NS, PA, PB1 and PB2 coding regions are also important for their incorporation into 
virions (Fujii et al., 2005; Fujii et al., 2003; Liang, Hong, and Parslow, 2005; Watanabe et al., 
2003b). Two main models of packaging have been proposed – random incorporation and 
selective incorporation (Duhaut and McCauley, 1996; Enami et al., 1991). Selective 
incorporation is based on the observation that the proportions of the eight vRNA produced are 
not equal and vary at different times of infection (Smith and Hay, 1982). Random 
incorporation is based on evidence that more than eight RNA segments can be packaged into 
a virion (Bancroft and Parslow, 2002; Enami et al., 1991; Hirst, 1973; Nakajima and Sugiura, 
1977; Scholtissek et al., 1978). 
 
M1 is the key to virus budding as virus-like particles are not formed in its absence (Gomez-
Puertas et al., 2000). In addition to binding to the vRNPs, M1 binds to HA and NA at both the 
cytoplasmic tail and transmembrane domain on reaching the site of assembly (Ali et al., 
2000). The plasma membrane undergoes a conformational change at the assembly site, giving 
the membrane an outward curvature (Nayak, Hui, and Barman, 2004). Finally, fusion of the 
apposing membranes leads to the bud being pinched off and the release of the new virion (Hui 
and Nayak, 2001). The mechanism of bud completion has not been fully elucidated and may 
be affected by a number of viral and host factors (Nayak, Hui, and Barman, 2004). However, 
it has been shown that influenza virus budding is an ATP-dependent process (Hui and Nayak, 
2001). Viral NA activity is required after budding and release to avoid aggregation of virus or 
the cell surface through HA binding (Palese et al., 1974). 
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1.2 ANTIGENIC VARIATION 
1.2.1 Genetic Reassortment 
The exchange of genetic markers in cells co-infected with different influenza A virus strains 
was first reported over 50 years ago (Burnet and Lind, 1951; Burnet and Lind, 1952; Hirst and 
Gotlieb, 1953). These early reports noted unusually high recombination frequencies in 
comparison with other animal or bacterial viruses. The discovery of the segmented nature of 
the influenza viral genome provided an explanation for this unusual genetic behaviour 
(Duesberg, 1968; Duesberg and Robinson, 1967). The cause of observed high recombination 
frequencies was subsequently shown to be reassortment of intact RNA segments between 
different viral progeny rather than classical recombination, in which either physical 
interchange of genetic material or post-transcriptional splicing of cRNA takes place (Shimizu 
et al., 1982). In theory, it is possible to generate a total of 256 (28) possible combinations of 
RNA segments by reassortment although this has never been achieved (de Jong et al., 2000). 
Co-segregation patterns of reassortment have been observed in avian influenza A viruses, 
especially between HA and M2, and PB2 and PA clusters (Grambas, Bennett, and Hay, 1992; 
Grambas and Hay, 1992; Hatchette et al., 2004; Sharp et al., 1997). Reassortment in nature 
has been described for influenza A, B and C viruses (Beare et al., 1977; Matsuzaki et al., 
2003; Racaniello and Palese, 1979). Rates of influenza B reassortment have most likely been 
underestimated, as the evolution of influenza B viruses has been measured using data 
obtained from HA genes alone (McCullers et al., 1999). Reassortment between influenza A, B 
and C viruses does not occur in nature or by co-infection in vitro. However, influenza A and 
B viruses have been genetically manipulated to produce chimeric influenza A viruses 
containing parts of or the entire NA and HA genes from influenza B strains (Flandorfer et al., 
2003; Ghate and Air, 1999; Luo et al., 1992; Muster et al., 1991). 
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1.2.2 Antigenic drift 
Antigenic drift is used to describe the accumulation of point mutations in the HA and NA 
genes, resulting in amino acid changes that can alter the major epitopes of expressed HA 
and/or NA (Webster et al., 1982). Antigenic drift occurs in all three influenza types but the 
rate of change is most rapid with influenza A viruses (Krystal et al., 1983; Wilson and Cox, 
1990). Differences in the patterns of antigenic drift have also been described. Multiple 
lineages of influenza A viruses of the H1N1 subtype and influenza B viruses have been 
shown to co-circulate. Viruses of the H3N2 influenza A subtype change more rapidly and 
older variants tend to be more rapidly replaced (Hay et al., 2001; Yamashita et al., 1988). 
These differences may be explained, in part, by the extent to which nucleotide changes result 
in amino acid substitutions (Air et al., 1990). Antigenic and sequence analyses of influenza B 
viruses isolated between 1940 and 1987 have shown evidence of co-circulating lineages (Bao-
Lan et al., 1983; Yamashita et al., 1988). Influenza B viruses from two distinct evolutionary 
lineages have co-circulated since 1983 (Rota et al., 1990). These lineages are represented by 
the B/Yamagata/16/88- and B/Victoria/2/87-like viruses. For unknown reasons viruses from 
either lineage have been present at different times over the past 20 years and also according to 
their geographical location. Since the early 1990s B/Victoria-like viruses have circulated in 
Asia but have been rarely isolated in Europe, Africa and the US (Hay et al., 2001). 
Reassortment among circulating influenza B viruses over six decades has given rise to new 
variants with distinct genome constellations, which has also added to the genetic diversity of 
influenza B viruses (Lindstrom et al., 1999).  
1.2.3 Antigenic shift 
Antigenic shift involves the complete replacement of the HA, and sometimes the NA, surface 
antigen genes by others from different subtypes (Webster et al., 1982). As there is no pre-
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existing immunity to the new influenza surface antigens, widespread infection can occur in all 
age groups (Potter, 1992). Antigenic shift has only been observed with influenza A viruses. 
Influenza B viruses possess HA and NAs of a single subtype and, despite recent reports of 
their occurrence in seals, do not have a recognised animal reservoir. Therefore, antigenic shift 
is not a recognised feature of influenza B viruses (Ohishi et al., 2002; Osterhaus et al., 2000). 
 
Two major mechanisms are considered to be responsible for antigenic shift – reassortment 
and adaptive mutation (Anonymous, 2005a). Until recently, a permissive intermediate host, 
susceptible to both human and avian influenza viruses, was considered necessary to increase 
the chances of reassortment and subsequent transmission. The domesticated pig was 
considered most likely to fulfil this role (Webster et al., 1992). However, there have now been 
several instances in recent years of the direct transmission of avian influenza viruses to 
humans. The first documented evidence for transmission to humans was reported in 1995 for 
an H7N7 virus in the UK from domestic ducks (Kurtz, Manvell, and Banks, 1996). During 
1997 in Hong Kong an outbreak caused by a highly pathogenic H5N1 avian influenza virus 
(A/Hong Kong/156/97) occurred that resulted in 18 infections, including 6 deaths (Subbarao 
et al., 1998; Yuen et al., 1998). H9N2 viruses have been isolated from humans, and in 2003 
an outbreak caused by H7N7 viruses resulted in 87 infections with one fatality being 
recorded. (Anonymous, 2003; Guo et al., 1999; Koopmans et al., 2003; Peiris et al., 1999). In 
2003 H5N1 viruses reappeared again in the human population, and there have been a total 175 
laboratory confirmed infections in humans and 95 deaths (Anonymous, 2006a). These human 
cases have been confined to 6 countries: Cambodia, China, Indonesia, Thailand, Turkey and 
Vietnam. H5N1 viruses in domestic and/or wild birds and cat species have now been detected 
in a number of Asian and European countries (Anonymous, 2006b). 
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Adaptive mutation is the process whereby a virus acquires changes in critical amino acids that 
affect the HA sialic acid (SA) receptor binding site (Anonymous, 2005a). Receptor specificity 
appears to be a major factor in limiting the host range of influenza A virus subtypes (Section 
1.1.3) (Webster et al., 1992). Alteration of receptor specificity would enable ready 
transmission to a new species of host and effective replication (Matrosovich et al., 2000). 
 
There have been three instances of influenza A antigenic shift over the past 100 years that 
have resulted in widespread human disease. These occurred with emergence of H1N1 subtype 
in 1918, in 1957 with the H2N2, and in 1968 the H3N2 subtype, all except the latter involving 
substitutions of both surface antigen genes (Nicholson, Wood, and Zambon, 2003). The new 
subtype that emerged with each shift rapidly replaced viruses of the previous subtype (Hay et 
al., 2001). However, in 1977 an unexpected and still unexplained reappearance of the H1N1 
subtype occurred, which was genetically similar to H1N1 epidemic viruses that were isolated 
during 1950 (Nakajima, Desselberger, and Palese, 1978). H1N1 viruses have since continued 
to co-circulate to this day. The 1957 and 1968 pandemic viruses were reassortant viruses 
(Webster, 2002). The HA, NA and PB1 of the 1957 H2N2 virus were of avian origin, with the 
other 5 gene segments being derived from the previous H1N1 viruses (Kawaoka, Krauss, and 
Webster, 1989). The 1968 H3N2 virus possessed HA and PB1 genes of avian origin, with the 
other 6 gene segments (including NA) being derived from the preceeding H2N2 virus (Fang 
et al., 1981; Kawaoka, Krauss, and Webster, 1989). Genetic analysis of the 1918 H1N1 virus 
has revealed that it is most closely related to early so-called swine influenza strains 
(Taubenberger et al., 1997). 
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1.3 RESPONSES TO CLINICAL INFLUENZA 
1.3.1 Initial clinical response 
Influenza viruses are usually transmitted in respiratory secretions by coughing or sneezing 
(Stephenson and Zambon, 2002). The majority of influenza infections are acute and self-
limiting. Symptoms may include the sudden onset of fever, chills, muscular aches, headaches, 
general malaise, sore throat, runny nose and a usually non-productive cough. The initial site 
of infection and viral replication in humans is the upper respiratory tract (Section 1.1.3). 
Symptoms involving the upper respiratory tract include runny nose, nasal stuffiness, sneezing, 
earache and sore throat while symptoms such as coughing, breathing difficulties, hoarseness 
and chest discomfort are typical of lower respiratory illness and usually arise later in infection 
(Hayden et al., 1998). Symptoms are caused by direct destruction of epithelial cells of the 
respiratory tract by viral growth and subsequent inflammatory responses. Cytokine responses 
play a major role in the development of symptoms. Interleukin (IL) 6 and interferon (IFN) α 
levels peak early and correlate directly with viral shedding in nasal fluids, increased 
temperature, mucus production and upper respiratory tract symptoms. Tumour necrosis factor 
(TNF) α levels peak later (days 3-4) as viral shedding and symptoms decrease. IL-8 peaks 
towards the end of illness and is related to lower respiratory tract symptoms (Gentile et al., 
1998; Hayden et al., 1998; Skoner et al., 1999). Wide variations in the severity of these 
symptoms occur between individuals and range from minor respiratory illness to the classic 
febrile infection with debilitating systemic illness (Blumenfeld et al., 1958; Piedra, 1995). The 
severity of illness is influenced by a number of factors, which include the viral dose, pre-
existing immunity, general health, the responsiveness of an individual’s immune system and 
the virulence of the particular strain of virus. (Noble, 1982; Wright and Webster, 2001). It has 
been estimated that between 25-50% of influenza A infections are asymptomatic (Noble, 
1982). 
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1.3.2 Complications 
Most influenza infections are resolved after three days of generally minor upper respiratory 
tract illness, although coughing may persist up to two weeks (Hayden et al., 1998). 
Gastrointestinal symptoms, ranging from nausea and vomiting to abdominal pain and 
diarrhoea, can sometimes occur and are more commonly found in children (Glezen, 1980; 
Meury, Zeller, and Heininger, 2004). However, in some cases the primary influenza infection 
progresses to viral pneumonia, or provides the conditions for secondary bacterial infections. 
Ciliated and non-ciliated cell destruction in the respiratory tract epithelium by influenza virus 
infection leads to pathological changes which inhibit the mucociliary escalator, thereby 
hindering tracheo-bronchial clearance (Camner, Jarstrand, and Philipson, 1973; Winther, 
Gwaltney, and Hendley, 1990; Anderson, 1991). Bacterial pneumonia arising from secondary 
bacterial infections often develops after a period of temporary relief from symptoms (Louria 
et al., 1959). Bacterial pathogens associated with secondary bacterial pneumonia include 
Staphylococcus aureus, Streptococcus pnuemoniae, Haemophilus influenzae and 
Pseudomonas aeruginosa (Oliveira, Marik, and Colice, 2001). A clinical syndrome consisting 
of combined influenza virus and bacterial pneumonia has been described (Louria et al., 1959). 
 
Underlying chronic diseases can be exacerbated by influenza infection, and there are a 
number of rarer non-respiratory complications that can follow an influenza infection. These 
include non-respiratory complications such as Reye’s syndrome (acute encephalopathy and 
fatty degeneration of the viscera that are associated mainly with influenza B infections) in 
children, encephalitis, and skeletal and cardiac muscle dysfunction. In general, complications 
are most likely to develop in children, adults with underlying chronic pulmonary or 
cardiovascular disease, diabetics, the immunosupressed, pregnant women (especially in the 
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second and third trimesters) and the elderly (Glezen, 1980; Louria et al., 1959; Noble, 1982; 
Piedra, 1995; Smith and Poland, 2000). 
1.3.3 Immune response 
Local innate host defences provide the first lines of defence against influenza and other 
respiratory viruses. These include the mucociliary escalator, natural killer cells, macrophages, 
dendritic cells, and pro-inflammatory cytokines such as IL-1, IL-6, TNF and IFN-α and -β. 
which are capable of limiting, but not preventing, infection within the time required for the 
development of the adaptive immune responses (Diebold et al., 2003; Kaufmann et al., 2001; 
Sheridan et al., 1998; Siren et al., 2004). 
Complex interactions take place between the infecting virus and the host and, if the virus is 
effective in overcoming host innate defences, protective antigens will be presented to and 
detected by the adaptive immune system. The adaptive immune response involves the 
induction of virus-specific humoral and cell-mediated responses which neutralise and destroy 
infectious virus (Esser et al., 2003). Following primary infection, the detection of virus-
specific antibodies occurs within 2 weeks (Brown et al., 1985). Recognition of a virus by 
elements of the adaptive immune system occurs following the uptake and processing of virus 
by antigen-presenting cells, principally the macrophages and dendritic cells (Tamura and 
Kurata, 2004). Humoral immunity involves the production of both systemic and secretory 
(local) antibodies by B cells. Stimulated B cells produce serum antibodies of the 
immunoglobulin (Ig) G, A and M isotypes and secretory IgA antibody in response to 
influenza viral antigens (Brown et al., 1985). Influenza infection generates a protective 
antibody response against HA and, to a lesser extent, NA. By themselves, the internal NP and 
M1 proteins play a relatively minor role in the protective response (Chen et al., 1998; 
Cretescu, Beare, and Schild, 1978). Protection against influenza infection is principally 
provided by HA-specific serum IgG and local secretory IgA (Clements et al., 1986a; Couch, 
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1993). The predominant immunoglobulin to HA in protection of the lower respiratory tract is 
IgG (Couch, 1993). Mucosal sIgA production is of major importance in preventing infection 
of the upper respiratory tract (Hodge et al., 2001; Renegar et al., 2004; Renegar and Small, 
1991). For influenza viruses, neutralisation involves prevention of attachment to specific cell 
receptors and is primarily mediated by antibodies against HA (Knossow et al., 2002; Outlaw 
and Dimmock, 1990; Taylor and Dimmock, 1985). Antibodies against NAs play a lesser role 
in the prevention of infection but are involved in the limitation of virus spread (Clements et 
al., 1986b; Johansson, Bucher, and Kilbourne, 1989; Schulman, Khakpour, and Kilbourne, 
1968). 
 
The cell-mediated immune response is mediated primarily by cytotoxic T cells (CTLs) of the 
CD8+ phenotype, in association with T helper cells of the CD4+ phenotype (Esser et al., 
2003). An efficient immune response to influenza infection requires complex interactions 
between cytotoxic T cells, antibody-secreting B cells and cytokine-secreting CD4+ cells 
(Brown, Roman, and Swain, 2004). In the presence of IL-12 and IFN-γ, naive CD4+ cells 
differentiate into T helper 1 (Th1) cells as a result of antigen presentation (Abbas, Murphy, 
and Sher, 1996). The primary role for Th1 cells is to initiate B cell differentiation, although 
they also have a role in the proliferation of CD8+ effector cells and in establishing CD8+ 
memory cells (Belz et al., 2002; Topham and Doherty, 1998). The main function of CD8+ T 
cells is to mediate viral clearance by either killing virus-infected cells or by the secretion of 
antiviral cytokines (Esser et al., 2003). It has been demonstrated in mice that, in the absence 
of a CD8+ response, viral clearance is impeded and, after challenge with highly pathogenic 
strains, rates of mortality increase (Bender et al., 1992). CD8+ T cell mechanisms that kill 
virus-infected cells include (a) perforin granule exocytosis, resulting in the release of 
perforins and granzymes, and (b) the receptor-mediated pathway via Fas/Fas ligand or TNF 
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receptor interaction (Price et al., 2005). Following the rapid clonal expansion of T and B cells 
and the subsequent clearance of virus and virus-infected cells, the vast majority of effector 
cells are eliminated from the blood stream (Jelley-Gibbs et al., 2005). The remaining 
differentiated T and B cells provide long term memory, being primed to respond quickly to 
any subsequent reinfection with the same antigen (Jelley-Gibbs et al., 2005; Turner et al., 
2001).  
 
1.4 PREVENTION & CONTROL OF INFLUENZA 
1.4.1 Antiviral chemotherapy 
Antiviral chemotherapy can be used to limit the length of illness and its intensity in those who 
have not been vaccinated or have not developed an adequate immune response to vaccination. 
There may also be a role for antiviral chemotherapy in limited situations where vaccines are  
unavailable, as in the case of a new pandemic virus where delays occur in preparing sufficient 
doses of an effective vaccine. Influenza antivirals have been classified according to their 
inhibitory activity as (a) general inhibitors of replication, (b) ion channel blockers and (c) 
neuraminidase inhibitors. Inhibitors of replication, which will not be discussed in detail, 
include ribavirin and arbidol. Ribavirin is a synthetic purine nucleoside analogue that has 
been shown to possess antiviral properties against both influenza A and B in cell culture and 
mice but has not been approved for general clinical use against influenza infections (Wright 
and Webster, 2001). Arbidol was synthesised by the Centre for Drug Chemistry in Moscow 
over 20 years ago and is licensed in Russia for prophylaxis and treatment of influenza A and 
B infections (Brooks, Sasadeusz, and Tannock, 2004). 
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1.4.1.1 Ion channel blockers 
The adamantane derivatives, amantadine (1-aminoadamantane hydrochloride) and 
rimantadine (α-methyl-1-adamantane methylamine hydrochloride) are structurally related 
symmetric tricyclic amines that affect the function of the influenza M2 protein ion-channel 
(Belshe et al., 1988; Meanwell and Krystal, 1996). These compounds target the M2 protein, 
blocking ion-channel function early in replication (Hay et al., 1985). Blockage inhibits viral 
replication by preventing the M2-mediated reduction in pH required for viral uncoating 
(Wang et al., 1993). Regulation of pH within the trans-Golgi compartments by the M2 proton 
pump during the transport of HA molecules to the plasma membrane is also inhibited by the 
action of amantadine and rimantadine (Ciampor et al., 1992; Grambas and Hay, 1992). These 
compounds are effective against influenza A but not influenza B viruses, which do not 
possess the M2 protein. Amantadine and rimantadine are effective in both the prevention of 
influenza A infection and in reducing the length and severity of symptoms (Demicheli et al., 
2000; Jefferson et al., 2006; Stephenson and Nicholson, 2001). Best results can be achieved 
when treatment commences within 48 h of the onset of symptoms, requiring a rapid, early and 
correct diagnosis for optimum use (Piedra, 1995; Shaw, Arden, and Maassab, 1992). While 
amantadine and rimantadine are both synthetic amine compounds with similar modes of 
inhibitory activity, they differ greatly in their absorption, metabolic properties and have a 
different spectrum of adverse effects after oral administration (Meanwell and Krystal, 1996). 
Adverse effects associated with therapeutic doses of amantadine include central nervous 
system (CNS) symptoms (insomnia, dizziness and hallucinations) and gastrointestinal 
symptoms (nausea and vomiting) (Jefferson et al., 2006; Stephenson and Nicholson, 2001). 
The emergence of resistant influenza A strains is a major problem associated with the use of 
these compounds. Amantadine resistance to H3N2 viruses appears to be more frequent than to 
H1N1 viruses (Saito et al., 2003). The genetic basis of resistance to amantadine and 
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rimantadine appears to be based on single amino acid changes in the transmembrane domain 
of the M2 protein, in particular at aa positions 26, 27, 30, 31 or 34 (Abed, Goyette, and 
Boivin, 2005; Belshe et al., 1988; Hay et al., 1985). Resistant mutants have been observed 
within as little as 2 days from the onset of treatment (Hayden et al., 1991). The rapid 
emergence of resistant mutants, adverse effects associated with their use and their specificity 
for influenza A viruses alone have restricted the clinical use of amantadine and rimantadine. 
 
1.4.1.2 Neuraminidase inhibitors 
NA enzymatic activity is necessary for the effective spread of virus and provides another 
suitable target for antiviral therapy. Computer modelling and analysis of the 3-dimensional 
structure of NA has been used to design NA inhibitors (Colman, 1994). One compound, in 
particular, 4-guanidino-Neu5Ac2en (5-acetylamino-2,6-anhydro-4-guanidino-3,4,5-trideoxy-
D-glycerol-D-galacto-non-2-enoic acid), was found to have a high binding affinity for 
influenza virus NA, as predicted by computer modelling, and was shown to inhibit viral 
replication in cell culture and to inhibit viral growth and viral-induced fever in ferrets (von 
Itzstein et al., 1993). 4-guanidino-Neu5Ac2en (GG167) was further studied in other animal 
models and in humans, and was then tested (initially as zanamivir and subsequently 
Relenza) in a series of clinical trials. Zanamivir has poor oral bioavailability and must 
administered intranasally or directly to the respiratory tract by oral inhalation using a 
Diskhaler device (Hayden et al., 1997; Hayden et al., 1996; Ryan et al., 1994). Effective 
treatment requires the commencement of treatment within 48 h of the onset of symptoms. 
Zanamivir has been shown to reduce the intensity of symptoms and their duration by 1-2 days 
(Fiddian, 2000; Jefferson et al., 2006; McNicholl and McNicholl, 2001). Adverse effects 
associated with zanamivir are minor, although the inhaled powder can exacerbate respiratory 
distress (Williamson and Pegram, 2000). 
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While resistant mutants can be generated in vitro by multiple passage in the presence of 
zanamivir, the generation of spontaneous resistants in humans does not appear to be a major 
problem (Blick et al., 1995; Gubareva et al., 1996; Gubareva et al., 1997; McKimm-
Breschkin et al., 1996). There has been only one report of a mutant influenza with reduced 
zanamivir sensitivity from an immunocompromised child with a prolonged influenza B 
infection (Gubareva et al., 1998). 
 
A series of compounds was designed in an attempt to increase the bioavailability of NA 
inhibitors, replacing the GG167 polar moiety with lipophilic side chains. GS4104, an ethyl 
ester pro-drug of the lipophilic compound GS4071, exhibited good oral bioavailability in a 
range of laboratory mammals (Li et al., 1998). Oral administration of GS4104 protected mice 
against lethal challenge with H1N1, H3N2 and influenza B viruses and reduced the fever, 
inflammatory response and nasal wash viral titres in ferrets challenged with H3N2 influenza 
A viruses (Mendel et al., 1998). GS4071 was evaluated in a series of clinical trials as 
oseltamivir (Tamiflu). As with zanamivir, effective treatment with oseltamivir requires 
commencement within 48 h of the onset of symptoms, and the drug was shown to be well 
tolerated and effective in reducing the severity of symptoms and their duration by 1-2 days 
(Nicholson et al., 2000; Treanor et al., 2000). No serious adverse affects have been associated 
with its use, although gastrointestinal side-effects (nausea and vomiting) are more frequent 
than with zanamivir (Fiddian, 2000; McNicholl and McNicholl, 2001; Rothberg, Bellantonio, 
and Rose, 2003; Stephenson and Nicholson, 2001). 
 
At first a very low incidence of the recovery of oseltamivir-resistant mutants from clinical 
samples was reported (0.4-4%) (Ison et al., 2002). Initially, the emergence of NA inhibitor 
mutants appeared to be a minor problem and a global Neuraminidase Inhibitor Susceptibility 
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Network was established in 1999 to monitor resistance in both research and clinical settings 
throughout the world (Zambon and Hayden, 2001). However the recent, large increase in the 
use of oseltamivir associated with the spread of avian H5N1 viruses has led to an increase in 
the observed occurrence of resistant mutants. One small study (50 children) showed that 18% 
of oseltamivir recipients developed resistance after 4 days of treatment (Kiso et al., 2004). 
Two Vietnamese patients, one who died on the 8th and the other on the 20th day of illness, 
developed oseltamivir-resistant H5N1 viruses (de Jong et al., 2005). A case of partial 
resistance to oseltamivir was reported with a mixed drug-resistant and drug-susceptible H5N1 
population present in a clinical sample from a Vietnamese patient (Le et al., 2005). Zanamivir 
activity has remained effective against oseltamivir-resistant virus variants, and the small 
increase in the clinical use of zanamivir reduces the likelihood of zanamivir-resistant mutants 
emerging (Hayden et al., 2005; Hayden, 2006). The extent to whether (a) the timing of 
initation of treatment, (b) the duration of treatment and (c) the use of suboptimal dosing 
affects oseltamivir resistance in children is unclear (Hayden et al., 2005; Moscona, 2005). The 
clinical impact of resistant mutants is also unclear as the biological fitness of these viruses 
varies, giving rise to resistant viruses with different replication and transmission capabilities 
(Yen et al., 2005). The majority of recent studies have reported resistant mutants with 
compromised growth and virulence, although two mutant variants have been shown to be 
transmissable between ferrets (Herlocher et al., 2004). 
 
While both zanamivir and oseltamivir are licensed for the treatment of influenza, only 
oseltamivir has been approved for prophylaxis against influenza infection (FDA, 2005). 
1.4.2 Vaccines 
Currently the most effective way to provide protection against influenza infection is through 
the use of vaccines. Vaccination is recommended for key at risk groups that include the 
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elderly, those with specific underlying respiratory syndromes, pregnant women in the third 
trimester, diabetics and health care personnel. 
 
Influenza vaccines are usually trivalent and contain representative influenza A H1N1, H3N2 
and influenza B surface antigens which must be re-evaluated each year to ensure that there is 
antigenic match with current circulating strains. The WHO publishes recommendations twice 
yearly for influenza vaccine composition, in February for the Northern hemisphere and 
October for the Southern hemisphere. The recommendations are based on review of 
surveillance data by WHO Collaborating Centres for Reference and Research on Influenza, 
based in Australia, the UK, Japan and the US. Deadlines for the preparation of sufficient 
updated vaccine are generally tight. The timing of these decisions leaves vaccine 
manufacturers approximately 6 months for the production and distribution of vaccine (Gerdil, 
2003). 
1.4.2.1 Inactivated vaccines 
The first crude influenza vaccines developed in the early 1930’s were prepared from lung 
homogenates from infected mice (Williams and Wood, 1993). In the late 1930’s the 
successful propagation of influenza viruses in the allantoic cavity of embryonated chicken 
eggs enabled large-scale influenza vaccine production for human use (Williams and Wood, 
1993). Inactivated influenza vaccines have been widely available for over 50 years (Arvin and 
Greenberg, 2006). The influenza A antigens of contemporary inactivated vaccines are usually 
prepared from reassortant viruses to increase yields. These reassortants contain the internal 
genes from a strain, usually A/Puerto Rico/34/8 (A/PR8), that specify high growth capacity in 
eggs and the genes for the surface antigens of the current epidemic strains. 
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Whole virus, split or subunit inactivated vaccines are available in most countries and are 
prepared from allantoic-grown virus that has been purified by zonal centrifugation and 
inactivated with formalin or β-propiolactone. Whole virus vaccines consist of intact, 
inactivated virus, while for split vaccines the virus is further treated with solubilising agents. 
This treatment degrades the viral lipid envelope, resulting in disrupted virus particles that are 
less reactogenic than whole virus, especially in young children (Couch, 1993; Williams and 
Wood, 1993). Subunit vaccines are prepared by further purification of split virus; the internal 
viral proteins are removed, leaving only the HA and NA surface antigens in the vaccine 
(Brede, 1995). A concentration of fifteen micrograms of HA per strain per dose is usually 
used (Renfrey and Watts, 1994). The production of inactivated vaccines is discussed in 
further detail in Section 1.5. 
 
Administration of inactivated vaccines is usually by subcutaneous or intramuscular injection 
(Piedra, 1995). The efficacy of inactivated influenza virus vaccines has been reported to be 70 
- 90% in healthy adults, but can be much less in young children and the elderly (Couch, 1993; 
Nichol, 2003). Although responses to vaccination are lower in the elderly, vaccination in 
those 65 years and older has been reported to be up to 80% effective in reducing 
hospitalisation and deaths from influenza-related complications (Patriarca et al., 1985). For 
children, vaccine-induced protection against influenza infection is also less than in adults, but 
a reduction in the rates of medically attended illness and hospitalisation from influenza 
infections in vaccinated children has been reported (Piedra et al., 2005). Children play an 
important role in the transmission of influenza to the wider community and high rates of 
vaccination in school children in Japan have been shown to decrease mortality from influenza 
in older people (Reichert et al., 2001). 
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1.4.2.2 Live intranasal vaccines 
Live intranasal vaccines against influenza have the potential to provide more effective 
immunity by inducing broader mucosal, systemic and CMI immune responses than is possible 
with conventional parenterally administered inactivated vaccines. Systemic, CMI and local 
mucosal immune responses induced by live vaccines are comparable with those induced by 
natural infection (Section 1.3.3), which are longer lasting than the responses to inactivated 
vaccines (Cox, Brokstad, and Ogra, 2004). Inactivated vaccines induce higher serum antibody 
responses than live intranasal vaccines, although their HA antigen concentration is much 
higher (Wareing and Tannock, 2001). Intranasal delivery of live vaccines by drops, spray or 
aerosol generator provides the additional advantage of avoiding the invasive injections 
required for the administration of inactivated vaccines. Live vaccines are prepared as 
reassortants containing the internal genes from a donor strain, which confer the properties of 
attenuation, temperature-sensitivity and cold-adaptation, and the genes for the surface 
antigens of the current epidemic strains. Of the approaches investigated, cold-adaptation has 
been shown over many years to be more suitable than previous methods for the production of 
genetically stable attenuated donor strains for use in human vaccines. 
 
1.4.2.2.1 Cold-adapted vaccines 
Cold-adapted (ca) vaccines have been developed independently since the 1960’s in the US 
and former USSR (Wareing and Tannock, 2001). Ca viruses grow efficiently at 25°C but 
show limited growth at 39°C compared with wild-type parent strains. In general, cold-
adaptation of wild-type influenza viruses is achieved by repeated serial passage at 
progressively lower temperatures to 25°C. This approach has been used for the development 
of both influenza A and B attenuated donor strains (Kendal et al., 1981; Maassab, 1969). 
Russian ca donor strains were attenuated by passage in embryonated chicken eggs, while U.S 
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ca viruses were obtained following passage in eggs and/or primary cultures prepared from 
chicken kidneys (Kendal, 1997). These donor strains were prepared from the virulent strains 
A/Ann Arbor/6/60 (H2N2), B/Ann Arbor/1/66, A/Leningrad/134/57 (H3N2) and 
B/USSR/60/69 (Wareing and Tannock, 2001). Reassortant viruses, containing the six internal 
genes of the ca donor strain and the surface antigen genes of current epidemic strains, are then 
selected and propagated for use as vaccines. 
 
Studies with reassortants have identified mutations in several genes that are associated with 
cold-adaptation and possible attenuation. Multiple mutations confer genetic stability to each 
donor strain, decreasing the chance of reversion to virulent wild type parental viruses. Amino 
acid substitutions in the PB2, PB1, PA, M1, M2, NS2 and NP proteins of 
A/Leningrad/134/47/ca have been reported (Klimov et al., 1992). Sequence analysis of A/Ann 
Arbor/6/60–ca and its wt parent revealed 24 nucleotide changes that encoded 11 amino acid 
substitutions in the PB2, PB1, PA, M2, NP and NS1 genes (Cox et al., 1988; Snyder et al., 
1988). The only mutation common to both ca A/Leningrad and ca A/Ann Arbor donor strains 
was nucleotide 969 of the M gene coding for the M2 protein (Herlocher, Clavo, and Maassab, 
1996; Klimov and Cox, 1995). Several unique amino acid substitutions have been identified 
in the PB2, PA, M1 and NP genes of B/Ann Arbor/1/66-ca, and their roles in temperature-
sensitivity, attenuation and cold-adaptation were confirmed by the application of reverse 
genetics (Chen et al., 2006; Hoffmann et al., 2005). Mutations in NP (A114 and H410), 
together with with PA (M431) are responsible for the expression of temperature-sensitivity. 
The same mutations, in association with others in M1 (Q159 and V183) are responsible for 
attenuation. Mutations in PB2 (R630), PA (M431) and NP (A114, H410 and T509) control ca 
expression. 
 
33 
There is a large body of data on the safety and efficacy of ca-vaccines dating back to the 
1970’s. Both Russian and US ca-vaccines have been shown to be well-tolerated, 
immunogenic and protective. The protective efficacy of ca vaccines has been reported in 
many individual trials and from meta-analysis of published studies (Beyer et al., 2002; 
Clements et al., 1986a; Mendelman, Cordova, and Cho, 2001; Nichol et al., 1999; Treanor et 
al., 1999; Treanor, Roth, and Betts, 1990). Whilst some concern has been expressed regarding 
the large-scale use of infectious influenza virus as vaccines, there has been no evidence of 
reversion to virulence or of reassortment with other epidemic strains following vaccination 
(Beyer et al., 2002; Wareing and Tannock, 2001; Youngner et al., 1994). 
 
Russian ca vaccines have been widely used in children aged 3-15 years since 1984 and in 
adults since 1981 (Ghendon et al., 1984). The trivalent ca vaccine FluMist (MedImmune 
Vaccines Inc) was approved by the FDA in June 2003 for use in healthy children and 
adolescents aged 5-17 years and healthy adults aged 18-49 years. FluMist has been developed 
using A/Ann Arbor/6/60-ca and B/B/Ann Arbor/1/66 as donor strains (Cha et al., 2000). 
1.4.2.3 New developments in vaccine technology 
While current inactivated and live vaccines can significantly reduce influenza-related 
morbidity and mortality, the protection they provide is less than that afforded by other viral 
vaccines. Current techniques lack the flexibility necessary for the rapid expansion needed to 
increase vaccine supplies in the face of pandemics. Relatively inexpensive, alternative vaccine 
manufacturing processes that do not require the use of large numbers of embryonated eggs or 
extensive purification and concentration steps could provide greater quantities of vaccine at 
lower cost. A number of new developments directed towards these ends and the improvement 
of responses to influenza vaccines are under investigation. 
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1.4.2.3.1 DNA vaccines 
DNA vaccines are administered as plasmid DNA preparations that encode genes for the 
expression of one or more viral antigens to stimulate protective responses. Several types of 
administration have been investigated and these include the use of the intramuscular, 
intravenous, intranasal and oral routes, delivery by topical application, electroporation and the 
gene gun (Jones et al., 1997; Kadowaki et al., 2000; Oh et al., 2001; Okuda et al., 2001; 
Watabe et al., 2001). Early studies demonstrated that a range of protective humoral and 
cellular immune responses were induced by influenza DNA vaccines in animal models 
(Fynan et al., 1993; Justewicz et al., 1995; Montgomery et al., 1993; Robinson, Hunt, and 
Webster, 1993; Ulmer et al., 1993). Vaccines based on the expression of internal influenza 
proteins (NP, M1 and/or M2) have also been investigated in an attempt to induce broader 
cross-protection against influenza infections (Kodihalli, Kobasa, and Webster, 2000; Okuda et 
al., 2001; Ulmer et al., 1994). Although protective immune responses have been observed 
with some studies in ferrets and non-human primates, responses in large animals and humans 
have generally not matched those seen in mice (Babiuk et al., 2003; Donnelly et al., 1995; 
Donnelly et al., 1997; Ulmer et al., 1994). The mechanisms by which DNA vaccines induce 
humoral and cellular immune responses are not fully understood - in particular, factors 
influencing protective humoral responses and antigen presentation for the induction of T cell 
responses (Oran and Robinson, 2004; Rush et al., 2006; Ulmer, 2002). Concerns have also 
been expressed regarding the consequences of possible plasmid integration into the host 
genome, the continued presence of foreign DNA and the extent of immune responses in 
human and non-human primates (Babiuk et al., 2003; Donnelly, Wahren, and Liu, 2005; 
Hanke, 2006; Rajcani, Mosko, and Rezuchova, 2005). The continuing presence of vaccine 
DNA in the host could trigger inappropriate responses to vaccines prepared against 
contemporary haemagglutinin antigens (i.e the phenomenon of original antigenic sin 
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(Klenerman and Zinkernagel, 1998; Singh, Rodgers, and Barry, 2002). However, despite this, 
considerable efforts are continuing towards the development of effective influenza DNA 
vaccines and a recent report describes a Phase I clinical trial in which a monovalent influenza 
epidermal DNA vaccine was evaluated (Drape et al., 2006). 
 
1.4.2.3.2 Vaccines based on recombinant baculovirus or adenovirus expression 
Early studies demonstrated the successful expression of HA and/or NA in both insect cells 
and larvae that had been inoculated with recombinant baculovirus (Mather et al., 1992; Price 
et al., 1989; Weyer and Possee, 1991). Later studies demonstrated that purified, secreted, 
recombinant NA protein prepared in a baculovirus expression system was protective in mice 
against lethal influenza challenge (Deroo, Min Jou, and Fiers, 1996; Vanlandschoot et al., 
1993). A number of vaccines based on recombinant baculovirus influenza proteins have been 
subsequently investigated. Baculovirus vaccines induce a serum antibody response and are 
well-tolerated in humans, although high doses are necessary to develop protective responses 
(Lakey et al., 1996; Powers et al., 1997; Powers et al., 1995; Treanor et al., 1996). The IN 
administration of a recombinant baculovirus that expressed HA induced protection in mice 
against a lethal dose of challenge virus (Abe et al., 2003). Responses to IN delivery were 
enhanced if the recombinant was combined with Proteosomes - meningococcal outer 
membrane proteins that naturally form vesicles (Jones et al., 2003). 
 
An inactivated baculovirus recombinant vaccine containing the HA of the A/Hong 
Kong/156/97 strain has been tested in humans for safety and reactogenicity (Treanor et al., 
2001). Although the vaccines were well tolerated, a protective neutralising antibody response 
was only observed in individuals who received high doses. Self-assembly of H9N2 virus-like 
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particles following expression of HA, NA and M1 recombinant baculovirus proteins in insects 
induced a serum antibody response in BALB/c mice (Pushko et al., 2005). 
 
Recombinant adenovirus (rAd) can be used used as influenza vaccines. They produce 
defective-interfering (DI) particles in humans and, therefore, pose no risk but can grow to a 
very high titre (greater than 1011 pfu/mL) in complementing cell lines, like PER.C6, that carry 
adenovirus E1 genes (Maranga, Aunins, and Zhou, 2005; Wu and Ataai, 2000). Adenoviruses 
can accommodate relatively large segments of foreign DNA and have been widely used as a 
vector for gene therapy (Prasad et al., 2001). Gene transfer via rAd vector activates T cells by 
direct transduction of dendritic cells and by cross-presentation of the transgenic product 
(Sarukhan et al., 2001). Two rAd swine H3N2 vaccines injected IM, one containing HA alone 
and the other HA and NP, induced a protective antibody-mediated immunity in weaned pigs, 
while rAd containing NP alone was not immunogenic (Wesley, Tang, and Lager, 2004). An 
NP DNA vaccine boosted with rAd-NP was more effective in mice than DNA vaccine alone 
and induced partial cross-protection (Epstein et al., 2005). A small study in healthy adults 
found that both IN and epicutaneous delivery of rAd-HA vaccine was well-tolerated, superior 
responses were observed following IN compared with epicutaneous delivery (Van Kampen et 
al., 2005). Full-length H5N1 HA expressed in rAd vaccine induced HA-specific antibodies 
and cellular immunity and was protective in mice and chickens against homologous challenge 
(Gao et al., 2006). 
 
1.4.2.3.3 Adjuvants 
Adjuvants are used to improve immune responses to vaccines. The mechanism of action is 
dependent on the type of adjuvant and include prolonged release of antigen through the 
formation of an antigen deposit, targeted delivery systems and specific stimulation of cells of 
the innate and humoral immune systems (Gupta et al., 1993; Pashine, Valiante, and Ulmer, 
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2005). Aluminium salts (alum) and mineral oil-water emulsions have been used as adjuvants 
with influenza vaccines (Ott, Barchfeld, and Nest, 1995). While alum has a long history of 
safe use in human vaccines, immune responses can vary and influenza HA adsorption to alum 
is poor (Singh et al., 2006; Skea and Barber, 1993). Early oil-water emulsions (Freund’s 
complete and incomplete adjuvants) are very effective adjuvants and are used in animal 
vaccines. However, because of their capacity to produce unacceptable side-effects in humans, 
notably sterile abscesses, their use was discontinued some years ago (Gupta et al., 1993). It is 
also noteworthy that, because of these side-effects, Freund’s complete adjuvant is now 
disallowed for use in animals in some countries. Few adjuvants other than alum have reached 
the final stages of licensure because of safety concerns regarding acute toxicity and delayed 
side-effects. However, because of recent developments towards the use of purified antigens, 
vaccines with potent adjuvants will probably be increasingly needed (Pashine, Valiante, and 
Ulmer, 2005). Some recent adjuvants for inclusion in influenza vaccines are described. 
 
1.4.2.3.3.1 MF59 
MF59 is an oil-water emulsion containing 5%v/v squalene, 0.5% v/v polysorbate 80 (Tween 
80) and 0.5% v/v sorbitan trioleate (Span 85) (Podda, 2001). Meta-analysis of the use of an 
inactivated subunit influenza vaccine adjuvanted with MF59 (Fluad, Chiron Vaccines) in 
more than 10,000 elderly people found it to be well-tolerated and induced significantly higher 
immune responses than non-adjuvanted vaccines (Podda, 2001). Local reactions were more 
frequent with the adjuvanted vaccine. A comparison of Fluad with a licensed, non-
adjuvanted, split influenza vaccine in 200 young adults showed it to be safe and well-
tolerated, although there was only a modest immunogenic benefit compared with the non-
adjuvanted vaccine (Frey et al., 2003). Recently, a study of immune responses in 119 elderly 
people demonstrated that Fluad can confer higher levels of protection against influenza 
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strains not fully-matched in the vaccine than conventional subunit or split-vaccines (Giudice 
et al., 2006). 
 
 
1.4.2.3.3.2 Liposomes & virosomes 
The term liposome refers to a broad range of particles with bilayer structures. Liposomes 
contain an internal space that allows the incorporation of hydrophilic antigens (or adjuvants), 
and amphiphilic antigens and adjuvants through bilayer association (Kersten and Crommelin, 
2003). Virosomes are a type of liposome that are formed by the reconstitution of influenza 
virus envelopes (Stegmann et al., 1987). This results in the formation of spherical, unilamellar 
vesicles of approximately 150nm diameter, with HA and NA intercalated into the lipid 
bilayer, while retaining their receptor-binding and membrane fusion properties of wild-type 
viruses (Zurbriggen, 2003). Antigens can be encapsulated within the virosome or linked to the 
virosome surface in a number of ways, that include integration/anchorage within the lipid 
bilayer, cross-linkage to the HA present or adsorption to the membrane (Gluck and Metcalfe, 
2003). The first virosomal vaccine to be licensed was a hepatitis A vaccine in 1996 (Gluck 
and Metcalfe, 2002). In 1997, a trivalent influenza virosome vaccine InflexalV (Berna 
Biotech Ltd) was licensed in Switzerland. InflexalV administered parenterally was shown to 
be safe and immunogenic in more than 2,500 healthy volunteers in 18 trials (Mischler and 
Metcalfe, 2002). Studies in children found that it was well-tolerated and induced immune 
responses comparable with standard subunit influenza vaccines (Herzog, Metcalfe, and 
Schaad, 2002). Currently another two influenza virosome vaccines have been licensed in 
several European countries, Influvac Plus (Solvay Pharma, Switzerland) and Invivac 
(Solvay Pharmaceuticals BV, The Netherlands). These vaccines have also shown to be safe 
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and effective, providing protective immunity up to one year after vaccination comparable to 
that of conventional inactivated vaccines (de Bruijn et al., 2004). 
 
A nasally-delivered inactivated virosomal influenza vaccine was developed (NasalFlu, 
Berna Biotech) and licensed for use in Switzerland. NasalFlu, administered as an IN spray, 
contained E.coli heat-labile toxin as a mucosal adjuvant to induce a mucosal immune 
responses (Glueck, 2001). No serious adverse affects were reported during prelicensure trials. 
However following the commercial introduction of NasalFlu in 2000 there were 46 reports 
of the occurrence of Bell’s palsy in individuals who received the vaccine. Distribution of the 
vaccine was suspended while the link between NasalFlu and Bell’s palsy was investigated. 
NasalFlu was found to have a strong association with Bell’s palsy and is no longer in 
clinical use (Mutsch et al., 2004). 
 
1.4.2.2.3.3 ISCOMs 
ISCOMs (immunostimulatory complexes) are spherical particles 30-40nm in diameter that 
form cage-like structures, into which antigens or other proteins can be incorporated 
hydrophobically (Deliyannis et al., 1998). Originally described in 1984, ISCOM and the 
newer variant ISCOMATRIX are currently the proprietary technology of CSL Ltd, 
Australia (Morein et al., 1984). ISCOMs consist of a saponin mixture (QuilA), cholesterol, 
phospholipids and the desired immunogen (Sjolander, Cox, and Barr, 1998). QuilA possesses 
adjuvant properties, and is a refined mixture of saponins extracted from the bark of Quillaja 
saponaria molina trees (Deliyannis et al., 1998). ISCOMs formed without the incorporated 
immunogen are termed the ISCOM matrix (ISCOMATRIX), and can be prepared for vaccine 
use by simply mixing with the desired antigen (Sjolander, Cox, and Barr, 1998; Windon et al., 
2001). Early studies showed that influenza HA and NA retained their biological activity after 
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incorporation into ISCOMs (Sundquist et al., 1988). Influenza ISCOM vaccine was 
subsequently shown to induce protective antibody responses that were greater and longer 
lasting than conventional influenza vaccines in mice, guinea pigs and horses (Sundquist, 
Lovgren, and Morein, 1988). Influenza ISCOM vaccines induce long-lasting systemic and 
humoral immune responses in non-human primates, and were shown to provide protection 
against homologous challenge, although they were not protective against distant drift variants 
of A/H3N2 viruses (Ahmeida et al., 1993; Deliyannis et al., 1998; Rimmelzwaan et al., 1997; 
Rimmelzwaan et al., 2001a). In a small study, two doses of a H5N1 ISCOM vaccine in 
roosters were shown to produce immunogenic responses and provide protection against lethal 
homologous challenge (Rimmelzwaan et al., 1999). In a comparative study of trivalent 
influenza ISCOM, ISCOMATRIX and conventional inactivated vaccines in a group of 25 
healthy, young adults found all three vaccines were shown to be immunogenic. The ISCOM 
and ISCOMATRIX vaccines induced antibody titres more rapidly after vaccination than the 
conventional vaccine, although only A/H3N2 antibody responses were significantly higher 
(Rimmelzwaan et al., 2001b). The intransal delivery of an influenza H1N1 ISCOMATRIX 
vaccine in mice and sheep induced both local and systemic immune responses and was more 
immunogenic than the subcutaneous vaccination of unadjuvanted vaccine (Coulter et al., 
2003). 
 
1.4.2.3.4 Other approaches 
The following is a brief overview of additional approaches to vaccine development. 
 
1.4.2.3.4.1 Influenza NS1 deletion mutants 
Influenza NS1 protein is involved in a number of virus replication steps and inhibits a variety 
of host cell antiviral responses (Section 1.1.2), providing a novel possibility for an influenza 
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vaccine (Garcia-Sastre et al., 1998). Influenza A and B mutant viruses with large deletions in 
the NS1 gene have been shown to be replication-deficient and to induce protective immunity 
against challenge with wt virus in mice following IN administration (Ferko et al., 2004; 
Stasakova et al., 2005; Talon et al., 2000). 
1.4.2.3.4.2 Novel delivery systems 
A recent development has been a proteosome delivery system using nanoparticles derived 
from purified Neisseria meningitidis outer membrane proteins, covalently linked to 
amphiphilic antigens (Langley et al., 2006). These vaccines, administered by the IN route, 
have proceeded to the Phase I clinical trial stage, as FluINsure Proteosome trivalent 
influenza vaccine (ID Biomedical Corporation, Quebec & Maryland). They have been 
reported to be well-tolerated with no serious adverse affects being observed in monovalent 
vaccine studies. Lower serum antibodies responses were induced but mucosal antibody 
responses were superior to those obtained with conventional inactivated vaccines (Treanor et 
al., 2006). Similar results have been reported with trivalent proteosome vaccines (Langley et 
al., 2006). 
Chitosan, a cationic bioadhesive polysaccharide derived from crustacean shells, has been 
investigated as a nasal delivery system for inactivated subunit influenza vaccines in humans 
(Read et al., 2005). Levels of seroconversion, seroprotection and mean geometric titres varied 
according to the HA antigens used, but were comparable to those induced by other 
adjuvant/carrier systems. Generally the vaccine was well-tolerated, although some mild 
rhinorrhea, and pain and bruising at the injection site were reported by recipients. 
1.4.2.3.4.3 Defective interfering particles 
Cells infected at high multiplicity produce defective-interfering (DI) influenza particles that 
interfere with the replication of complete (infectious) particles (Nayak, Chambers, and 
Akkina, 1985). Interfering vaccines containing DI viruses have been shown to provide 
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protection against influenza A infections by reducing progeny virus in the respiratory tract to 
levels that only cause subclinical infections (Noble, McLain, and Dimmock, 2004). This type 
of proposed vaccine has also been shown to be immunogenic and to provide protection in 
mice and ferrets after challenge with wt virus (Duhaut and Dimmock, 1998; Mann et al., 
2006) 
1.4.2.3.4.4 Novel adjuvants 
Although cholera toxin (CT) is a strong mucosal adjuvant, concerns regarding toxicity and 
safety have limited its widespread use in human vaccines. The use of trace amounts of CT in 
association with cholera toxin B subunits (CTB*) reduces its overall toxicity (Hagiwara et al., 
2001). CTB*-adjuvanted influenza vaccines administered IN to mice have been shown to 
elicit mucosal and serum antibody responses, although levels of protection varied from 
complete in young mice to partial in aged mice (Asanuma et al., 2001; Watanabe et al., 
2003a). 
The immunogenic properties of a parasite-derived (Taenia crassiceps cysticerci) synthetic 
peptide (GK1) after co-administration with inactivated influenza vaccine have been 
investigated in young and elderly mice (Segura-Velazquez et al., 2006). Administration of the 
GK1-adjuvanted vaccine induced greater serum antibody levels than the non-adjuvanted 
vaccine in the elderly mice, while the responses in young mice were similar for both vaccines. 
Reduced viral pathology in the lung was observed following challenge of both groups of 
mice. 
The use of heat labile E.coli enterotoxin as an adjuvant in a skin patch following vaccination 
in the elderly has also been investigated. Patches placed directly over or in close proximity to 
the IM injection site of Inflexal V virosomal trivalent influenza vaccine were shown to be 
safe, although mild rash and diarrhoea were noted in some recipients. The patches enhanced 
immune responses in the elderly to all three antigens in the vaccine (Frech et al., 2005). 
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1.4.2.3.4.5 Universal A or B vaccines 
A vaccine (M2e-HBc) based on the highly conserved, extracellular domain of influenza M2 
protein has been developed in an attempt to produce a universal influenza A vaccine, using 
hepatitis B core antigen particles as an adjuvant. This construct was immunogenic in mice but 
provided only partial protection against a lethal challenge dose (De Filette et al., 2005). The 
M2e-HBc vaccine has been recently combined with a gene fusion protein, CTA1-DD. CTA1-
DD is a combination of the ADP-ribosylating domain of cholera toxin with a dimer of the D-
fragment of S.aureus protein A. In a recent study all mice vaccinated with nasally 
administered M2e-HBc-CTA1-DD vaccine survived lethal challenge (De Filette et al., 2006).  
A universal influenza B peptide conjugate vaccine has been developed based on the highly 
conserved maturational cleavage site of influenza B HA0 (Bianchi et al., 2005). The HA0 
peptide was conjugated to a carrier protein (N.meningitidis outer membrane protein complex) 
and adjuvanted with alum and QS21 (an isolated fraction from the QuilA saponin mix). Mice 
receiving three doses of this vaccine survived lethal challenge with influenza B viruses from 
the two major lineages (B/Yamagata/16/88-like and B/Victoria/2/87-like). 
 
1.5 CURRENT INACTIVATED INFLUENZA VACCINE PRODUCTION 
1.5.1 Reassortment 
Newly isolated influenza strains often grow poorly in eggs and the strategy for increasing 
yields of influenza A viruses over the past 30 years has been to prepare reassortants of high-
yielding donor strains for use in inactivated vaccines (Baez, Palese, and Kilbourne, 1980; 
Robertson et al., 1992). This process is generally not used for influenza B inactivated 
vaccines because of a lack of suitable high-yielding influenza B donor strains that are 
sufficiently distinct antigenically and/or in possession of unique genetic markers to identify 
gene segment origin in progeny virus (Beare et al., 1977). Modern molecular techniques, in 
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conjunction with classical tests of antigenic identity and growth potential are now useful for 
the screening of vaccine seeds. Reassortment is used in the selection of live attenuated ca 
vaccine candidate strains because the donor strains do have unique genetic markers and there 
are satisfactory biological screening methods for strain selection. However, problems remain 
in the selection of high yielding influenza B strains for use in inactivated vaccines by serial 
egg passage in attempts to improve yield, a procedure that is quite unpredictable. 
 
1.5.2 Egg-based production 
The majority of viruses for inactivated vaccine production is prepared by growth in the 
allantoic cavity of embryonated chicken eggs. Virus in harvested allantoic fluid is purified, 
concentrated and inactivated. Further purification steps must be taken to minimise reactogenic 
contaminants, such as egg proteins, and final stages in manufacture vary according to the type 
of vaccine (Section 1.4.2.1). After purification, the vaccine may still contain a small amount 
of endotoxin, egg proteins, formaldehyde and preservative (Wright and Webster, 2001). 
Yields of egg-adapted viruses are usually high, but there are a number of problems associated 
with the use of eggs. These include 1) the limited flexibility afforded to increase supply for 
expanded vaccine manufacture, 2) unforeseen problems that may occur due to the presence of 
diseases in layer flocks and 3) the possibility of sterility problems arising during the 
processing of infected allantoic fluids. Additionally, the growth of epidemic viruses in eggs 
often selects variants that differ in their glycosylation pattern and are antigenically distinct 
from original clinical isolates. 
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1.5.3 Host selected virus variants 
Passage of influenza B viruses in eggs can select variant populations that are antigenically 
distinct from the same viruses passaged in mammalian cell cultures. Egg-grown compared 
with Madin Darby canine kidney (MDCK)-grown influenza B clinical isolates exhibited clear 
differences in antigenicity based on double immunodiffusion and haemagglutination-
inhibition tests using anti-HA monoclonal antibodies (Schild et al., 1983). The molecular 
basis of variation is a single amino acid substitution at amino acids 196-198 of the HA 
molecule, which results in a change in glycosylation at the HA distal tip (Robertson et al., 
1985). Host cell selection of antigenic variants have also been reported for both H1N1 and 
H3N2 influenza A viruses (Katz, Naeve, and Webster, 1987; Oxford et al., 1987; Robertson et 
al., 1987).  
 
Viruses from clinical samples taken from one individual over 48h during infection by an 
H3N2 virus and isolated in MDCK cells were shown to possess antigenic and structurally 
identical HAs (Katz and Webster, 1988). The same clinical samples isolated in eggs, 
however, showed three distinct viral sub-populations with HAs that were antigenically and/or 
structurally distinct from each other. This pattern of heterogeneity within egg-grown isolates 
was confirmed in studies with larger patient numbers. Three variants with substitutions in 
HA1 at residues 156, 145 or 138 were described (Wang, Katz, and Webster, 1989). All 
clinical samples that were egg-passaged contained at least two of the three egg-grown variants 
and similar findings have been reported for influenza A H1N1 and influenza B isolates 
(Oxford et al., 1991). Isolation studies were conducted by the polymerase chain reaction 
(PCR), using primers specific for the HA1 region on clinical samples, prior to and following 
passage in MDCK cells or eggs. Results indicated that the original clinical isolates and 
MDCK-passaged viruses possessed HAs that were similar and relatively homogeneous, 
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whereas HAs from egg-passaged viruses were heterogenous (Katz, Wang, and Webster, 1990; 
Robertson et al., 1990; Robertson et al., 1991; Rocha et al., 1993). H3N2 viruses passaged 
once or twice in MDCK, LLC-MK2 (monkey kidney), MRC-5 (human foetal lung), WI-38 
(human embryonic lung), primary guinea pig kidney and chicken kidney cells were all 
antigenically similar and had identical HA1 amino acid sequences (Katz and Webster, 1992). 
A single egg passage of the chicken kidney-grown virus resulted in an amino acid substitution 
at residue 156. Clinical samples obtained from a number of countries during 1987-1990 and 
subsequently grown in eggs and cell culture were similarly diverse antigenically. The most 
common change in egg-grown strains occurred at position 186 of the HA1, resulting in a 
substitution of isoleucine for serine (Meyer et al., 1993). 
 
Influenza A viruses passaged by the amniotic route, as distinct from viruses passaged by the 
allantoic route, usually retain their sequence identity (Robertson et al., 1993). Amniotic cells 
possess both SAα2,3Gal linkage receptors (specific for avian influenza viruses) and 
SAα2,6Gal receptors (specific for human influenza A viruses; Section 1.1.3). Allantoic cells 
possess only SAα2,3Gal linkage receptors. The absence of SAα2,6Gal receptors in the 
allantois provides pressure for the selection of variants with altered specificities (Ito et al., 
1997). Most non-egg adapted human influenza A viruses bind weakly to allantoic cells, but do 
not penetrate the cell membrane (Williams and Robertson, 1993). Egg-adaptation of human 
influenza viruses also selects viruses with impaired ability to bind to SAα2,6Gal receptors 
(Gambaryan, Robertson, and Matrosovich, 1999). 
 
Nucleotide changes associated with the egg adaptation of human influenza A and B viruses 
are predominantly located around the HA receptor binding site of the HA1 region. Receptor 
binding site changes can affect host-dependent glycoslyation sites, and the position of 
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carbohydrate side-chains can influence the ability of virus to bind to receptors with specific 
carbohydrate linkages (Gambaryan et al., 1998).  
 
1.5.4 Immune responses to egg-adapted viruses 
Accredited seed viruses used to prepare current vaccines are grown in eggs. Virus variants 
have been found in vaccine virus seed stocks and several studies have been undertaken to 
investigate responses to vaccines prepared from egg- and cell culture-derived viruses in 
animal models and humans (Robertson et al., 1994). 
 
In several studies experimental MDCK-grown vaccine viruses were prepared from MDCK 
isolates and passaged seed viruses. Live H3N2 vaccine viruses grown in eggs or MDCK cells 
provided equivalent protection in ferrets challenged with virus grown in either substrate; 
similar findings were noted with an influenza B recombinant vaccinia virus vaccine, 
containing either an egg-derived or a MDCK-derived HA (Katz, Naeve, and Webster, 1987; 
Rota, Shaw, and Kendal, 1989; Rota, Shaw, and Kendal, 1987). H1N1 inactivated vaccines 
prepared from viruses grown in eggs or MDCK cells were similarly immunogenic in ferrets, 
guinea pigs and hamsters, although the MDCK vaccine induced antibodies that were more 
broadly cross-reactive when measured by single-radial-haemolysis (Wood et al., 1989). In 
hamsters higher rates of protection against homologous challenge were obtained with the 
MDCK vaccine. Antigenically distinct egg-grown H3N2 variants have been shown to be 
equally immunogenic and protective after homologous or heterologous challenge in mice 
(Johansson and Kilbourne, 1992). A comparison of inactivated, whole H3N2 vaccines 
prepared from viruses grown in eggs or MDCK cultures revealed that both vaccines induced 
cross-reactive neutralising antibody in ferrets, although the MDCK vaccine induced higher 
antibody titres and greater protection against challenge by virus grown in either substrate 
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(Katz and Webster, 1989). The same clinical sample isolated and passaged in eggs or MDCK 
cells resulted in two egg-grown variants while the cell culture grown viruses retained identical 
HA1 sequence to that present in the original clinical isolate. One egg-adapted variant with a 
single amino acid substitution (glutamine to lysine at position 156 in the HA) resulted in a 
lowered response to an H3N1 inactivated reassortant vaccine in mice, as measured by B-cell 
responsiveness (Kodihalli et al., 1995). The other egg-adapted variant with a single 
substitution at a different HA1 location (HA Ile-186) was shown to induce an immune 
response similar to that observed with MDCK-grown viruses. Sub-unit egg-grown H1N1 
vaccines derived from viruses in the same clinical sample, one containing cell culture-like 
virus and the other an egg-like variant, induced high levels of cross-reactive protective 
antibodies. However, the cell culture-like virus induced higher levels of strain-specific 
antibody response (Newman et al., 1993). Analysis of H3N2 reference strains from the 
Centers for Disease Control and Protection (Atlanta, USA), the National Institute for Medical 
Research (Mill Hill, UK) and the Central Public Health Laboratory (Colindale, UK) over the 
period 1987-1989 and field strains from 1988-1990 revealed that 3 of 7 reference strains and 
all the egg-grown field strains contained virus variants (Gubareva et al., 1994). Only the 
MDCK-grown field strains had HA1 sequences identical to the original clinical isolates. 
When MDCK cells were co-infected with an excess of MDCK-derived virus over egg-
adapted virus, the progeny virus was largely egg-adapted (Robertson et al., 1995). 
 
In summary, the growth of influenza viruses in embryonated eggs selects variants with amino 
acid changes in the HA close to the receptor-binding pocket. Some substitutions result in 
variants that are antigenically distinct from the parental viruses isolated from clinical material. 
Egg-adaptation can confer a growth advantage due to an increased capacity of the variant to 
bind and internalise during the early events of infection. Virus sub-populations selected 
during egg passage include a number of variants some of which may be similar to those in the 
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clinical isolate. Egg-grown viruses used as vaccine seeds or for epidemiological surveillance 
may be unrepresentative of the viruses present in clinical isolates. The effect of egg-
adaptation on immune responses to vaccines appears to vary according to the location of the 
amino acid substitution(s) present after egg passage. Although selection of variants does not 
usually occur after passage in mammalian cell culture, it would be prudent to monitor for 
changes, especially when considering viruses for use as vaccine seeds. 
 
1.6 CELL CULTURE & THE GROWTH OF INFLUENZA VIRUSES 
1.6.1 Primary cell lines 
The growth of influenza viruses in cell cultures was initially investigated as a tool for research 
into their genetic, biochemical and biological properties. Studies with primary cultures 
prepared from foetal pig lungs, pig kidneys, calf kidneys, monkey kidneys, chicken embryo 
fibroblasts, chicken and chicken embryo kidneys produced variable results and many were 
difficult to prepare (Lehmann-Grube, 1964). The addition of crystalline trypsin improves the 
yield in cell lines that lack specific host proteases necessary for the proteolytic cleavage of 
HA to produce infectious virus (Klenk et al., 1975). The use of primary cell lines presents a 
number of drawbacks including the availability and cost of source organs, batch variation and 
their potential for contamination with adventitious agents (Zambon, 1999). 
 
1.6.2 Continuous cell lines 
Some continuous lines of epithelial origin do support the growth of influenza viruses, in the 
presence of added trypsin to levels approximating those achieved by primary epithelial cells 
(Govorkova et al., 1995; Tobita et al., 1975). These cells can be maintained frozen and 
expanded for large-scale use as required. 
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1.6.2.1 The MDCK cell line 
The MDCK cell line was derived from the kidney of a normal female cocker spaniel in 1958 
(Gaush, Hard, and Smith, 1966). This cell line has been extensively studied as it provides an 
excellent model for the study of kidney function and epithelial development (Simmons, 
1982). MDCK cells exhibit differentiated kidney-specific transport properties and retain their 
ability to regenerate kidney tubular-structures under appropriate conditions (Rindler et al., 
1979). In addition, MDCK cells have a polarised morphology, forming two-sided 
asymmetrical sheets with distinct apical and basolateral surfaces (Cereijido et al., 1978; 
Misfeldt, Mamamoto, and Pitelka, 1979). Biosynthetic pathways sort proteins and lipids into 
transport vesicles destined for either the apical or basolateral surface (Lin et al., 1998; 
Wandinger-Ness et al., 1990). When grown on non-permeable supports, such as plastic cell 
culture plates, MDCK cells are not fully polarised as only the apical surface is exposed to the 
culture medium (Butor and Davoust, 1992). However, this does not affect influenza virus 
growth in anchorage-dependent cell culture as budding and release only takes place from the 
apical plasma membrane (Boulan and Sabatini, 1978; Matlin and Simons, 1984). MDCK cells 
have been used for the plaque assay of influenza A and B viruses since the mid-1960’s and 
are commonly used for the clinical isolation of influenza viruses (Gaush and Smith, 1968; 
Meguro et al., 1979; Tobita, 1975; Tobita et al., 1975). 
 
A number of experimental MDCK-grown vaccines have been developed and have been 
reported to be safe, well-tolerated and immunogenic in healthy young adults, the elderly and 
in children (Brands, Palache, and van Scharrenburg, 1996; Brands et al., 1999; Halperin, 
Nestruck, and Eastwood, 1998; Palache, Brands, and van Scharrenburg, 1997; Palache et al., 
1999). A meta-analysis of vaccines prepared from viruses grown in MDCK cultures and 
trialled in 1995-1996 indicated that levels of reactogenicity were comparable to others 
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prepared from egg-grown viruses that both fulfilled European criteria based on serum 
responses (Palache et al., 1999). Solvay Pharmaceuticals have approval from Dutch 
regulatory authorities for the production of an MDCK-grown influenza vaccine in the 
Netherlands and are attempting to obtain registration throughout Europe and in the US. The 
Chiron Corporation has developed an influenza vaccine using MDCK cells grown in 
suspension and is currently seeking European registration. An MDCK-derived live ca 
attenuated trivalent influenza vaccine, prepared on microcarriers in a 10L culture vessel, was 
shown to be genetically stable and clinical trials are planned (Ghendon et al., 2005). 
1.6.2.2 The Vero cell line 
The African Green monkey kidney (Vero) cell line was first established in Japan in 1962 for 
the study of the simian virus SV-40. It was transferred to the American Type Culture 
Collection at the 113th passage (Montagnon, Vincent-Falquet, and Saluzzo, 1999). Accredited 
preparations of the Vero cell line have been used in the preparation of poliomyelitis and 
rabies vaccines for over 20 years as more satisfactory alternatives to primary monkey kidney 
cells (Montagnon, 1989). Initial studies indicated that influenza viruses grew poorly in Vero 
cells (Lau and Scholtissek, 1995; Nakamura and Homma, 1981). Improvements in yields 
were later obtained by the addition of trypsin to the cultures, and Vero cells are now 
considered suitable for use in clinical isolation and for the growth of vaccine viruses 
(Govorkova et al., 1995; Govorkova et al., 1996; Kaverin and Webster, 1995). 
 
Vero-grown vaccines have been studied in animal models. Inactivated whole vaccines were 
shown to be as immunogenic as egg-grown vaccines in mice and chimpanzees. Analysis of 
the chimpanzee serological responses to the Vero derived vaccines showed that rates of 
seroconversion, geometric mean titre increase and percentage of subjects achieving a 
protective titre all met human European guidelines (Kistner et al., 1998; Kistner et al., 1999). 
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When delivered as a live intranasal vaccine, Vero-grown whole virus vaccines induced levels 
of influenza specific secretory IgA levels that were comparable to commercially available 
egg-grown whole vaccines. The cell-mediated immunity induced was significantly higher in 
mice receiving Vero-derived compared with egg-derived vaccines, as determined by 
proliferation and cytokine release assays (Bruhl et al., 2001). Baxter International Inc has new 
facilities in Austria and the Czech Republic for the production of an inactivated Vero-grown 
influenza vaccine, InfluJect. InfluJect was approved for use in the Netherlands in 2002 and 
the company is seeking registration in other European countries and the US. 
 
Live ca influenza A vaccines have been produced in the Vero cell line, using a donor strain 
adapted to growth at 25°C in Vero cells (Romanova et al., 2004). The donor strain retained ts 
phenotype and attenuation properties in mice, and was protective in ferrets against a wt 
challenge. H1N1 and H2N2 ca reassortants using the ca Vero-grown donor strain and 
prepared in the Vero line were shown to be safe, well tolerated and suitably immunogenic in a 
small group of healthy adults.  
1.6.2.3 Other cell lines 
The diploid cell line MRC-5 (normal human foetal lung fibroblast) has been evaluated as a 
substrate for influenza growth. Yields of the ca donor strain A/Ann/Arbor/6/60 of 106-107 
TCID50 per mL of culture fluid were obtained in primary chicken kidney and chicken embryo 
kidney cells while yield from the MRC-5 line was about 100 fold less (Tannock, Bryce, and 
Paul, 1985). A porcine lung epithelial cell line established from a normal 4-week old female 
Yorkshire pig (SJPL) supports the growth of influenza A and B viruses, with titres for a 
number of human influenza viruses of 2 - 6.5 log10 TCID50 (Seo et al., 2001). 
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The Vero and most MDCK cell lines are anchorage-dependent and require propagation on 
plastic surfaces or suspended microcarriers. Recently, some non anchorage-dependent cell 
lines have been evaluated which support the growth of influenza viruses. The PER.C6, BHK-
21/BRS and Chiron MDCK lines are anchorage-independent and have been developed for the 
growth of vaccine viruses in the absence of serum. They can be rapidly expanded for growth 
in bioreactors and are potentially more suited to rapid scale-up than anchorage-dependent 
lines. The PER.C6 line has been prepared from a human foetal retinoblasts which have been 
immortalised by transfection with an E1 minigene of adenovirus type (Fallaux et al., 1998). 
The PER.C6 line can be propagated to high concentrations and supports the growth of 
influenza viruses to titres comparable with those attainable in eggs (Pau et al., 2001). 
Production processes suitable for a PER.C6-derived influenza vaccine are currently in 
development (Kapteyn et al., 2006). The BHK-21/BRS line is used for the preparation of 
veterinary vaccines but yields of influenza viruses are relatively low (Merten et al., 1999) 
Acceptability of transformed cell lines as a substrate is dependent on the particular cell line 
and its passage history. Acceptability criteria also vary according to individual regulatory 
authorities. 
 
1.6.3 Serum- and protein-free media 
The growth of cells in culture requires the use of medium that provides all the components 
necessary for cell attachment, proliferation and normal function. Serum, usually foetal calf 
serum (FCS), has been regarded as a critical supplement to medium to achieve growth in 
culture. Serum provides a complex mixture of hormones, growth factors, carrier proteins, 
attachment and spreading factors, and nutrients (Griffiths, 1987). However, its use presents 
problems that arise from lot variability, presence of undefined components, cost and the 
possible introduction of contaminating agents (Merten, 2002). Contamination by fungi, 
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bacteria, viruses or the agents of transmissible spongiform encephalopathies (TSE) has raised 
regulatory concerns for the safety of human vaccines. The first step towards avoiding these 
problems was the development of serum-free (SF) media, although many such formulations 
still contain animal or human-derived proteins, including peptones, hydrolysates and albumin 
fractions (Keay, 1978). Animal- and human-derived proteins can also be replaced by 
synthetic, recombinant or plant proteins. The use of chemically defined protein-free media 
minimises risks from TSE and viruses but development is complicated and usually depends 
on specific requirements for particular cell lines (Merten, 2002). 
 
1.7 CONCLUSIONS & RESEARCH AIMS 
Despite great advances in recent years, influenza remains a disease of major public health 
significance. Currently the most effective measure for protection against the disease is the use 
of annually updated vaccines. As new influenza A isolates used to prepare vaccine seeds often 
grow poorly in eggs, attempts must be made to enhance their growth characteristics, usually 
by the use of seeds prepared by reassortment of current epidemic strains with donor strains of 
high growth potential. Reassortant viruses contain the surface glycoproteins of specified 
epidemic strains and the internal genes of a high-yielding egg-adapted strain, most often the 
H1N1 strain A/PR/8. Although reassortment of influenza B viruses for the preparation of 
seeds for inactivated vaccines is not usually undertaken due to the lack suitable donor strains, 
such an approach could improve vaccine yields, lower costs and introduce a further element 
of predictability to vaccine manufacture. The growth of influenza viruses in eggs selects egg-
adapted variants which may be antigenically distinct from the original parent strain. In 
addition, the supply of fertile eggs is limited and long-term planning is necessary to 
significantly increase egg supply to rapidly increase the supply of vaccines. Such increases 
can be adversely affected by the sudden and unpredictable occurrence of avian diseases in 
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flocks. Another consideration is the unsuitability of egg-grown vaccines for those with egg 
allergies. The use of stable cell lines for vaccine virus growth would largely overcome these 
problems, if yield and safety issues could be successfully addressed. 
 
The research aims of this project were: 
 
1) To develop and evaluate potential influenza B donor strain(s) for the preparation of 
reassortant vaccine seeds. 
 
2) To prepare reassortants using the potential donor strains and compare them with the 
parental donor and epidemic strains. 
 
3) To evaluate the growth of influenza B epidemic strains, potential donor strain (s) and 
reassortant viruses in serum-free and serum-containing cell culture 
 
4) To compare the yields of influenza B epidemic strains, potential donor strain (s) and 
reassortant viruses obtained in cell culture and in eggs. 
 
 ________________________________________________________________ 
CHAPTER TWO: 
MATERIALS & METHODS 
 
 
 
 
___________________________________________________________________________ 
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2.1 CHEMICALS 
 
Acetic acid, glacial (AnalaR) BDH Chemicals, Poole, UK 
Acetone (AnalaR) BDH Chemicals, Poole, UK 
Agarose (bacteriological grade) Oxoid, Basingstoke, Hampshire, UK 
Agarose (Molecular biology grade)  Promega Corp., Annandale, NSW, Australia 
Ammonium iron (III) sulphate dodecahydrate  
(NH4)Fe(SO4)2.12H2O 
Sigma Aldrich Corp., St.Louis, MO, USA 
Ampicillin Roche Diagnostics Australia Pty. Ltd., Castle 
Hill, NSW, Australia 
Amphotericin B (Fungizone)  Sigma Chemical Co., St.Louis, MO, USA 
Bromophenol Blue Asia Pacific Specialty Chemicals Ltd. 
Seven Hills, NSW, Australia 
Calcium chloride BDH Chemicals, Poole, UK 
Citric acid (AnalaR) BDH Chemicals, Poole, UK 
DMEM/F12, Dulbecco’s Modified Eagle 
Medium: Nutrient Mixture F-12 (Ham) 1:1 
Gibco-BRL Life Technologies, Grand Island, 
NY, USA 
dimethylsulphoxide (DMSO) (AnalaR) BDH Chemicals, Poole, UK 
Eagle’s modified minimum essential medium 
(MEM) 
Trace Bioscience Pty. Ltd., Castle Hill, NSW, 
Australia 
Epidermal growth factor, human recombinant Sigma Aldrich Corp., St.Louis, MO, USA 
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Ethanol (AnalaR) BDH Chemicals, Poole, UK 
Ethylenediamine tetra-acetic acid (EDTA), 
disodium salt, molecular biology grade 
Research Organics Inc., Cleveland, OH, USA 
Evans Blue ICN Biomedicals, Seven Hills, NSW, 
Australia 
EX-CELL™ MDCK Serum-free medium JRH Biosciences Pty Ltd, Brooklyn, VIC, 
Australia 
D-glucose (AnalaR) BDH Chemicals, Poole, UK 
L-glutamine, 200 mM, supplied in 0.85% NaCl Gibco-BRL Life Technologies, Grand Island, 
NY, USA 
Glycerol (AnalaR) BDH Chemicals, Poole, UK 
Hepes:[N-2-Hydroxyethylpiperazine-N'-(2-
ethanesulphonic acid)]  
Research Organics Inc., Cleveland, OH, USA 
Hydrocortisone, water soluble, cell culture 
tested 
Sigma Aldrich Corp., St.Louis, MO, USA 
Ilium xylazil-20 [200 mg mL-1 2-(2,6-
xylidino)-5,6-dihydro-4H-1,3-thiazine 
hydrochloride] 
Troy Laboratories, Smithfield, NSW, Australia 
Insulin, sodium salt, human, recombinant 
expressed in E.coli. Cell culture tested 
Sigma Aldrich Corp., St.Louis, MO, USA 
Isopropanol Sigma Aldrich Corp., St.Louis, MO, USA 
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Isopropylthio-β-galactosidase (IPTG) Promega Corp., Madison, WI, USA 
Ketamil (100 mg mL-1 ketamine 
hydrochloride) 
Troy Laboratories, Smithfield, NSW, Australia 
Methanol (AnalaR) BDH Chemicals, Poole, UK 
Neutral Red, cell culture tested Sigma Chemical Co., St.Louis, MO, USA 
Nuclease-free water ICN Biomedicals, Seven Hills, NSW, 
Australia 
Opti PRO-SFM Gibco-BRL Life Technologies, Grand Island 
NY, USA 
Penicillin G CSL Ltd., Parkville, VIC, Australia 
Potassium acetate BDH Chemicals, Poole, UK 
Potassium chloride Ajax Chemicals, Auburn, NSW, Australia 
Potassium dihydrogen orthophosphate 
(AnalaR) 
BDH Chemicals, Poole, UK 
Sodium dodecyl sulphate (SDS); (AnalaR) BDH Chemicals, Poole, UK 
Sodium bicarbonate (AnalaR) BDH Chemicals, Poole, UK 
Sodium chloride (AnalaR) BDH Chemicals, Poole, UK 
Sodium citrate dihydrate (AnalaR) BDH Chemicals, Poole, UK 
di-sodium hydrogen orthophosphate 
(anhydrous) 
BDH Chemicals, Poole, UK 
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Sodium hydroxide Asia Pacific Specialty Chemicals Ltd., 
Seven Hills, NSW, Australia 
Soybean trypsin inhibitor Sigma Aldrich Corp., St.Louis, MO, USA 
Streptomycin sulphate CSL Ltd., Parkville, VIC, Australia 
Tris ((hydroxy methyl) methyl amine) AMRESCO, Solon, OH, USA 
Trypan Blue ICN Biomedicals Seven Hills, NSW, Australia 
Trypsin, 2.5% 
Cat.No. 15090-046 
Gibco-BRL Life Technologies, Grand Island 
NY, USA 
Trypsin (2x crystallized bovine pancreas) 
Cat.No. 101179 
ICN Biomedicals Seven Hills, NSW, Australia 
Tryptone Oxoid, Basingstoke, Hampshire, UK 
VP-SFM serum-free medium Gibco-BRL Life Technologies, Grand Island 
NY, USA 
X-Gal: [5-bromo-4-chloro-3-indolyl-β-D-
galactoside] 
Astral Scientific, Gymea, NSW, Australia 
Xylene cyanol FF Sigma Aldrich Corp., St.Louis, MO, USA 
Yeast extract Oxoid, Basingstoke, Hampshire, UK 
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2.2 BIOLOGICALS 
 
2.2.1 Virus stocks 
B/Lee/40, B/Panama/45/90, B/Johannesburg/5/99 and A/PR/8/34 were kindly provided by Ms 
Marta Swiderska, Dr Mike Hocart and Mr Peter Schoofs, Influenza Process Development 
Department, CSL Ltd, Parkville, VIC, Australia. All other influenza viruses were kindly 
provided by Professor Greg Tannock, School of Applied Sciences, RMIT University, VIC, 
Australia. 
 
2.2.2 Cell lines 
The MDCK cell line used (X1274 MDCK, Seed Lot dated 27/08/2001) was kindly provided 
by Mr Julian Keane, Fermentation & Purification Development, CSL Research and 
Development, Parkville, VIC, Australia. These cells were tested and known to be 
mycoplasma free.  
 
2.2.3 Bacterial strains 
The DH5α strain of Escherichia coli used for cloning was kindly provided by Dr George 
Moutafis, School of Applied Sciences, RMIT University, VIC, Australia. 
 
2.2.4 Serum 
Foetal calf serum (FCS) was purchased from ThermoTrace Ltd, Melbourne, VIC, Australia. 
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2.2.5 Red blood cells 
Chicken red blood cells (RBCs) were kindly provided by Ms Marta Swiderska, Mr Peter 
Schoofs and Ms Ann Curtis, Influenza Product Development, CSL Ltd, Parkville, VIC, 
Australia. 
 
2.2.6 Embryonated chicken eggs 
Specific-pathogen-free (SPF) chicken eggs were purchased from SPAFAS Australia Pty. Ltd., 
Woodend, VIC, Australia. Non-SPF eggs were purchased from Research Poultry, Research, 
VIC, Australia. 
 
2.2.7 SPF chickens 
Five-week old SPF chickens (White Leghorn strain) were purchased from SPAFAS Australia 
Pty. Ltd., Woodend, VIC, Australia. 
 
2.2.8 Monoclonal antibodies 
Mouse anti-influenza A monoclonal antibody (specific for nucleoprotein) and mouse anti-
influenza B antibody (specific for both nucleoprotein and haemagglutinin) were purchased 
from Chemicon International, Temecula, CA, USA. 
 
2.3 BUFFERS & STOCK SOLUTIONS 
All buffers and stock solutions were prepared using Milli-Q® water, unless otherwise stated. 
 
2.3.1 General solutions 
Evans Blue: 1% (w/v) in PBS, stored at 4°C. 
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Phosphate buffered saline (PBS): 0.14 M NaCl. 30 mM KCl, 82.1 mM Na2HPO4.12H2O, 14.7 
mM KH2PO4, pH 7.2. 
Trypan Blue: 0.4% (w/v), stored at 4°C. 
 
2.3.2 Cell culture 
Citrate saline: 0.1 M NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 10 mM D-glucose, 3.0 mM 
sodium citrate. 
Chicken embryo kidney (CEK) trypsinizing solution: citrate saline containing 100 U mL-1 
penicillin, 100 µg mL-1 streptomycin, 1 µg mL-1 amphotericin B and 0.125% (w/v) trypsin II. 
Neutral Red: 0.1% (w/v), stored wrapped in foil at 4°C. 
Soybean trypsin inhibitor: 0.25% (w/v) in PBS. 
Trypsin I: crystallized bovine pancreas grade, stock solution containing 0.1% (w/v) in PBS. 
Trypsin II: 2.5% (w/v) trypsin in PBS. 
Trypsin/EDTA: 0.5 mM EDTA, 0.25% (v/v) trypsin II, prepared in PBS. 
 
2.4 MEDIA 
All media were prepared using Milli-Q® water, unless otherwise stated. 
 
2.4.1 Mammalian cell culture media 
MEM Growth medium (G-MEM): 
Eagle’s modified minimal essential medium (MEM) supplemented with 1.0 M Hepes (pH 
6.8), 0.14% (w/v) sodium bicarbonate, 5% (v/v) foetal calf serum (FCS), 100 U mL-1 
penicillin, 100 µg mL-1 streptomycin, and 1 µg mL-1 amphotericin B. 
 
MEM Maintenance medium (M-MEM): 
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MEM supplemented with 1.0 M Hepes (pH 6.8), 0.14% (w/v) sodium bicarbonate, trypsin(I)1 
µg mL-1, 100 U mL-1 penicillin, 100 µg mL-1 streptomycin, 1 µg mL-1 amphotericin B. 
 
 
Serum-containing cell freezing medium (SC-CFM): 
MEM supplemented with 15% (v/v) FCS, 0.14% (w/v) sodium bicarbonate, 10% (v/v) 
dimethylsulphoxide (DMSO), 100 U mL-1 penicillin, 100 µg mL-1 streptomycin, 1 µg mL-1 
amphotericin B. 
 
VP-SFM: commercially available serum-free medium (Gibco-BRL Life Technologies, Grand 
Island NY, USA) formulated without human- or animal-derived components, supplemented 
with 4 mM L-glutamine. 
 
SF1: serum-free medium modified from a previously described formulation (Taub et al., 
1979). DMEM/F12 (1:1) supplemented with 10 ng mL-1  epidermal growth factor, 5 µg mL-1 
insulin, 0.5 µg mL-1 ammonium iron (III) sulphate dodecahydrate, 50 nM hydrocortisone and 
4 mM L-glutamine. Formulated without human- or animal-derived components. 
 
OPTI-PRO SFM: commercially available serum-free medium (Gibco-BRL Life 
Technologies, Grand Island NY, USA) formulated without human- or animal-derived 
components, supplemented with 4 mM L-glutamine. 
 
EX-CELL MDCK: commercially available serum-free medium (JRH Biosciences Pty Ltd, 
Brooklyn, VIC, Australia.) formulated without human- or animal-derived components, 
supplemented with 4 mM L-glutamine. 
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EX-CELL MDCK Maintenance medium : 
EX-CELL MDCK supplemented with4 mM L-glutamine and trypsin(I)1 µg mL-1 
 
Serum-free cell freezing medium (SF-CFM): EX-CELL MDCK supplemented with 10% 
DMSO. 
 
2.4.2 Bacterial culture media 
SOC medium: 2% (w/v) Bacto tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 2 mM glucose, 0.5% yeast extract. 
 
Luria-Bertani (LB) broth: 1% (w/v) Bacto tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract. 
 
LB agarose: 1% (w/v) Bacto tryptone, 1% (w/v) NaCl, 0.5% (w/v) yeast extract, 1.5% (w/v) 
agarose (bacteriological grade). 
 
Ampicillin: 5 mg mL-1 stock solution, used in LB broth and LB agarose at a final 
concentration of 100 µg mL-1. 
 
IPTG: 0.1 M stock, used in LB agarose at a final concentration of 0.5mM. 
 
X-gal: 50 mg mL-1 stock solution, used in LB agarose at a final concentration of 80 µg mL-1. 
 
2.5 AGAROSE OVERLAYS 
Nutrient overlay for plaque assays: 
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Equal proportions of 2x MEM medium and 1.8% (w/v) molecular biology grade agarose plus 
0.2% (v/v) trypsin I. 
 
Staining overlay for plaque assays: 
42% (v/v) 2x MEM medium, 50% (v/v) molecular biology grade agarose (1.8% w/v), 8% 
(v/v) 0.1% Neutral Red. 
 
2.6 MOLECULAR BIOLOGY KITS 
ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit ver 3.1 (PE 
Applied Biosystems, Foster City, CA, USA). 
pGEM -T Easy Vector System (Promega Corporation, Madison, WI, USA). 
QIAamp Viral RNA Mini Kit (QIAGEN GmbH, Hilden, Germany). 
QIAquick PCR purification Kit (QIAGEN GmbH, Hilden, Germany). 
SuperScript One-Step RT-PCR with Platinum Taq System (Invitrogen life technologies). 
Wizard Plus SV Minprep DNA Purification System (Promega Corporation, Madison, WI, 
USA). 
 
2.7 ENZYMES 
RNase A Roche Diagnostics GmbH, Mannheim, 
Germany 
Receptor-destroying enzme (RDE) – Denka 
Seiken II 
Blackaby Diagnostics, Darlington, WA, 
Australia 
NciI Promega Corporation, Madison, WI, USA 
BamHI Promega Corporation, Madison, WI, USA 
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HindIII Promega Corporation, Madison, WI, USA 
PstI Promega Corporation, Madison, WI, USA 
BglII Promega Corporation, Madison, WI, USA 
DraI Promega Corporation, Madison, WI, USA 
ScaI Promega Corporation, Madison, WI, USA 
HaeIII Promega Corporation, Madison, WI, USA 
 
 
2.8 OLIGONUCLEOTIDES 
Oligonucleotides were purchased as desalted preparations at concentrations of 40-50 nmol, 
from either Gibco-BRL Life Technologies, Grand Island, NY,USA (Gibco) or Geneworks 
Pty. Ltd., Thebarton, SA, Australia (Geneworks) (Table 2.1). 
 
Table 2.1 Oligonucleotides 
PRIMER SEQUENCE (5’ TO 3’) SYNTHESISED 
BY 
HA-FOR2 CTA ATA TCC ACA AAA TGA AGG C Gibco 
HA-REV2 CGT TTC TTT GTA ATG GTG ACA AG Gibco 
NA-FOR2 CAT ATT CTT AGA ACT GAA GTG AAC 
AGG 
Gibco 
NA-REV2 CAG AAA CAA TTA AAT CTA GTA AGA 
ACA AC 
Gibco 
NA-FRAG-FOR TGA CCC ATT ATG CAG CTC AG Geneworks 
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NA-FRAG-REV GCA GGC ACT TTC TTG TGT TC Geneworks 
M-FOR2 CAC TTT CTT AAA ATG TCG CTG TTT G Gibco 
M-REV2 CCA GTT TTA TTC ACT GAC ATT GAT 
TAC 
Gibco 
PB1-FRAG-FOR TGA CCC ATT ATG CAG CTC AG Geneworks 
PB1-FRAG-REV TGG CTG TTT GTG CCG TTG CT Geneworks 
PB2-FRAG-FOR CAG CAG TTA CCT GGT GGA AT Geneworks 
PB2-FRAG-REV ACA GGC TAC ATC ACC TCC AT Geneworks 
PA-FRAG-FOR GCA GAC TCA CAG AAC TTC AG Geneworks 
PA-FRAG-REV CCA AGC AGC CAC TCT ACA TT Geneworks 
PRIMER SEQUENCE (5’ TO 3’) SYNTHESISED 
BY 
NS-FOR1 AGG ATT TAT TTA GTC ACT CGC AAA C Geneworks 
NS-REV1 TTC ATA AGC ACT GCC TGC TGT AC Geneworks 
NP-FRAG3-FOR GGC TGC AAC TGA TGA CAA GA Geneworks 
NP-FRAG3-REV CCG AAG CAC GAC ATG AAG AA Geneworks 
SP6 ATT TAG GTG ACA CTA TAG AA Geneworks 
T7 GTA ATA CGA CTC ACT ATA GGG C Geneworks 
 
2.9 ANAESTHESIA 
Immediately prior to cardiac bleeding, a solution consisting of ketamine (16.7 mg mL-1) and 
xylazine (10 mg mL-1) was administered to chickens by wing vein inoculation. The solution 
was used at a dose of 0.5 mL kg-1 bodyweight. 
 
2.10 IMMUNOFLUORESCENCE REAGENT 
Cell fixing solution: 50% (v/v) methanol, 50% (v/v) acetone. 
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2.11 MOLECULAR BIOLOGY REAGENTS 
Alkaline lysis miniprep solution 1: 5.0 mL 1 M Tris-HCl pH 8, 2.0 mL 0.5 M EDTA, 1.0 mL 
Rnase A (5 mg mL-1) mixed and dissolved in water to a final volume of 100mL. 
 
Alkaline lysis miniprep solution 2: 4.0 mL 5 M NaOH, 10 mL 10% SDS mixed and dissolved 
in water to a final volume of 100 mL. 
 
Alkaline lysis miniprep solution 3: 60 mL 5 M Kac, 11.5 mL glacial acetic acid mixed and 
dissolved in water to a final volume of 100 mL. 
TAE buffer: 0.04 M Tris-acetate, 1.0 mM EDTA. 
 
DNA markers: 1Kb DNA Plus Ladder (Gibco-BRL Life Technologies, Grand Island, NY, 
USA). 
 
DNA loading buffer (6x): 0.25% (w/v) Bromophenol Blue, 0.25% (w/v) xylene cyanol, 30% 
(v/v) glycerol. 
 
 
2.12 EQUIPMENT 
Analytical balance: Sartorius BP 210S Sartorius AG, Goettingen, Germany 
Biological Safety Cabinet Class II LAF Technologies, North Ringwood, VIC, 
Australia 
Cell culture T-flasks (25, 75 &175 cm2) Greiner Laboratechnik, GmbH, 
Frickenhausen, Germany 
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Cell culture plates (6- & 24-well) Greiner Laboratechnik, GmbH, 
Frickenhausen, Germany 
CO2 incubators: Sanyo MCO-17AI Quantum Scientific Pty. Ltd, QLD, 
Australia 
Centrifuge, benchtop: Sigma 3K10 Quantum Scientific Pty. Ltd, QLD, 
Australia 
Centrifuge, Avanti J.25I, rotor: JLA-16.250 Beckman Coulter, Fullerton, CA, USA 
Dry block heater: Ratek Labquip Technologies, Boronia, VIC, 
Australia 
Eppendorf centrifuge: Sigma 1-5 Quantum Scientific Pty. Ltd, QLD, 
Australia 
Egg incubators Multiplo Pty. Ltd., Sydney, NSW, Australia 
Electroporator Bio-Rad Laboratories Pty. Ltd., Regents 
Park, NSW, Australia 
Gel Doc 1000 Imaging System Bio-Rad Laboratories Pty. Ltd., Regents 
Park, NSW, Australia 
Gel electrophoresis equipment Bio-Rad Laboratories Pty. Ltd., Regents 
Park, NSW, Australia 
Inverted microscope: Olympus IMT-2 Olympus Optical Corporation Ltd., Tokyo, 
Japan 
Microtitre plate (V-bottom), 96-well Greiner Laboratechnik, GmbH, 
Frickenhausen, Germany 
Phase-contrast microscope Olympus Optical Corporation Ltd., Tokyo, 
Japan 
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Spectrophotometer: Cary 50 Bio Varian Deutschland GmbH, Darmstadt,  
Germany 
Thermocycler: GeneAmp PCR system 2400 The Perkin-Elmer Corporation, Norwalk, 
CT, USA 
UV microscope: Nikon Diaphot Nikon Corporation, Tokyo, Japan 
 
 
 
 
2.13 METHODS 
2.13.1 Cell Culture 
2.13.1.1 Viable cell counts 
Cells were counted in suspension using the method of Absher (Absher, 1973). An aliquot of 
cell suspension was diluted 1:10 and 1:100 in 0.4% (w/v) Trypan Blue. The cells were then 
transferred to a Neubauer haemocytometer and viable cells were counted in 5 squares, each of 
10-4 mL, and averaged. The following formula was used to calculate viable cell number: cell 
count = average cell number x dilution factor x 104 cells mL-1. 
 
2.13.1.2 Freezing cells 
Near-confluent cell monolayers were harvested from flasks using trypsin/EDTA solution. 
After detachment, the cell suspensions were centrifuged at 1200 x g for 5 min and the 
trypsin/EDTA poured off. Cells were then gently resuspended in a small volume of SC-CFM 
or SF-CFM (Section 2.4.1) and an aliquot taken for viable cell counting (Section 2.13.1.1). 
Cells were diluted to 2 x 106 cells mL-1 in CFM and dispensed into aliquots. After freezing, 
the aliquots were kept in liquid nitrogen for long-term storage. 
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2.13.1.3 Thawing cells 
An aliquot of the required cell line was removed from LN2 and rapidly thawed in a 37°C 
waterbath. The thawed cells were added to 10 mL of warmed G-MEM (Section 2.4.1) and the 
suspension transferred to a 25 cm2 flask. After 4 h, the medium was removed and replaced 
with fresh growth medium to remove residual DMSO. 
 
2.13.1.4 Serum-containing (SC) MDCK cell culture 
Stock MDCK cells required for growth experiments and plaque assays were grown in 75 cm2 
or 175 cm2 cell culture flasks containing G-MEM at 37°C in a 5% CO2 incubator. Cells were 
grown to near-confluence and were dispersed using trypsin/EDTA and subcultured at split 
ratios of 1:3 - 1:5. Cells were maintained as seed lots for 30-40 subcultures. 
 
2.13.1.5 Serum-free (SF) MDCK cell culture 
Stock MDCK cells required for SF growth experiments were grown in 75 cm2 or 175 cm2 cell 
culture flasks containing EX-CELL MDCK medium at 37°C in a 5% CO2 incubator. Cells 
were grown to near-confluence, dispersed using trypsin/EDTA and subcultured at split ratios 
of 1:2 - 1:5. Trypsin/EDTA activity was inhibited by incubation for 5 min at RT with soybean 
trypsin inhibitor (Section 2.3.2). 
 
2.13.1.6 Preparation of primary chicken embryo kidney (CEK) cells. 
Kidneys were removed from 17-18 day old chicken embryos and used to prepare primary 
kidney (CEK) cultures, as previously described (Tannock, Bryce, and Paul, 1985). Briefly, the 
kidneys were washed twice with citrate saline and minced finely before incubating overnight 
at 4°C in Trypsinizing Solution (Section 2.3.2, ~10 mL per embryo). On the following 
morning the trypsinized kidney suspension was shaken gently for 3 min, then filtered through 
sterile 100 µM stainless steel filters. The filtrate was then centrifuged at 700 x g for 5 min. 
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Cell pellets were washed with ice-cold PB, centrifuged at 700 x g for 5 min and the packed 
cell volume was estimated. The supernatant was removed and the cells resuspended in a small 
volume of warmed G-MEM. This suspension was poured through sterile 100 µM stainless 
steel mesh filters, diluted 1:200 with G-MEM and dispensed into culture vessels, as required. 
 
2.13.2 Egg-passage of stock viruses. 
A frozen aliquot of virus was rapidly thawed and diluted 10-3 in PBS. Ten to eleven day-old 
(d.o) embryonated chicken eggs were then inoculated with 0.1 mL of diluted virus via the 
allantoic cavity, and incubated at 34°C. After 2 days, the eggs were chilled at 4°C overnight. 
The allantoic fluid was removed with a needle and syringe and clarified by centrifugation at 
5000 x g for 10 min. The supernatant was frozen in small aliquots at -80°C for later use as 
stock virus. 
 
2.13.3 Virus titration 
2.13.3.1 Plaque assays 
Plaque assays were performed using previously described methods (Tannock, Bryce, and 
Paul, 1985; Tannock, Paul, and Barry, 1984). Briefly, MDCK or CEK monolayers were 
prepared in 6-well cell culture plates using G-MEM and incubated at 37°C with 5% CO2. 
Once confluent, the cells were washed with PBS and inoculated with 200 µL of virus 
dilutions. After adsorption at RT for 30 min, 3 mL nutrient overlay were added to each well. 
Plates were then incubated at 34°C with 5% CO2 for 4 days, or for 10 days at 25°C. Plaques 
were counted after overnight incubation with staining overlay. Each assay was set up in 
triplicate and viral titres were expressed as mean plaque forming units (pfu) mL-1. 
 
2.13.3.2 Haemagglutination (HA) and Haemagglutination inhibition (HI) assays 
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Haemagglutination (HA) and haemagglutination inhibition (HI) assays were performed, as 
previously described (Palmer et al., 1975), using 96-well V-bottomed microtitre plates and 
0.5% chicken red blood cells. Plates were tilted at 45° to read the haemagglutination 
endpoints. The endpoint for HA assays was the reciprocal of the highest dilution at which 
complete haemagglutination could be detected. The endpoint for HI assays was the reciprocal 
of the highest dilution at which complete haemgglutination inhibition could be detected, using 
4HA units in 0.025mL (as determined by back titration) in all virus-serum mixtures.  
 
2.13.3.3 Egg Infectivity assay 
Ten to eleven day-old embryonated eggs were inoculated in quadruplicate with 0.1 mL of 
virus (diluted 10-5 – 10 –9 in PBS) via the allantoic cavity and incubated at 34°C. After 
incubation for 2 days at 34°C, the eggs were chilled at 4°C overnight. Fifty microlitres of 
allantoic fluid were removed from each egg with a separate pipette tip and transferred to wells 
of a 96-well V-bottomed microtitre plates. Fifty microlitres of 0.5% chicken red blood cells 
were then added per well and the plate shaken and held at RT for 30 min. Endpoints were 
determined according to the presence of haemagglutination, as described in Section 2.13.3.2. 
Viral titres were expressed as log10 egg infectious doses (EID50) mL-1 and were calculated by 
the method of Reed and Muench (Reed and Muench, 1938). 
 
2.13.3.4 Estimation of Tissue Culture Infectious Dose (TCID50) 
MDCK monolayers were prepared in 24-well plates using G-MEM, which were placed at 
37°C in a 5% CO2 incubator. Once confluent, the cells were washed with PBS and inoculated 
in quadruplicate with 100 µL of different virus dilutions. After adsorption at RT for 45 min, 
the inoculum was removed and 1 mL of M-MEM added to each well. The plate was then 
placed at 34°C in the 5% CO2 incubator for 5 days. The presence of CPE was detected using 
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an inverted microscope. Confirmation of the end-points was achieved by microscopic 
observation for haemadsorption after adding 0.05% chicken RBCs to each well. Each assay 
was set up in triplicate. Viral titres were expressed as mean log10 TCID50 mL-1 and were 
calculated by the method of Reed and Muench (Reed and Muench, 1938). 
 
2.13.4 Preparation of antisera in chickens 
Seven-week-old SPF chickens (White Leghorn) were inoculated via the wing vein with 5 mL 
of a 1:1 mixture of allantoic fluid and PBS. A booster dose was given 3 weeks later. One 
week later all chickens were exsanguinated. Individual bloods were held in a waterbath at 
37°C for 1-2 h and then at 4°C overnight. On the following morning each was centrifuged at 
5000 x g for 10 min at 4°C. Serum was then removed, dispensed into smaller aliquots and 
stored at -80°C. 
 
2.13.5 Neutralisation of donor strain viruses with chicken antisera 
CEK monolayers were prepared in 6-well plates (Section 2.13.1.6) using G-MEM. Doubling 
dilutions of polyclonal antisera (1:20 – 1:10,240) were prepared in PBS. Virus (titre of 5-6 log 
PFU) was added to an equal volume of each antiserum dilution and the mixture shaken and 
held at 4°C overnight.Each antiserum dilution was added to one well of a 6-well plate, with 2 
plates required for each assay. Cells were washed with PBS and individual wells were 
inoculated with each virus-antiserum mixture. After adsorption at RT for 30 min, 3 mL 
nutrient overlay were added per well and the plates were placed in a 5% CO2 incubator for 4 
days at 34°C. A staining overlay was then added and, after overnight incubation, plaques were 
counted. Endpoints were determined as the highest antiserum dilution at which plaque 
formation was completely suppressed. The particular antiserum dilution was used in 
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coinfection experiments (Chapter 4), in order to remove the donor strain present in the 
mixture. 
 
2.13.6 Virus purification by chicken RBC adsorption/elution 
SPF chicken RBCs were washed three times in chilled PBS, and aliquots of virus-infected 
allantoic fluid were clarified by centrifugation at 3,000 g for 5 min at 4°C. Clarified virus was 
then added to chicken RBCs at a ratio of 3:2, mixed well and held on an ice slurry for 2 hr, 
with intermittent stirring. The mixture was then centrifuged at 1,000 g for 5 min at 4°C and 
the supernatant was discarded. The pellet was washed with chilled PBS and then centrifuged 
again at 1,000 g for 5 min at 4°C. The wash and centrifuge step was then repeated twice. A 
1:100 dilution of the chicken rbc’s was prepared in chilled PBS, 100µL of which was then 
inoculated into 10-11 d.o embryonated SPF eggs, and passaged as per Section 2.13.2. 
 
2.13.7 Immunofluorescence assay (IFA) 
MDCK monolayers were prepared in 24-well plates using G-MEM and placed at 37°C in a 
5% CO2 incubator. Once confluent, the monolayers were washed with PBS and 100 µL 
aliquots of virus inoculated to each well. After adsorption at RT for 30 min, 1 mL of M-MEM 
was added to each well and the plate placed in a 5% CO2 incubator for 2-3 days at 34°C. The 
presence of CPE was detected using an inverted microscope. Cells were fixed with cell-fixing 
solution (Section 2.10) and examined for viral antigen (nucleoprotein for influenza A and 
both nucleoprotein and HA for influenza B) by IFA. Briefly, cells were air-dried and 100 µL 
mouse anti-chicken influenza A or B monoclonal antibodies (Chemicon International, CA, 
USA) diluted 1:100 were added to the wells. Plates were held at 37°C for 30 min and the cells 
were then washed with PBS and air-dried. One hundred microlitres of fluorescein-conjugated 
secondary antibody (goat anti-chicken IgG, FITC-conjugated, Chemicon International) 
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diluted 1:20 in Evans Blue (Section 2.3.1) were then added per well. The plates were then 
held at 37°C for 30 min. Cells were washed once with PBS and once with milliQ water and 
were examined for immunofluorescence under a UV microscope. 
 
2.13.8 Extraction of viral RNA from allantoic fluid 
RNA was extracted from infected allantoic fluid using QIAamp Viral RNA minikits 
according to the manufacturer’s instructions. RNA was eluted in a final volume of 60 µL. 
 
2.13.9 Reverse transciption-polymerase chain reaction (RT PCR) 
RT-PCR amplification of viral RNA was achieved using SuperScript One-Step RT-PCR 
with Platinum Taq System, in accordance with the manufacturer’s instructions.  Reaction 
volumes (50 µL) contained approximately 500 ng of template RNA, 0.2 µM of specific-sense 
and anti-sense primers, and 1.2 – 2.0 mM MgSO4 and 0.4 µM each dNTP. A Gene Amp PCR 
system 2400 thermocycler was used to perform the reactions. Synthesis of cDNA was 
achieved with an initial cycle of 50°C for 30 min, followed by denaturation at 94°C for 2 min. 
Amplification was achieved by 35 cycles, each consisting of denaturation at 96°C for 15 s, an 
annealing step at 55°C for 30s and an extension at 68°C for 2 min. A final extension at 72°C 
for 10 min was used to complete the reaction. PCR products were stored at 4°C for short- or -
20°C for long-term storage. 
 
2.13.10 Agarose gel electrophoresis 
Electrophoresis in agarose gel (Sambrook, Fritsch, and Maniatis, 1989) was used to identify 
PCR products and DNA fragments. DNA was diluted to a concentration of approximately 200 
ng with 1X TAE Buffer and 6x DNA Loading Buffer, then loaded into gels containing 1-2% 
molecular biology grade agarose in 1x TAE buffer. Electrophoresis was carried out at 70-80V 
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until the dye front had migrated as far as required, usually after 1-2 h. The gel was stained in a 
solution containing 0.5 µg mL-1 ethidium bromide for 10 min and was destained in running 
water for 30-40 min. Bands were visualised under UV light and the images recorded using the 
Gel Doc system. 
 
2.13.11 Restriction enzyme (RE) digestion 
RE digestion of PCR products were performed as previously described (Sambrook, Fritsch, 
and Maniatis, 1989), using buffers supplied by the manufacturer. Digestions were carried out 
in accordance with the manufacturer’s instructions. Samples were incubated for 2 h on a dry 
block heater at the recommended temperature for each enzyme. 
 
2.13.12 Purification of PCR products 
PCR products were purified using QIAquick PCR purification kits, according to the 
manufacturer’s instructions. Column-purified PCR products were eluted in a final volume of 
30 µL. 
 
2.13.13 Preparation of electrocompetent cells 
A 10mL overnight culture of DH5α cells was used to inoculate a 500 mL LB broth, which 
was then incubated at 37°C on a shaker. When absorbances of 0.8 – 1.0 OD600 nm were 
achieved, the culture was placed on ice for 45 min and centrifuged at 4000 x g for 10 min at 
4°C. The pellet was resuspended gently in 500 mL of 10% glycerol and centrifuged at 8000 x 
g for 12 min at 4°C. It was then resuspended gently in 250 mL of 10% glycerol and 
centrifuged at 16,300 x g for 12 min at 4°C. The pellet was then resuspended gently in 10 mL 
of 10% glycerol and centrifuged at 23,500 x g for 10 min at 4°C. It was finally resuspended in 
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0.5 – 1.0 volumes of 50% glycerol and dispensed into 40 µL aliquots, which were rapidly 
frozen in LN2. Frozen aliquots were stored at -80°C. 
 
2.13.14 PCR product ligation 
PCR products from gene segments of interest were column-purified (Section 2.13.12) and 
then ligated using the pGEM-T Easy Vector System, in accordance with the manufacturer’s 
instructions. A 3:1 molar ratio of insert:vector DNA was used in a final volume of 10 µL. 
The reaction mixture contained 3 Weiss units of T4 DNA ligase and was incubated at RT for 
1-2 h. 
 
2.13.15 Transformation of electrocompetent cells 
Electrocompetent DH5α cells (Section 2.13.13) were transformed using a ligation reaction. A 
1 mL electroporation cuvette containing 40 µL of competent cells and 3 µL of ligation 
reaction was loaded into a BioRad GenePulser Electroporator. Electroporation conditions 
used were 25 µF, 200 ohms and 2.25 kV. One millilitre of SOC broth was then added to the 
cuvette and the contents carefully mixed and transferred to an Eppendorf tube which was 
incubated at 37°C for 1 h. The culture was then plated out onto an LB agarose plate 
containing IPTG, X-gal and ampicillin, in accordance with the manufacturer’s instructions. 
 
2.13.16 Confirmation of cloning 
Two methods were used to confirm that cloning had taken place. Plasmid DNA, purified by 
the alkaline lysis method (Section 2.13.17), was cut using the restriction enzyme EcoRI 
(Section 2.13.14). It was then electrophoresed in a 1% agarose gel and the size of the bands 
observed. Alternatively, parts of single white colonies were inoculated to LB agarose plates, 
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the remainder of which was emulsified in 50 µL of water. The samples were then boiled for 5 
min, chilled and a PCR to confirm the presence of the insert was performed. 
 
2.13.17 Plasmid DNA purification 
Two procedures for small-scale plasmid purification were used. In one, an adaptation of the 
alkaline lysis method (Sambrook, Fritsch, and Maniatis, 1989) was performed. DH5α cells 
containing plasmid DNA were grown overnight at 37 °C in 2 mL LB broth cultures 
containing ampicillin. Approximately 1.5 mL of the culture was centrifuged at 14,000 x g for 
1 min, and the pellet resuspended in 300 µL of ice-cold Solution 1 (Section 2.11). Three 
hundred microlitres of RT Solution 2 (Section 2.11) were then added and the contents mixed 
by gentle inversion 6 times. Three hundred microlitres of ice-cold Solution 3 (Section 2.10) 
were then added, mixed as described above, and placed on ice for 2 min. The lysate was then 
centrifuged for 10 min at 14,000 x g and the supernatant transferred to a clean Eppendorf 
tube. Seven hundred microlitres of isopropanol were added to precipitate the DNA and, after 
mixing, the tube was centrifuged at 14,000 x g for 5 min. The supernatant was removed and 
the pellet washed with 500 µL of 70% ethanol. The tube was then centrifuged at 14,000 x g 
for 5 min and the ethanol removed. The pellet was air-dried and resuspended in 20 µL of 
nuclease-free water. Alternatively, plasmid DNA was purified from 5 mL broth cultures using 
the Wizard Plus SV Minprep DNA Purification System (Promega Corporation, USA), in 
accordance with the manufacturer’s instructions. 
 
2.13.18 DNA Sequencing 
Sequencing reactions were performed using the ABI Prism BigDye Terminator Cycle 
Sequencing Ready Reaction Kit version 3.1 using PCR primers specific to sites in the plasmid 
vectors. After sequencing, reactions were purified using QIAquick PCR purification kits 
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(Section 2.13.11) and precipitated with ethanol/sodium acetate, in accordance with the 
manufacturer’s instructions. Electrophoresis and sequence analysis was performed by 
Micromon DNA Sequencing Facility, Mona sh University, Clayton, VIC, Australia. 
 ________________________________________________________________ 
CHAPTER THREE: 
PREPARATION OF POTENTIAL INFLUENZA B DONOR STRAINS 
 
________________________________________________________________ 
 
Potential donor strains were prepared from B/Lee/40 by two approaches involving the 
selection of stable cold- and high- temperature mutants. Initial passaging was undertaken in 
SPF CEK cultures and later passage in SPF embryonated chicken eggs. Both approaches were 
successful, although fewer plaques produced viable progeny at 38°C and it was, therefore, 
necessary to screen a higher number of clones at that temperature. Potential donor strains, 
isolated by selection at either temperature and plaque-purified in SPF CEK cultures, were 
tested for HA titre, infectious titre compared with the original parental strain by three 
methods, and for differences in antigenicity by cross-HI tests. Potential donor strains selected 
at temperatures of 25°C (C25) and 38°C (H38) produced HA titres of 320 units/50µL and 
infectivities of 8.57 and 8.39 EID50, respectively, when grown in eggs at the permissive 
temperature (34°C). The haemagglutinin of parental and temperature-adapted strains were 
shown to be antigenically similar. Partial nucleotide sequencing showed that passage of 
B/Lee40 at 25°C in the preparation of C25 resulted in one residue change from Ile to Thr at 
position 48 in the HA2 protein. 
________________________________________________________________ 
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3.1 INTRODUCTION 
Influenza viruses freshly isolated from clinical samples generally grow to a low titre in eggs 
and can be difficult to purify due to their heterogenous morphology (Robertson et al., 1992). 
Yields of influenza A strains for use as seeds in the preparation of inactivated vaccines can be 
increased by reassortment of specified epidemic strains with a high-yielding egg-adapted 
donor strain such as A/PR/8. Reassortment of influenza B viruses has been observed and can 
be demonstrated experimentally and has been used for the preparation of live influenza B 
vaccine seeds (Barr et al., 2003; Goodeve, Jennings, and Potter, 1985; Lindstrom et al., 1999; 
McCullers et al., 1999; Wareing and Tannock, 2001). However, few suitable influenza B 
donor strain parents are available that are sufficiently distinct antigenically and possess 
genetic markers, such as the ca phenotype, that can be screened by biological or molecular 
techniques (Beare et al., 1977). Improvement in the yields of influenza B seeds for use in 
inactivated vaccine production is usually attempted by limited egg passage, with variable 
results. 
 
Reassortment of influenza B viruses in the preparation of inactivated vaccine seeds could 
improve vaccine antigen yields and lower costs if suitable donor strains were available. In the 
experimental work to be described in this chapter, potential influenza B donor strains with 
specific biological markers were prepared from an early influenza B strain and their properties 
compared. Cold-adaptation, which has been a successful strategy for the development of 
donor strains for the preparation of ca vaccines, provided a starting point for these 
experiments. However, egg-passage at 25° requires an incubation step of 5 days compared 
with 3 days at the optimal growth temperature of 34°C; for growth in CEK cultures at the 
same temperatures these times are 10 and 5 days. As these longer incubations lengthen the 
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times for reassortment accordingly, adaptation to growth at higher temperatures was also 
undertaken. 
 
3.2 SELECTION AND INITIAL CEK PASSAGE OF B/LEE/40 AS A PARENTAL 
DONOR STRAIN 
Influenza B/Lee/40 (B/Lee) is an established, well-characterised virus whose entire genome 
has been described (GenBank® NIH genetic sequence database accession numbers: M14880, 
AF101982, AF102017, K00423, K01395, J02095, J02094, and J02096 for B/Lee gene 
segments 1-8, respectively). B/Lee was originally isolated from a clinical sample in 1940, 
being the first influenza type B virus to be identified (Francis, 1940). Because of the length of 
time since its initial isolation, it seemed reasonable to assume that it would have been 
significantly different antigenically from contemporary strains, due to antigenic drift. Rates of 
amino acid change in the HA1 region of influenza B viruses of 6.2% (B/Lee compared with 
B/Singapore/222/79) to 6.6% (B/Lee compared with B/Hong Kong/8/73) have been reported, 
which are less than those observed with influenza A viruses over similar times (Section 1.2.2) 
(Krystal et al., 1983; Verhoeyen et al., 1983). More recently, evolutionary rates for the HA1 
regions of Yamagata-like lineage viruses of 3.1-3.8 x 10-3 nucleotides/site/year and 2.5-3.3 x 
10-3 for Victoria-like viruses have been reported, with models indicating 2.7% of amino acid 
sites under selective pressure (Ansaldi et al., 2003; McCullers et al., 1999; Pechirra et al., 
2005). Early influenza B viruses like B/Lee have been shown to cluster in a separate 
phylogenetic tree branch than either Yamagata- or Victoria-like viruses (McCullers et al., 
1999). 
 
Aliquots of a B/Lee vaccine seed (B/Lee/40, CSL VI-1394 SPF seed lot) were kindly 
provided by CSL Ltd, Influenza Product Development Department. The original seed lots 
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were purified by 3 cycles of adsorption to and elution from SPF chicken RBC’s (Section 
2.13.6). This procedure was undertaken as a precaution to eliminate vertically transmitted 
avian non-haemagglutinating viruses, especially leukosis viruses. The virus was then 
passaged in SPF eggs to obtain parental stock (B/Lee parent.SPF1) and its HA and plaque 
titres determined (Sections 2.13.2, 2.13.3.2 and 2.13.3.1). The HA titre of B/Lee parent.SPF1 
was 80 units/50 µL. All embryos and primary CEK cultures used for subsequent passages 
were of SPF origin. B/Lee parent.SPF1 was then passaged in primary CEK cells (Sections 
2.13.1.6 and 2.13.3.1) at incubation temperatures of 34 or 37 in egg incubators or 39°C in 
CO2 incubators. Plaque assays at each temperature were set up in triplicate in CEK cultures 
and agarose plugs containing viral progeny from single plaques were aspirated with a Pasteur 
pipette. Each plug was mixed thoroughly with 200mL of PBS and the suspension inoculated 
to a 10-11 d.o. SPF embryonated egg. A minimum of 16 plaques were selected at each 
passage. After 2 days incubation at 34°C, the eggs were chilled and individual allantoic fluids 
were harvested and tested for the presence of HA; fluids with the highest titres were re-
passaged in primary CEK cells and the remaining allantoic fluids stored separately at -80°C. 
This procedure was repeated a total of 4 times (Figure 3.1). Plates incubated at 39°C did not 
produce plaques, although some cells lifted from the well surface at dilutions of 10–1, 
indicating cell death. As plaques were not produced during incubation at 39°C, an incubation 
temperature of 38°C was used after the 3rd CEK-egg passage cycle. Virus selected from the 
4th CEK-egg passage cycle was passaged once more in eggs and the virus progeny was 
designated as Clone 4 (G4-38.5, SPF5.CEK4). It was characterised by HI, IFA and PCR 
techniques (Sections 2.13.3.2, 2.13.7 and 2.13.9). The HA titre and growth conditions for 
selected clones at each step of the procedure are shown in Table 3.1. 
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Figure 3.1 Flow diagram for the preparation of B/Lee-derived Clone 4. 
 
B/Lee parent.SPF1 
CEK passage at 34, 37 or 39°C 
 
Progeny from 16 plaques passaged 
individually in eggs at 34°C 
Select allantoic fluid with highest 
HA titre 
Repeated 3 times 
CEK passage at 34, 37 or 38°C 
Progeny from 16 plaques passaged 
individually in eggs at 34°C 
Harvest and select allantoic fluid 
with highest HA titre 
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Table 3.1 HA titres and growth conditions for selected clones in the preparation of B/Lee-derived virus Clone 4 
 
Cycle number Virus passaged1 Passage type2 
 
Selected/egg-passaged clone Incubation 
temperature (°C) 
HA titre1 
      
1a B/Lee parent.SPF1 CEK P37.5, SPF1.CEK1 37 NA 
 
1b P37.5, SPF1.CEK1 Egg P37.5, SPF2.CEK1 34 256 
 
2a P37.5, SPF2.CEK1 CEK P37.5b, SPF2.CEK2 37 NA 
 
2b P37.5b, SPF2.CEK2 Egg P37.5b, SPF3.CEK2 34 256 
 
3a P37.5b, SPF3.CEK2 CEK P34, SPF3.CEK3 34 NA 
 
3b P34, SPF3.CEK3 Egg P34, SPF4.CEK3 34 256 
 
4a P34, SPF4.CEK3 CEK P38.5, SPF4.CEK4 38 NA 
 
4b P38.5, SPF4.CEK4 Egg P38.5, SPF5.CEK4 34 256 
 
1
 P plaque selected 
2 CEK primary chicken embryo kidney cultures 
3 NA not applicable 
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Clone 4 was egg-passaged once more to obtain a pool of stock virus and then used separately 
as the starting material for the preparation of both cold temperature adapted mutants and for 
growth in eggs at 38°C. The HA titre of the Clone 4 final stock (P38.5, SPF6.CEK4) was 160 
units/50µL. 
 
3.3 TEMPERATURE ADAPTATION AND PLAQUE-PURIFICATION OF CLONE 4 
Because Clone 4 produced plaques at the first CEK passage at 38°C, possibly indicating some 
adaptation to growth at a higher temperature, further egg-passage was attempted at 39°C 
using a range of inoculum sizes. This proved unsuccessful and a series of egg passages at 
38°C was then undertaken in attempt to increase titres. Variable yields (80-320 HA 
units/50µL) were obtained; virus from the 4th passage, designated Clone 4-H (HC4-38.4, 
SPF11.CEK4), was selected for plaque purification before evaluation as a high-temperature 
donor strain (Table 3.2). Clone 4-H was plaque purified in SPF CEK cells (Table 3.3). To 
increase the possibility of obtaining viruses with higher yields, larger plaques were selected 
during the plaque purification process. Agarose plugs containing viral progeny from 11 single 
plaques were selected for egg passage at 34°C at the first attempt but all allantoic fluids were 
HA negative. At the next round of plaque purification, agarose plugs containing viral progeny 
from 17 single plaques were selected for egg passage at 34°C but only two allantoic fluids 
were HA positive. The plaque-purified clone with the highest HA titre following egg passage 
was selected as the high temperature donor strain, and was designated H38 (HC4-38, 
SPF12.CEK5). 
 
Attempts were also made to prepare cold-adapted progeny of Clone 4. Adaptation involved 
the reduction of incubation temperatures in three steps from 34 to 25°C, followed by seven 
further passages at 25°C in SPF eggs. Virus from the 6th egg-passage at 25°C, designated 
89 
Clone 4-C (CC4-38.4, SPF16.CEK4), was selected for plaque purification before evaluation 
as a cold-adapted donor strain (Table 3.4). Clone 4-C was plaque-purified in SPF CEK 
cultures, again selecting larger plaques to increase the possibility of obtaining viruses with 
higher yields (Table 3.5). A minimum of 20 plaques were selected at each round of 
purification, and a much higher rate of HA positive allantoic fluids after egg passage was 
observed than for the selection of Clone 4-H. At the final round of plaque purification, 
agarose plugs containing viral progeny from 29 single plaques were passaged in eggs at 34°C. 
The plaque-purified clone with the highest HA titre was selected as the cold-adapted donor 
strain, and was designated C25 (CC4-25, SPF19.CEK8). C25 and H38 had initial HA titres of 
320-640 units/50µL. 
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Table 3.2 HA titres of egg-passaged Clone 4 at 38°C 
 
Virus passaged 
 
Virus harvested1 Passage number2 HA titre 
    
Clone 4 (P38.5, SPF6.CEK4) 
 
Clone 4 SPF2 (P38.5, SPF7.CEK4) SPF2 (34°C) 320 
Clone 4 SPF2 (P38.5, SPF7.CEK4) 
 
HC4-38.1 (SPF8.CEK4) 
 
H1 160 
HC4-38.1 (SPF8.CEK4) 
 
HC4-38.2 (SPF9.CEK4) H2 160 
HC4-38.2 (SPF9.CEK4) 
 
HC4-38.3 (SPF10.CEK4) H3 160 
HC4-38.3 (SPF10.CEK4) 
 
HC4-38.4 (SPF11.CEK4) H4 320 
HC4-38.4 (SPF11.CEK4) 
 
HC4-38.5 (SPF12.CEK4) H5 80 
HC4-38.5 (SPF12.CEK4) 
 
HC4-38.6 (SPF13.CEK4) H6 160 
HC4-38.5 (SPF13.CEK4) 
 
HC4-38.7 (SPF14.CEK4) H7 80 
HC4-38.5 (SPF14.CEK4) 
 
HC4-38.8 (SPF15.CEK4) H8 40 
HC4-38.8 (SPF15.CEK4) 
 
HC4-38.9 (SPF16.CEK4) H9 80 
HC4-38.9 (SPF16.CEK4) 
 
HC4-38.10 (SPF17.CEK4) H10 80 
HC4-38.10 (SPF17.CEK4) 
 
HC4-38.11 (SPF18.CEK4) H11 160 
1
 HC4 - high temperature clone 4 
2
 incubated at 38°C, except where indicated 
Selected virus, designated Clone 4-H 
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Table 3.3 Clone 4-H[ plaque purification at 38°C 
 
Cycle number Virus passaged Passage type 
 
Selected/egg-passaged clone Incubation 
temperature (°C) 
HA titre1 
      
1a 
 
Clone 4-H (SPF11.CEK4) CEK Clone 4-H (SPF11.CEK5) 38 NA 
1b 
 
Clone 4-H (SPF11.CEK5) Egg Clone 4-H (SPF12.CEK5) 34 All –ve2 
 
 
     
1a - repeat 
 
Clone 4-H (SPF11.CEK4) CEK Clone 4-H (SPF11.CEK5) 38 NA 
1b – repeat 
 
Clone 4-H (SPF11.CEK5) Egg Clone 4-H (SPF12.CEK5) 34 6403 
 
1
 NA: not applicable 
2 11 individual plaques selected and grown in eggs: all HA –ve 
3 17 individual plaques selected and grown in eggs: 15 were HA –ve and 2 had titres of 640 
 
 
 
 
Selected virus, designated H38 
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Table 3.4 HA titres of Clone 4 adapted to growth in eggs at 25°C 
 
Virus passaged1 
 
Virus harvested2 Passage number Incubation 
temperature (°C) 
HA titre 
     
Clone 4 (P38.5, SPF7.CEK4) 
 
CC4-31.1 (SPF8.CEK4) C1 31 640 
CC4-31.1 P1 (SPF8.CEK4) 
 
CC4-29.3 (SPF9.CEK4) C2 29 640 
CC4-29.3 (SPF9.CEK4) 
 
CC4-27.3 (SPF10.CEK4) C3 27 320 
CC4-27.3 (SPF10.CEK4) 
 
CC4-25 (SPF11.CEK4) C4 25 320 
CC4-25 (SPF11.CEK4) 
 
CC4-25 (SPF12.CEK4) C5 25 160 
CC4-25 (SPF12.CEK4) 
 
CC4-25 (SPF13.CEK4) 
 
C6 25 320 
CC4-25 (SPF13.CEK4) 
 
CC4-25 (SPF14.CEK4) 
 
C7 25 320 
CC4-25 (SPF14.CEK4) 
 
CC4-25 (SPF15.CEK4) 
 
C8 25 320 
CC4-25 (SPF15.CEK4) 
 
CC4-25 (SPF16.CEK4) 
 
C9 25 640 
CC4-25 (SPF16.CEK4) 
 
CC4-25 (SPF17.CEK4) 
 
C10 25 160 
1
 P plaque selected 
2 CC4 cold Clone 4 
Selected virus, designated Clone 4-C 
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Table 3.5 Clone 4-C plaque purification at 25°C 
Cycle number Virus passaged Passage type 
 
Selected/egg-passaged clone Incubation 
temperature (°C)1 
HA titre2 
      
1a 
 
CC4-25 (SPF15.CEK4) CEK CC4-25 (SPF15.CEK5) 25 NA 
1b 
 
CC4-25 (SPF15.CEK5) Egg CC4-25 (SPF16.CEK5) 34 320 
2a 
 
CC4-25 (SPF16.CEK5) CEK CC4-25 (SPF16.CEK6) 25 NA 
2b 
 
CC4-25 (SPF16.CEK6) Egg CC4-25 (SPF17.CEK6) 34 640 
3a 
 
CC4-25 (SPF17.CEK6) CEK CC4-25 (SPF17.CEK7) 25 NA 
3b 
 
CC4-25 (SPF17.CEK7) Egg CC4-25 (SPF18.CEK7) 34 640 
4a 
 
CC4-25 (SPF18.CEK7) CEK CC4-25 (SPF18.CEK8) 25 NA 
4b 
 
CC4-25 (SPF18.CEK8) Egg CC4-25 (SPF19.CEK8) 3 34 640 
 
1
 25°C CEK plaque assays incubated for 10 days 
2 NA: not applicable 
3 29 individual plaques selected and grown in eggs: 4 were HA –ve and 25 had titres of 256-512 
Selected virus, designated C25 
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3.4 CHARACTERISTICS OF PARENTAL AND ADAPTED STRAINS 
The parental B/Lee/40 and the two potential donor strains were assayed in triplicate for HA 
and their infectious titres determined by three different methods (Table 3.6). Plaque titres of 
B/Lee, Clone 4, C25 and H38 in CEK cultures at various temperatures were determined as 
part of the adaptation and plaque purification process (Table 3.7). Antigenic relationships 
were examined by HI tests using antisera raised in SPF chickens against allantoic-grown 
preparations of each virus (Table 3.8). 
 
Table 3.6 Characteristics of parental B/Lee and adapted strains 
Virus HA1 TCID502 EID503 PFU/mL 
(log10)4 
Plaque size 
at 34°C 
      
B/Lee/40 
 
160 8.10 7.93 7.51 2-3mm 
C25 
 
320 8.36 8.57 8.01 2-4mm 
H38 
 
320 7.92 8.39 8.07 2-4mm 
1 HA titre: units/50µL 
2
 Incubation temperature 34°C. Each figure represents the mean of three assays, each carried 
out in triplicate. 
3 Incubation temperature 34°C. Each figure represents the mean of three assays. 
4
 Plaque titres in MDCK monolayers 
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Table 3.7 Plaque titres in CEK monolayers at optimum and restrictive temperatures 
 Plaque titres in CEK monolayers at:1,2 
 
 
 
Virus 
25°C 
 
Plaque 
size 
34°C 
 
Plaque 
size 
38°C 
 
Plaque 
size 
39°C 
 
Plaque 
size 
B/Lee/40 <1 0 7.33 2-3mm 6.43 1-2mm <1 0 
B/Lee/40-C25 7.86 2-4mm  8.014 2-4mm ND - ND - 
B/Lee/40-H38 ND - 6.19 2-3mm 6.35 2mm <1 0 
1 Titres expressed as log10 pfu/mL. 
2
 Weighted mean calculated from duplicate plates 
3
 ND: not done 
4 plaque titre in MDCK cells (of comparable sensitivity) 
 
Table 3.8 Antigenic relationships between parental B/Lee and adapted strains, as 
determined by HI 
 HI titre against1 
 
Virus 
B/Lee/40 
 
B/Lee/40-C25 B/Lee/40-H38 
B/Lee/40 
 
1280 1280 1280 
B/Lee/40-C25 
 
1280 1280 1280 
B/Lee/40-H38 
 
1280 1280 1280 
1 Using strain specific antisera raised against allantoic virus 
 
3.5 GENOTYPE ANALYSIS OF PARENTAL AND C25 HA GENE 
Partial nucleotide sequencing of the HA gene of the original B/Lee/40 and C25 was 
undertaken. This was undertaken to ensure that the processes involved with cold-adaptation 
had not resulted in major variation of the HA sequence. Briefly, near full-length PCR 
products (Table 2.1) were column-purified and then ligated using the pGEM-T Easy Vector 
System (Section 2.13.14). Electrocompetent DH5α cells were transformed using a ligation 
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reaction and were incubated overnight at 37°C before being tested to confirm the presence of 
clones (Sections 2.13.15 and 2.13.16). Plasmid DNA was purified from broth cultures and 
used in sequencing reactions, which were then purified and precipitated (Sections 2.13.17 and 
2.13.18). Electrophoresis and sequence analysis was performed, as described in Section 
2.13.18. 
 
For both B/Lee/40 and C25, a consensus sequence was derived from two clones that had been 
sequenced in both directions using SP6 and T7 primers (Table 2.1). Amino acids translated 
from the nucleotide sequences were aligned with the published B/Lee/40 HA reference 
sequence (GenBank Accession number J02093), using Sequence Navigator  ABI Version 
1.0.1 software. The sequence data (i.e the translated protein sequence from the signal 
polypeptide to the end of the HA2 protein) are detailed in Appendix 1 and residue and 
nucleotide differences are shown in Tables 3.9 and 3.10. Nine residue changes were identified 
in the B/Lee parent when compared with the published B/Lee/40 sequence, eight of which 
were also shared by C25. One residue change, an isoleucine replaced by threonine at amino 
acid position 48, was noted in the HA2 protein coding region of C25, in comparison with the 
B/Lee parent. A further seven nucleotide changes, common to both the B/Lee parent and C25, 
were noted although they were not associated with amino acid changes. 
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Table 3.9 Residue and nucleotide differences in the HA gene of the published B/Lee/40 data, B/Lee/40 parent and B/Lee/40-C25 
 
Published B/Lee/40 reference sequence Parental B/Lee/40 B/Lee/40-C25 Amino acid position 
Amino acid Codon triplet1 Amino acid Codon triplet1 Amino acid Codon triplet1 
HA1 PROTEIN       
53 Lys aaa Arg aga Arg aga 
91 Thr aca Ile ata Ile ata 
105 Ala gct Val gtt Val gtt 
142 Thr aca Ala gca Ala gca 
164 Gly ggg Arg agg Arg agg 
HA2 PROTEIN       
48* Ile ata Ile ata Thr aca 
54 Tyr tat Ser tct Ser tct 
72 Glu gag Gly ggg Gly ggg 
73# Leu ctt Pro cct Leu ctt 
181 Gly ggc Asp gac Asp gac 
1
 Bases that differed from the published reference B/Lee/40 sequence are highlighted in grey 
* C25 sequence differed from the published reference B/Lee/40 sequence and the B/Lee/40 parent sequence 
# The B/Lee/40 parent sequence differed from the published reference B/Lee/40 sequence and B/Lee/40-C25 sequence 
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Table 3.10 Silent nucleotide differences in the HA gene of the published B/Lee/40 data, B/Lee/40 parent and B/Lee/40-C25 
 
Published B/Lee/40 reference sequence Parental B/Lee/40 B/Lee/40-C25 Amino acid position 
Amino acid Codon triplet1 Amino acid Codon triplet1 Amino acid Codon triplet1 
HA1 PROTEIN       
82 Leu cta Leu ttg Leu ttg 
83 Gly ggc Gly ggt Gly ggt 
93 Pro ccc Pro cct Pro cct 
254 Leu cta Leu tta Leu tta 
HA2 PROTEIN       
126 Gly ctt Gly ctg Gly ctg 
202 Leu tta Leu ttg Leu ttg 
 
1
 Bases that differed from the published B/Lee/40 reference sequence are highlighted in grey 
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3.6 DISCUSSION 
B/Lee was selected as a potential donor strain for adaptation because of its well-defined 
genomic sequence and antigenic differences from current epidemic strains. The selection of 
suitable reassortants can be greatly assisted by screening procedures that exploit differences in 
the capacity of the progeny of mixed infections to grow at restrictive temperatures in the 
presence of antiserum to a donor strain, as in the preparation of live ca vaccines (Section 
1.4.2.2.1). Growth at the selective temperature in the presence of antiserum specific for the 
donor strain should favour the growth of reassortant viruses that contain surface antigens of 
the epidemic strain and the internal genes from the donor strain. These screening techniques 
can provide an indication as to which clones are more likely to possess the required gene 
constellation(s) and could eliminate the need for blind screening and subsequent molecular 
characterisation of large numbers of clones. Two approaches to the use of temperature 
selection of B/Lee were followed. In the first, adaptation to growth at higher temperatures was 
examined. An incubation temperature of 38°C was the highest temperature that allowed the 
formation of plaques in CEK monolayers from which virus progeny could be isolated. 
Increased plaque size served as an indicator of higher growth and potentially higher yields in 
eggs. After four cycles of CEK plaque purification and egg passage, one clone (Clone 4) 
readily produced plaques in CEK cultures at 38°C and was subsequently passaged 11 times in 
eggs at that temperature. HA titres of allantoic fluids obtained were variable, and virus from 
the 4th passage was selected for final plaque purification (Clone 4-H). Ca influenza B donor 
strains have a lower shut-off temperature of growth (37°C) than influenza A strains (39°C), 
which is consistent with the results obtained with B/Lee(Kiseleva et al., 2004; Shaw, Arden, 
and Maassab, 1992). 
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It was necessary to select a reasonably high number of clones in order to successfully isolate 
virus from plaques formed at 38°C (2-5 HA positive clones out of a total of 17-21 after egg 
passage). In another approach, using a method for selection based on one used for the 
preparation of ca reassortants, Clone 4 was adapted to growth at 25°C. Adaptation was 
achieved in three steps from 34 to 25°C, followed by another seven egg passages at 25°C. 
High-titred virus from the 6th egg-passage at 25°C was selected for final plaque purification 
(Clone 4-C), again using increased plaque size as an indicator of higher growth and 
potentially higher yields in eggs. HA titres, after subsequent egg passage of plaque-purified 
Clone 4-H and 4-C (now designated H38 and C25), were 320 units/50 µL. Adaptation of the 
original B/Lee parent to growth in CEK cultures at 38°C (Clone 4) involved the individual 
selection and egg passage of 61 plaque-derived clones. Preparation of H38 from Clone 4 
required a further 11 egg passages and the selection of an additional 49 plaque-derived clones 
while the preparation of C25 involved 10 egg passages and the selection of 84 plaque-derived 
clones. These figures do not include attempts to isolate virus at 39°C, from which a total of 31 
agarose plugs from cell monolayers that exhibited damage did not produce infectious 
progeny. 
 
Comparison of virus growth at optimum and restrictive temperatures provides an indication of 
successful temperature adaptation. Plaque titres in CEK cultures for B/Lee, Clone 4, C25 and 
H38 from plaque purification data are presented in Table 3.7. Plaque titres for H38 at 38°C 
and 34°C in CEK monlayers were similar (6.35 and 6.19 log10 pfu/mL respectively). Assays 
of the C25 virus at 25°C in CEK cultures revealed a plaque titre of 7.86 log10 pfu/mL, and 
8.01 log10 pfu/mL at 34°C in MDCK cultures, which were of comparable sensitivity (B/Lee 
log10 pfu/mL of 7.51 and 7.33 in MDCK and CEK cultures, respectively). The temperature-
adapted phenotypes of H38 and C25 remained stable over at least 10 egg passages, with HA 
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titres of 80-320 and 160-640 HA units/50µL, respectively, being recorded at each passage for 
both viruses grown at their selective temperatures (Tables 3.2 and 3.4). H38 and C25 were 
similarly stable when passaged in CEK cultures at the selective temperatures; HA titres from 
egg-passaged plaque progeny were 640 and 320-640 units/50µL, respectively (Tables 3.3 and 
3.5). However, a smaller proportion of HA-positive progeny could be isolated from CEK 
plaques grown at 38°C (H38) than at 25°C, and here it was necessary to select a larger 
number of clones for egg passage. 
 
Yields of infectious titres for B/Lee and the temperature adapted donor strains C25 and H38 
were not significantly different when assayed by three methods (Table 3.6). A two-fold 
difference in HA titre between the parental B/Lee and the two temperature adapted strains is 
within the expected limits of variability for the assay. Based on cross-HI tests (Table 3.8), the 
HAs of B/Lee, C25 and H38 were antigenically similar - an important property of any 
potential donor strain, as it indicated that antigenic variation of the donor strain would be 
unlikely to occur during reassortment at restrictive temperatures.  
 
Partial nucleotide sequencing of the C25 and B/Lee parent HA gene showed that passage of 
B/Lee at 25°C in the preparation of C25 resulted in one residue change to the HA protein 
(Table 3.9). The change was noted at amino acid position 409 in the HA0 protein, where a 
Thr replaced an Ile. In the cleaved conformation, the substitution is located at amino acid 
position 48 in the HA2 polypeptide chain. This is located within amino acids HA2 38-56, 
which form the 3 larger helices of the HA2 structure, and would not affect the fusion peptide 
nor any other significant structure or function. Nine residue changes were noted when the 
B/Lee parent was compared with the B/Lee reference sequence, which was published in 1982. 
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Cold adaptation has been used successfully for the attenuation of influenza viruses for use as 
live vaccines. The optimum temperature for the replication of influenza viruses in humans is 
about 33°C - similar to that of the human upper respiratory tract (Stern and Tippett, 1963). 
Cold adaptation selects viruses that grow efficiently at low and optimum temperatures but 
poorly or not at all at higher temperatures and this property is associated with a decrease in 
virulence (Maassab and Bryant, 1999, Murphy, 2002 #1022). Reduced growth at non-
permissive temperatures, termed temperature sensitivity (ts), has been observed to occur 
naturally in some epidemic viruses (Chu et al., 1982). The influenza A virus ts phenotype is 
characterised by highly restricted growth at 39°C while, for influenza B viruses, the restrictive 
temperature is 37°C (Murphy and Coelingh, 2002). Studies have shown that the temperature-
sensitive block occurs late in the multiplication cycle and causes a decrease in infectivity by 
reducing the M protein content of virus progeny (Giesendorf et al., 1986; Kendal et al., 1977). 
Influenza viruses with ca and ts phenoypes can replicate efficiently in the upper airways 
without producing clinical disease (Chen et al., 2006). Egg passage of reassortants prepared 
using ca donor strains lengthens the time to produce potential vaccine seeds, requiring 
typically an additional 3 days for egg and 5 days for CEK growth at 25°C which increases the 
time needed for the preparation of vaccine seeds. Against this, the use of high temperature 
adapted strains, which could allow the selection of reassortants within a shorter time, may 
result in the selection of viruses that grow at higher temperatures and could be associated with 
increased virulence, with occupational health and biosafety implications for vaccine 
manufacturers (Maassab and Bryant, 1999; Maassab and DeBorde, 1985). 
 ________________________________________________________________ 
CHAPTER FOUR: 
REASSORTMENT OF TEMPERATURE-ADAPTED INFLUENZA 
DONOR B STRAINS WITH EPIDEMIC STRAINS 
 
________________________________________________________________ 
 
The growth of a panel of epidemic viruses at restrictive temperatures (25 and 38°C) varied, 
with 4/28 being positive for growth at 25°C and 9/28 at 38°C. C. A set of PCR primers was 
designed and used in tests for gene identification using different restriction enzymes. 
Reassorting experiments using the B/Lee-derived potential donor strains C25 and H38 and the 
epidemic strain B/Johannesburg/5/99 showed that the preparation of reassortant progeny with 
both epidemic strain HA and NA was problematic. In the first experiment with 
B/Johannesburg all viral progeny contained NA of the donor strain. The protocol was varied 
and the experiment repeated, with 1/24 of the resulting reassortants possessing both the HA 
and NA of the epidemic strain. Co-infection with B/Panama/45/90 (B/Panama) and either 
donor strain by Protocol 2 produced little reassortment, with 17/22 clones being identical to 
B/Panama. Further variations to Protocol 2 increased the proportion of reassortants but none 
possessed the desired 6:2 gene constellation (i.e. the two surface antigens of the epidemic 
strain and the remainder from the donor strain). The infectious titre of selected progeny from 
the reassortment experiments were assayed by three methods and compared with the 
respective epidemic parents and showed that the infectious titre of CP2 (TCID50) was 
significantly lower than that of B/Panama and that of CJ4 (EID50) was significantly higher 
than that of B/Johannesburg. 
__________________________________________________________________________ 
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4.1 INTRODUCTION 
The segmented nature of the influenza genome allows for genetic reassortment when a single 
cell is infected with two or more viruses of the same type. Because early transcriptional 
events in all segments of both influenza A and B viruses occur independently, it is 
theoretically that possible 256 (28) different combinations of genome segments could be 
present in the progeny following co-infection with two strains. In reality, however, this has 
not been achieved due to patterns of co-segregation, especially between HA and M2, and PB2 
and PA clusters that have been observed in avian influenza A viruses (Section 1.2.1) (de Jong 
et al., 2000). Following co-infection, reassortment procedures can be manipulated to facilitate 
the selection of progeny possessing the required 6:2 gene constellation (i.e with the internal 
genes of a high yielding parent and the surface antigens of an epidemic strain). 
 
In the experiments to be described in this chapter, C25 and H38 were evaluated as potential 
influenza B donor strains. Molecular screening tools were designed to distinguish between 
gene segments derived from donor and epidemic strains. Protocols for reassortment were 
developed and the resulting progeny were screened by biological and molecular techniques 
and compared with the parental donor and epidemic strains. Attempts made to optimise the 
proportion of reassortants produced that possessed the surface antigens of the epidemic 
strains. Characteristics of parental, epidemic and selected reassortant progeny viruses were 
then compared. 
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4.2 ANTIGENIC RELATIONSHIPS BETWEEN DONOR AND EPIDEMIC 
STRAIN VIRUSES 
4.2.1 Selection of epidemic strains 
The epidemic strains chosen for the reassortment experiments were B/Johannesburg/5/99 
(B/Johannesburg) andB/Panama/45/90 (B/Panama). B/Johannesburg, a B/Sichuan/379/99-like 
virus of the B/Yamagata lineage, which grew poorly in eggs (80 HA units/50µL) but was 
recommended for inclusion in Australian vaccines in 2001-2, was selected as a prototype 
strain in attempts to improve yields. It was compared with B/Panama, a B/Yamagata/16/88-
like virus that was recommended for influenza vaccine inclusion in 1991-1995 and produced 
higher yields (320 HA units/50µL). 
 
4.2.2 Antigenic differences between donor and epidemic strain viruses 
The reassortment protocols developed in these experiments (Section 4.5) used passage in the 
presence of donor-specific antiserum for the selection of reassortant progeny with the surface 
antigens of the epidemic strain. Selection is predicated on the need for significant antigenic 
differences between the donor and epidemic strains. The choice of B/Lee for the preparation 
of potential influenza B donor strains was based on assumed differences from current 
epidemic strains due to antigenic drift. To examine these relationships, cross-HI tests were 
performed using antisera raised in SPF chickens against allantoic preparations of B/Lee, 
B/Lee-C25, B/Lee-H38, B/Johannesburg and B/Panama (Table 4.1). 
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Table 4.1 Antigenic relationships as determined by cross HI titre 
 
 HI titre against1 
Virus B/Lee/40 B/Lee/40-C25 B/Lee/40-H38 B/Johannesburg/5/99 B/Panama/45/90 
B/Lee/40 1280 1280 1280 160 40 
B/Lee/40-C25 1280 1280 1280 160 40 
B/Lee/40-H38 1280 1280 1280 80 40 
B/Johannesburg/5/99 10 10 10 1280 160 
B/Panama/45/90 10 40 <10 2560 10240 
 
1 Using strain-specific antisera raised against whole allantoic viruses 
107 
4.3 GROWTH OF EPIDEMIC VIRUSES AT 25 AND 38°C 
Mutations associated with cold adaptation, temperature sensitivity and attenuation have been 
reported to be present in the PB1, PB2, PA, M, NP and NS2 genes of ca influenza A vaccine 
donor strains (Section 1.4.2.2.1). Mutations in the PB2, PA and NP segments have been 
associated with the expression of the cold phenotype in ca influenza B donor strains (Chen et 
al., 2006; Hoffmann et al., 2005). Growth at restrictive temperatures was used in the 
reassortment experiments in an attempt to maximise the selection of reassortant progeny 
possessing of the internal genes associated with growth at restrictive temperatures. Because 
this selective advantage would be lost if the epidemic viruses also grew at either restrictive 
temperature, a panel of epidemic influenza B viruses was screened for growth in eggs at 25° 
and 38°C. All viruses used were standard egg-grown stock that had been incubated at 34°C. 
The panel included the two epidemic influenza B strains chosen for the reassortment 
experiments and other representatives from the major influenza B virus lineages - 
B/Yamagata/16/88 and B/Victoria/2/87. Eggs were inoculated in quadruplicate with 100µL of 
virus diluted 10-3 in PBS, and incubated for 2 days at 38° or 5 days at 25°C (Table 4.2). 
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Table 4.2 Growth of epidemic influenza B viruses at 25 and 38°C 
Virus Lineage 1 HA titre at 25°C HA titre at 38°C 
    
B/Victoria/505/2000 Yamagata 1) < 1 
2) < 1 
3) < 1 
4) < 1 
1) 64 
2) 128 
3) < 1 
4) < 1 
 
B/Beijing/184/93 Yamagata 1) < 1 
2) < 1 
3) < 1 
4) < 1 
1) < 1 
2) < 1 
3) < 1 
4) < 1 
 
B/Shandong/7/97 Victoria 1) < 1 
2) 12,3 
3) 1 
4) < 1 
1) < 1 
2) < 1 
3) 32 
4) 16 
 
B/Yamanashi/166/98 Yamagata 1) < 1 
2) < 1 
3) < 1 
4) < 1 
1) < 1 
2) < 1 
3) 4 
4) < 1 
 
B/Brisbane/32/2002 Victoria 1) < 1 
2) < 1 
3) < 1 
4) < 1 
 
1) 16 
2) < 1 
3) 16 
4) < 1 
B/Johannesburg/5/99 Yamagata 1) < 1 
2) < 1 
3) < 1 
4) < 1 
1) < 1 
2) < 1 
3) < 1 
4) < 1 
 
B/Panama/45/90 Yamagata 1) 64 
2) 128 
3) < 1 
4) < 1 
1) < 1 
2) < 1 
3) 4 
4) 8 
    
 
1 Yamagata: B/Yamagata/16/88; Victoria: B/Victoria/2/87 
2 Replicate eggs, numbered 1-4 
3 1: haemagglutination was only present in the first well; <1 indicates no detectable 
haemagglutination. 
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4.4 IDENTIFICATION OF THE ORIGIN OF GENE SEGMENTS 
4.4.1 PCR primer design 
Primers were designed to amplify most of each gene segment using the published sequences 
for B/Lee that are available in GenBank®. With exception of the PB1 primer pair, all primers 
could be used to amplify B/Lee RNA segments. These primers also amplified C25 and H38 
RNAs, again with the exception of the PB1 pair. However, only three primer pairs (specific 
for HA, M and NS) could be used to amplify both B/Johannesburg and B/Panama RNAs. 
New primers were designed for NA, NP, PB1, PB2 and PA, based on common sequences for 
both B/Lee and B/Panama, and regions of homology between B/Lee and B/Panama that were 
suitable for primer binding (Table 4.3). Unfortunately, these could only amplify fragments of 
each gene. It was not possible to include B/Johannesburg sequences in the primer design 
because limited data was available in GenBank®. A set of primers designed for NA, PB1, PB2 
and PA fragments was specific for all five strains. Because the initial NP fragment primers 
were not specific for B/Johannesburg, another pair was designed. However, restriction 
enzyme digestion of the NP PCR product was not successful (full details in Section 4.4.2), 
and an additional fourth pair of NP primers was designed. The final primer set used for PCR 
amplification is shown in Table 2.8. All virus gene segments were amplified individually and 
the sizes of PCR products were determined by gel electrophoresis (Section 2.13.10). A series 
of restriction enzyme digests was then performed on the PCR products (Section 2.13.11). 
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Table 4.3 Strain specificity of PCR primers 
Gene segment Primer specificity for strain: 
 
Primers Full-length or 
Fragment1 B/Lee/40 B/Lee/40-C25 B/Lee/40-H38 B/Panama B/Johannesburg 
Haemagglutinin HA L + + + + + 
Neuraminidase NA-1 L + + + - - 
 NA-Frag F + + + + + 
Matrix protein M L + + + + + 
Basic polymerase 1 PB1-1 L - - - - - 
 PB1-Frag F + + + + + 
Basic polymerase 2 PB2-1 L + + + - - 
 PB2-Frag F + + + + + 
Acidic polymerase PA-1 L + + + - - 
 PA-Frag F + + + + + 
Non-specific protein NS L + + + + + 
Nuceloprotein NP-1 L + + + - - 
 NP-Frag1 F + + + + - 
 NP-Frag2 F + + + + + 
 NP-Frag3 F + + + + + 
1
 Primers amplified the full length (L) or a fragment (F) of the gene segment 
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4.4.2 Selection of restriction enzymes 
Restriction enzymes (REs) specific for either B/Lee or B/Panama were chosen according to 
restriction site data available in GenBank®. Digestion of the RT-PCR products of all segments 
of B/Lee, C25, H38 and B/Panama, except NP, was achieved. B/Lee possessed an NP 
restriction site for the BstXI enzyme that was not present in B/Panama. Digestion of the 
B/Lee NP PCR product should have resulted in two fragments of 221 and 178 bp. However, 
because BstXI did not digest the NP RT PCR products of B/Lee, C25 or H38, another pair of 
primers was designed to amplify a larger fragment (816bp), located further towards the 5’ end 
of the segment. The new PCR product included a restriction site for ScaI specific for the 
B/Lee NP RT-PCR product that would produce two fragments of 319 and 496 bp. This fourth 
NP primer pair was specific for all five strains and RE digestion of the NP RT-PCR products 
with ScaI produced two fragments for B/Lee, C25 and H38; the B/Panama RT-PCR products 
remained uncleaved. The full RE set was subsequently used successfully on B/Johannesburg 
RT-PCR products. Details of the enzymes and digestion products are shown in Table 4.4. All 
digested PCR products were separated by gel electrophoresis and visualised under UV (Figure 
4.1). 
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Table 4.4 Details of restriction enzyme digestions 
Gene segment 
 
PCR product size 
 
Restriction enzyme 
 
Strain(s) possessing 
restriction site 
 
Position (bp1)of 
restriction site 
 
Size of fragments 
(bp) 
 
HA 
 
1793 
(bp 20-1813) 
 
NciI B/Panama/45/90 
B/Johannesburg/5/99 
320 300 
1493 
NA 
 
293 
(bp 448-740) 
 
BamHI B/Lee/40 588 140 
152 
M 
 
1131 
(bp 13-1144) 
 
HindIII B/Lee/40 345 332 
799 
PB1 
 
654 
(bp 1019-1672) 
 
PstI B/Lee/40 1351 321 
332 
PB2 
 
644 
(bp 287-930) 
 
BglII B/Lee/40 769 161 
482 
PA 
 
692 
(bp 515-1206) 
 
DraI B/Panama/45/90 633 
 
118 
496 
NP 
 
816 
(bp 414-1229) 
 
ScaI B/Lee/40 733 319 
496 
NS 
 
1033 
(bp 12-1045) 
 
HaeIII B/Panama/45/90 706 339 
694 
1 bp: base pairs 
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Figure 4.1 Electrophoresis gel showing NA gene RE-digested PCR products from 
B/Panama/45/90 – B/Lee/40-C25 Reassortment Experiment 2. M indicates DNA marker, in 
lanes 1 & 19. Digestion with BamHI results in either uncut PCR product of 293 bp (Panama 
origin) or, travelling together, cut fragments of 140 & 152 bp (C25 origin). Lane 17 contains 
B/Panama control and Lane 18 contains C25 control. Arrows in lanes 10 & 13 indicate 
reassortants with B/Panama-like NA. 
 
 
 
 
 
 
M M 
Pan 
C25 
Reassortants 
Lane 1 Lane 19 
M M 
  5 15 10 
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4.5 ATTEMPTS TO ENHANCE THE YIELDS OF B/JOHANNESBURG BY 
REASSORTMENT WITH THE C25 AND H38 POTENTIAL DONOR STRAINS 
 
4.5.1 Neutralisation of donor strain viruses with chicken antisera 
As previously discussed (Section 4.2.2), selection of reassortant progeny with the surface 
antigens of the epidemic strain can be achieved by passage in the presence of donor-specific 
antiserum. This approach had been used successfully in the preparation of influenza A 
reassortant viruses for the preparation of vaccine seeds (Wareing and Tannock, 2001). 
Chicken antiserum was raised in SPF chickens against C25 and H38, and the dilution required 
to completely neutralise allantoic preparations containing 5-6 log10 PFU of potential donor 
strains was subsequently determined (Section 2.13.5). A dilution of 1:640 was used in all 
antiserum passages of both C25 and H38. 
 
4.5.2 Development of a protocol for the preparation of reassortants (1) 
Suitable conditions for reassortment in eggs were investigated in an initial experiment using 
both C25 and H38 as potential donor strains and B/Johannesburg. The protocol is summarised 
in Figure 4.2. Titres of donor strains used for co-infection were 3-5 log10 pfu/mL, while the 
B/Johannesburg concentration was 4.5 log10 pfu/mL in a total inoculum volume of 100µL. 
Individual infectivity ratios used for C25 or H38:Johannesburg co-infections are shown in 
Table 4.5. Virus mixtures were inoculated to two eggs, which were then incubated for 2 days 
at 34°C. HA titres of the allantoic fluids from co-infected eggs were 256-512 units/50µL. 
Progeny from the co-infection was re-passaged in eggs in the presence of antiserum to the 
relevant donor strain. Equal volumes of the coinfected allantoic fluids and antiserum (diluted 
to 1:640 in PBS, Section 4.5.1) were mixed together and placed in a 37°C waterbath for 1h. 
Then 200µL of each allantoic fluid-antiserum mixture were inoculated to a minimum of two 
10-11 d.o embryonated eggs. Eggs inoculated with mixtures containing C25/Johannesburg 
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(CJ) progeny were incubated for 5 days at 25°C, while those containing H38/Johannesburg 
(HJ) progeny were incubated for 2 days at 38°C. Under these conditions there was no 
detectable haemaglutinin in any of the CJ allantoic fluids; of the 16 HJ allantoic fluids there 
was no detectable haemagglutinin in 11, and 5 had a low HA titres (2-32 units/50µL). To 
increase the HA titre, all allantoic fluids were further passaged in the absence of antiserum in 
eggs for 2 days at 34°C. Resulting HA titres for the CJ viruses were 128-256 and for the HJ 
viruses 32-256 units/50µL. Higher titred viruses were selected for a 2nd antiserum passage at 
the same selective temperature, followed by a passage in the absence of antiserum at 34°C. 
Higher titred CJ and HJ viruses from the 2nd blind passage were then selected for plaque 
purification in CEK cultures. Each selected allantoic virus was inoculated to one 6-well 
culture of confluent CEK cells at dilutions of 10-2 – 106 and incubated for 5 days at 34°C 
(Section 2.13.3.1). A minimum of 16 agarose plugs containing viral progeny from single 
plaques were aspirated with a Pasteur pipette. Each plug was mixed thoroughly with 200µL of 
PBS and the suspension inoculated to a 10-11 d.o. embryonated egg. At least one plaque was 
sampled from each 6-well plate; selected larger plaques were well separated. Larger plaques 
were selected to increase the likelihood of successful isolation of viable virus, as selection 
from small plaques in Chapter 3 had proved challenging. The eggs were incubated for 2 days 
at 34°C and the HA titre of the allantoic virus determined. Higher-titred allantoic fluids were 
selected for a further plaque-purification in CEK cells. Following the 2nd plaque-purification 
and egg-passage, 8/10 CJ reassortants (titres 128-512) and 7/10 HJ reassortants (titres 128-
256 HA units/50 µL) were HA-positive. The HA-positive allantoic fluids obtained from 
plaques were tested for HA identity by HI using antisera raised against B/Johannesburg, C25 
and H38. These tests revealed that all progeny possessed the HA of B/Johannesburg (Table 
4.6). To further identify the genes present, RNA was then extracted, amplified using RT-PCR 
and screened by RE digestion in order to confirm the identity of the HA and to determine the 
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origin of the NA gene (Sections 2.13.8-11). Results for HA confirmed the HI data (Table 4.6). 
However, results for NA indicated that all progeny NA was derived from the donor strains 
(Table 4.6). In order to overcome this a second protocol was developed. 
 
 
 
Table 4.5 Donor:B/Johannesburg strain infectivity ratios used in co-infection mixtures. 
 
Co-infection Donor strain 
concentration1 
Epidemic strain 
concentration1 
Infectivity ratio2 
B/Lee/40-C25 and  5.01 4.48 1:0.3 
B/Johannesburg/5/99 4.01 4.48 1:3 
 3.01 4.48 1:30 
    
B/Lee/40-H38 and  5.07 4.48 1:0.26 
B/Johannesburg/5/99 4.07 4.48 1:2.6 
 3.07 4.48 1:26 
1
 Log10 pfu/mL 
2 Donor strain:B/Johannesburg
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Figure 4.2 Flow diagram of Reassortant Protocol 1. 
Co-infection of 
B/Johannesburg with C25 or 
H38 
Egg- passage at 34°C for 2 days 
Incubation of virus-antiserum 
mixtures for 1h at 37°C 
Egg-passage virus-antiserum 
mixtures at either 25°C for 5 days 
or 38°C for 2 days 
Repeated once 
Harvest, then blind-passage 
(34°C) of antiserum-passaged 
allantoic fluids 
CEK plaque purification (34°C) of 
selected allantoic fluids 
Egg-passage (34°C) of plaque-
purified viruses 
Repeated once 
Biological & molecular testing of 
plaque-purified reassortants 
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Table 4.6 Results from Reassorting Protocol 1: C25/Johannesburg1 and H25/Johannesburg1 
 
 
 Gene segment origin2 
Virus HI titre3 HA NA 
CJ1/14 2560 J C 
CJ1/2 2560 J C 
CJ1/3 2560 J C 
CJ1/4 2560 J C 
CJ1/5 2560 J C 
CJ1/6 2560 J C 
CJ1/7 2560 J C 
CJ1/8 2560 J C 
HJ1/14 5120 J H 
HJ1/2 5120 J H 
HJ1/3 5120 J H 
HJ1/5 5120 J H 
HJ1/6 5120 J H 
HJ1/7 5120 J H 
HJ1/8 5120 J H 
 
1
 B/Lee/40-C25 and B/Johannesburg/5/99; B/Lee/40-H38 and B/Johannesburg/5/99 
2
 C: B/Lee/40-C25; J: B/Johannesburg/5/99 
3
 HI titre, using antiserum raised against allantoic B/Johannesburg/5/99. Titres for 
B/Johannesburg/5/99, B/Lee/40-C25 and B/Lee/40-H38 were 2560, <10 and <10, 
respectively. 
4
 CJ1: C25/Johannesburg Protocol 1 progeny; HJ1: H38/Johannesburg Protocol 1 progeny 
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4.5.3 Development of a protocol for the preparation of reassortants (2) 
A number of adjustments were made to Reassortant Protocol 1 in attempts to obtain 
reassortant progeny possessing both the HA and NA of the epidemic strain. The new protocol 
is summarised in Figure 4.3. The first change made was to the donor:B/Johannesburg 
infectivity ratios used for co-infection of eggs. The infectious titre of B/Johannesburg was 4.5 
log10 pfu/mL, while that of C25 and H38 was decreased to 1-3 log10 pfu/mL. The infectivity 
ratios of C25 and H38:Johannesburg are shown in Table 4.7. A change was also made to the 
virus-antiserum incubation step, in accordance with those used by the Research Institute of 
Experimental Medicine, Russian Academy of Medical Sciences, St Petersburg, Russia 
(Wareing, Marsh, and Tannock, 2002). Briefly, equal volumes of allantoic progeny from co-
infected eggs and antiserum to the corresponding donor strain (diluted to 1:640 in PBS, 
Section 4.5.1) were mixed together and held at 4°C overnight. Then 200µL of each mixture 
were inoculated to two 10-11 d.o. embryonated eggs. Eggs inoculated with mixtures 
containing C25xJohannesburg (CJ) progeny were incubated for 5 days at 25°C, while those 
containing H38xJohannesburg (HJ) progeny were incubated for 2 days at 34°C. After the 2nd 
passage in the presence of antiserum at the selective temperature and subsequently in its 
absence at 34°C, HA titres were 64-512 for the CJ and 64-1028 units/50µL for the HJ 
reassortants. 
 
A single CEK plaque purification of the selected allantoic fluids was then carried out and 
selected plaque progeny were passaged in eggs. For both the CJ and HJ reassorting 
experiments 13/15 plaque-purified progeny were HA-positive, with titres of 256-1024 and 
128-512 units/50µL, respectively. The HA-positive allantoic fluids obtained from plaques 
were tested for HA identity by HI using antisera raised against B/Johannesburg, C25 and H38. 
These tests revealed that all progeny possessed the HA of B/Johannesburg (Tables 4.8 and 
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4.9). To further identify the genes present, RNA was then extracted, amplified using RT-PCR 
and screened by RE digestion in order to confirm the identity of the HA and to determine the 
identity of the other genes (Tables 4.8 and 4.9). Results for HA confirmed the HI data. Results 
for NA revealed that, of all CJ and HJ progeny, only one CJ reassortant NA possessed NA 
derived from B/Johannesburg. Full details of the origin of the 6 internal genes for all 
reassortants are shown in Tables 4.8 and 4.9. 
 
 
Table 4.7 Donor:B/Johannesburg strain infectivity ratios used in Protocol 2. 
 
Co-infection Donor strain 
concentration1 
Epidemic strain 
concentration1 
Infectivity ratio2 
B/Lee/40-C25 and  3.01 4.48 1:30 
B/Johannesburg/5/99 2.01 4.48 1:300 
 1.01 4.48 1:3000 
    
B/Lee/40-H38 and  3.07 4.48 1:26 
B/Johannesburg/5/99 2.07 4.48 1:260 
 1.07 4.48 1:2600 
1
 Log10 pfu/mL 
2 Donor strain:B/Johannesburg
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Figure 4.3 Flow diagram of Reassorting Protocol 2 
Egg- passage at 34°C for 2 days 
Incubation of virus-antiserum 
mixtures overnight at 4°C 
Egg-passage virus-antiserum 
mixtures at either 25°C for 5 days 
or 38°C for 2 days 
Repeated once 
Harvest, then blind-passage 
(34°C) of antiserum-passaged 
allantoic fluids 
CEK plaque purification (34°C) of 
selected allantoic fluids  
Egg-passage (34°C) of plaque-
purified viruses  
Biological & molecular testing of 
plaque-purified reassortants 
Co-infection of B/Johannesburg with 
C25 or H38 
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Table 4.8 
Gene composition of C25xJohannesburg1 reassortants prepared by Protocol 2 
 
 Gene segment origin2  
Virus HI titre3 HA NA M PB1 PB2 PA NP NS 
CJ2/14 2560 J C C J C J C J 
CJ2/2 640 J C C J C J C J 
CJ2/3 1280 J C C C C J J J 
CJ2/4 640 J J C C C J J J 
CJ2/5 320 J C J C C J J J 
CJ2/6 640 J C C J C J J J 
CJ2/7 640 J C C J C J J J 
CJ2/8 160 J C C J C J J J 
CJ2/9 1280 J C C J C J J J 
CJ2/10 640 J C C J C J J J 
CJ2/12 1280 J C C J C J J J 
CJ2/13 1280 J C C J C J J J 
CJ2/14 640 J C C J C J J J 
1
 B/Lee/40-C25 and B/Johannesburg/5/99 
2
 C: B/Lee/40-C25; J: B/Johannesburg/5/99 
3
 HI titre, using antiserum raised against allantoic-grown B/Johannesburg/5/99. Titres for 
B/Johannesburg/5/99 and B/Lee/40-C25 were 640 and <10, respectively. 
 
4
 CJ2/4: C25/Johannesburg Protocol 2 reassortant 
 
 
 
   Selected reassortant, CJ2/4 
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Table 4.9 
Gene composition of H38xJohannesburg1 reassortants prepared by Protocol 2 
 
 
 Gene segment origin2 
Virus HI titre3 HA NA M PB1 PB2 PA NP NS 
HJ2/14 640 J H H J H J J J 
HJ2/2 640 J H H J H J J J 
HJ2/3 160 J H H J H J J J 
HJ2/4 1280 J H H J H J H J 
HJ2/6 1280 J H H J H J J J 
HJ2/7 1280 J H H J H J J J 
HJ2/8 640 J H H J H J J J 
HJ2/9 640 J H H J H J J J 
HJ2/10 640 J H H J H J J J 
HJ2/11 5120 J H H J H J J J 
HJ2/12 640 J H H J H J J J 
1
 B/Lee/40-H38 and B/Johannesburg/5/99 
2
 H: B/Lee/40-C25; J: B/Johannesburg/5/99 
3
 HI titre, using antiserum raised against allantoic-grown B/Johannesburg/5/99. Titres for 
B/Johannesburg/5/99 and B/Lee/40-H38 were 640 and <10, respectively. 
4
 HJ2: H38/Johannesburg Protocol 2 reassortant 
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4.6 B/PANAMA REASSORTING EXPERIMENTS 
4.6.1 Preparation of B/Panama reassortants (1) 
The preparation of reassortants was attempted by co-infection with B/Panama and C25 or 
H38, using Reassorting Protocol 2 (Figure 4.3). The infectious titre of B/Panama used was 4.2 
log10 pfu/mL, while the titres of the donor strains were 1-3 log10 pfu/mL. Virus mixtures were 
inoculated to five eggs, which were then incubated for 2 days at 34°C. The infectivity ratios 
used in C25 and H38:Panama co-infections are shown in Table 4.10. Virus-antiserum 
mixtures were held at 4°C overnight before passaging in eggs at the selective temperatures. 
Allantoic progeny was then passaged in the absence of antiserum for 2 days at 34°C and the 
entire process then repeated. This was followed by a single CEK plaque purification at 34°C. 
A minimum of 16 agarose plugs containing viral progeny from single plaques were aspirated 
with a Pasteur pipette, and suspensions of each in PBS were inoculated to individual eggs 
which were incubated at 34°C for 2 days. For the C25xPanama (CP) co-infection experiment 
17/19 plaque-purified reassortants were HA-positive and 5/16 were positive for the 
H38xPanama (HP) co-infection experiment. HA titres of CP and HP progeny were 160-2560 
and 320-2560 units/50µL, respectively. HA-positive allantoic fluids obtained from plaques 
were tested for HA identity by HI using antisera raised against B/Panama, C25 and H38. 
These tests revealed that, although all 5 HP progeny possessed the HA of the epidemic strain, 
13 CP clones possessed the HA of B/Panama and 4 the HA of C25 (Table 4.11 and 4.12). 
RNA was then extracted, amplified using RT-PCR and screened by RE digestion in order to 
confirm the identity of the HA and to determine the origin of the other genes. Results revealed 
that all gene segments of the 5 HP progeny were B/Panama-like (Table 4.12). Twelve of the 
CP possessed all 8 gene segments derived from B/Panama and there were 5 CP reassortants. 
One (CP1/7) possessed an M gene derived from C25 and the remainder from B/Panama, and 
there were 4 reassortants (CP1/14-17) with a 3:5 gene constellation (Table 4.11). Two of the 
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3:5 CP reassortants possessed B/Panama-derived NA, PB1, PB2, PA and NS, while their HA, 
M and NP were derived from C25. The other two CP reassortants possessed NA, PB1, PB2, 
NP and NS from B/Panama and the HA, M and PA from C25. 
 
 
 
 
 
Table 4.10 Donor:B/Panama strain infectivity ratios used in co-infection mixtures. 
 
Co-infection 
mixtures  
Donor strain 
concentration1 
Epidemic strain 
concentration1 
Donor:epidemic 
infectivity ratios2 
B/Lee/40-C25 and  3.01 4.24 1:17 
B/Panama/45/90 2.01 4.24 1:170 
 1.01 4.24 1:1700 
  
 
 
B/Lee/40-H38 and  3.07 4.24 1:15 
B/Panama/45/90 2.07 4.24 1:150 
 1.07 4.24 1:1500 
1
 Log10 pfu/mL 
2 Donor strain:B/Panama
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Table 4.11 
Gene composition of C25xPanama1 progeny prepared by Protocol 2 
 
 
Gene segment origin2 
Virus HI titre3 HA NA M PB1 PB2 PA NP NS 
CP1/14 2560 P P P P P P P P 
CP1/2 2560 P P P P P P P P 
CP1/3 2560 P P P P P P P P 
CP1/4 2560 P P P P P P P P 
CP1/5 2560 P P P P P P P P 
CP1/6 1280 P P P P P P P P 
CP1/7 1280 P P C P P P P P 
CP1/8 2560 P P P P P P P P 
CP1/9 5120 P P P P P P P P 
CP1/10 2560 P P P P P P P P 
CP1/11 2560 P P P P P P P P 
CP1/12 1280 P P P P P P P P 
CP1/13 5120 P P P P P P P P 
CP1/14 20 C P C P P P C P 
CP1/15 40 C P C P P C P P 
CP1/16 80 C P C P P P C P 
CP1/17 20 C P C P P C P P 
 
1
 B/Lee/40-C25 and B/Panama/45/90 
2
 C: B/Lee/40-C25; P: B/Panama/45/90 
3
 HI titre, using antiserum raised against allantoic-grown B/Panama/45/90. Titres for 
B/Panama/45/90 and B/Lee/40-C25 were 1280 and <10, respectively. 
4
 CP1: C25/Panama Protocol 2 progeny 
 
 
 selected virus, designated CP1 
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Table 4.12 
Gene composition of H38xPanama1 progeny prepared Protocol 2 
 
 Gene segment origin2 
Virus HI 
titre3 
HA NA M PB1 PB2 PA NP NS 
HP1/14 5120 P P P P P P P P 
HP1/2 2560 P P P P P P P P 
HP1/3 1280 P P P P P P P P 
HP1/4 2560 P P P P P P P P 
HP1/5 5120 P P P P P P P P 
 
1
 B/Lee/40-H38 and B/Panama/45/90 
2
 H: B/Lee/40-H38; P: B/Panama/45/90 
3
 HI titre, using antiserum raised against allantoic-grown B/Panama/45/90. Titres for 
B/Panama/45/90 and B/Lee/40-H38 were 1280 and <10, respectively. 
4
 HP2: H38/Panama Protocol 2 progeny 
 
 
 Selected virus, designated HP1 
 
 
 
4.6.2 Preparation of B/Panama reassortants (2). 
Because few reassortants of B/Panama were isolated using Protocol 2, a further co-infection 
experiment was carried out in which the infectious titre of the C25 and H38 candidate donor 
strains was increased to 3-5 log10 pfu/mL, while that of B/Panama was held at 4.2 log10 
pfu/mL. The donor strain:B/Panama infectivity ratios used are shown in Table 4.13. Because 
the higher concentrations of the candidate donor strains represent the only changes to Protocol 
2, the modified procedure was designated Protocol 2b. From the allantoic progeny of both 
C25xPanama and H38xPanama co-infections, 21 agarose plugs containing viral progeny from 
single plaques were aspirated with a Pasteur pipette and passaged individually in eggs at 
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34°C. For the C25xPanama experiment (CP2), 14/21 plaque-purified progeny were HA-
positive and, for the H38xPanama (HP2) experiment, 12/21 were HA-positive. HA titres of 
CP2 and HP2 progeny were 256-1024 and 128-512 units/50µL, respectively. The HA-positive 
allantoic fluids obtained from plaques were tested for HA identity by HI using antisera 
prepared against B/Panama, C25 and H38. The HAs of all 14 CP2 progeny were similar to the 
epidemic strain, while those of the HP2 progeny were similar to the H38 donor. RNA from 
each purified clone was then extracted, amplified using RT-PCR and screened by RE 
digestion in order to confirm the identity of the HA gene and to determine the origin of the 
other 7 genes. Results revealed that only two of the CP2 and HP2 progeny, CP2/9 and 
CP2/12, possessed NAs derived from B/Panama (Tables 4.14 and 4.15). CP2/9 and CP2/12 
were identical to B/Panama, while the remaining CP2 and HP2 progeny displayed varying 
degrees of reassortment (Tables 4.14 and 4.15). None of the progeny possessed the desired 
6:2 configuration. 
 
Table 4.13 Donor:B/Panama strain infectivity ratios used in Protocol 2b. 
 
Co-infection Donor strain 
concentration1 
Epidemic strain 
concentration1 
Infectivity ratio2 
B/Lee/40-C25 and  5.01 4.24 1:0.17 
B/Panama/45/90 4.01 4.24 1:1.7 
 3.01 4.24 1:17 
  
 
 
B/Lee/40-H38 and  5.07 4.24 1:0.15 
B/Panama/45/90 4.07 4.24 1:1.5 
 3.07 4.24 1:15 
1
 Log10 pfu/mL 
2 Donor strain:B/Panama
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Table 4.14 Results from Protocol 2b: C25/Panama1 
 
 Gene segment origin2 
Virus HI titre3 HA NA M PB1 PB2 PA NP NS 
CP2/14 5120 P C C P P P C P 
CP2/2 5120 P C C P P P C P 
CP2/3 5120 P C P P P P C P 
CP2/4 5120 P C P P P P C P 
CP2/5 5120 P C P C C C C C 
CP2/6 10240 P C C C P P C P 
CP2/7 5120 P C C P P P C P 
CP2/8 5120 P C P P P P C P 
•CP2/9 2560 P P P P P P P P 
CP2/10 5120 P C P P P P C P 
CP2/11 5120 P C P P P P P P 
CP2/12 5120 P P P P P P P P 
CP2/13 5120 P C P P P C C P 
CP2/14 5120 P C C P P P C P 
1
 B/Lee/40-C25 and B/Panama/45/90 
2
 C: B/Lee/40-C25; P: B/Panama/45/90 
3
 HI titre, using antisera raised against allantoic B/Panama/45/90. Titres for B/Panama/45/90 
and B/Lee/40-C25 were 10, 240 and <10, respectively. 
4
 CP2: C25/Panama protocol 2b progeny 
 
 
•  selected virus, designated CP2 
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Table 4.15 Results from Protocol 2b: H38/Panama1 
 
 Gene segment origin2 
Virus HI titre3 HA NA M PB1 PB2 PA NP NS 
HP2/14 1280 H H H H H H H P 
HP2/2 1280 H H H H H H H P 
HP2/3 1280 H H H H H H P P 
HP2/4 1280 H H H H H H P P 
HP2/5 640 H H H H H H P P 
HP2/6 1280 H H H H H H P P 
HP2/7 640 H H H H H H P P 
HP2/8 640 H H H H H H P P 
HP2/9 1280 H H H H H H H P 
HP2/10 640 H H H H H H P P 
HP2/11 640 H H H H H H P P 
HP2/12 640 H H H H H H P P 
 
1
 B/Lee/40-H38 and B/Panama/45/90 
2
 HI titre, using antiserum raised against allantoic-grown B/Panama/45/90. Titres for 
B/Panama/45/90 and B/Lee/40-H38 were 10,240 and <10, respectively. 
3
 H: B/Lee/40-C25; J: B/Panama/45/90 
4
 HP2: H38/Panama Protocol 2b progeny 
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Selection criteria for the CJ reassortant for use in later growth experiments were the 
possession of both surface antigens of the epidemic strain. For progeny identical to the 
epidemic strain (CP and HP), selection was based on the HA titre. Details of the four selected 
viruses are presented in Table 4.16. 
 
Table 4.16 Selected viruses from B/Johannesburg and B/Panama reassortant experiments 
Experiment1 Virus HA titre2 Original co-infection 
ratio (donor strain: 
epidemic strain) 
Gene configuration 
Johannesburg x C25 
Co-infection #2 
(Protocol 2) 
 
CJ4 256 1:3000 3:5 
(donor M, PB1 & PB2) 
 
Panama x C25 
Co-infection#1 
(Protocol 2) 
 
CP1 1024 1:170 0:83 
 
Panama x H38 
Co-infection #1 
(Protocol 2) 
 
HP1 512 1:1500 0:83 
 
Panama x C25 
Co-infection #2 
(Protocol 2b) 
CP2 1024 1:17 0:83 
1
 Johannesburg: B/Johannesburg/5/99; Panama: B/Panama/45/90; C25: B/Lee/40-C25;  
H38: B/Lee/40-H38 
2
 HA units/50µL 
3 All gene segments were derived from B/Panama/45/90 
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4.7 INFECTIVITY:HA RATIOS OF PARENTAL, DONOR, EPIDEMIC AND 
REASSORTANT VIRUSES 
A summary of the HA and infectious titres of the parental B/Lee/40, potential donor strains 
C25 and H38, epidemic strains B/Johannesburg and B/Panama and selected progeny viruses 
prepared using different reassorting protocols (CJ4, CP1, HP1 and CP2) is given in Table 
4.17. Infectious titres were determined by three different assays and the infectious titre:HA 
ratio for each was determined. For the purposes of calculation infectious titres obtained from 
the more accurate plaque assays was used. Comparable ratios for B/Lee, B/Panama, C25, 
H38, CP1 and HP1 of 2-9,200 PFU/HA were obtained; for B/Johannesburg and its reassortant 
progeny CJ4 the ratios were 19,300 and 13,000. However, for CP2, with a high HA titre but 
low infectious titre, the ratio was only 270. 
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Table 4.17 Characteristics of parental, epidemic and selected reassortant viruses  
 Titre 
Virus HA1 TCID502 EID503 PFU/mL4 PFU:HA 
ratio 
B/Lee/40 320 8.10 7.93 7.51 5,100 
B/Panama/45/90 320 8.24 7.80 7.24 2,700 
B/Johannesburg/5/99 80 6.74 7.50 7.49 19,300 
B/Lee/40-C25 640 8.36 8.57 8.01 8,000 
B/Lee/40-H38 640 7.92 8.39 8.07 9,200 
CJ4 320 7.83 7.98 7.92 13,000 
CP1 1280 7.80 8.08 7.62 1,600 
HP1 640 7.57 8.21 7.42 2,100 
CP2 1280 6.93 7.57 6.83 270 
1 HA units/50µL 
2
 Each figure represents the mean of three assays, each carried out in triplicate. 
3 Each figure represents the mean of three assays. 
4
 Assayed in MDCK monolayers. Each figure represents the mean of three assays, each 
carried out in triplicate. 
5
 Ratio antilog PFU/mL; HA units/mL 
 
All infectivity assays were carried out at 34°C. 
 
 
4.8 DISCUSSION 
For the attempted preparation of high-yielding reassortants of influenza B viruses, the 
assumption was made that accumulated antigenic changes from the first appearance of B/Lee 
in 1940 to the present would be sufficient to allow effective selection of reassortants 
containing the surface antigens of the epidemic strain in presence of antiserum to donor 
strains derived from B/Lee. Cross-HI tests showed clear antigenic differences between the 
donor strains and the epidemic strains B/Johannesburg and B/Panama. Some cross-reactivity 
was observed between the epidemic strains (Table 4.1). 
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The panel of epidemic viruses screened for growth in eggs at 25°C and 38°C included 
representatives of the two influenza B lineages that have co-circulated since 1983, 
B/Yamagata and B/Victoria (Section 1.2.2). The seven viruses assayed were egg-derived 
stock grown at 34°C, so capable of growth (and HA positive results) at that temperature. Of 
the 7 viruses assayed, two had at least two HA-positive replicates when grown at 25°C. For 
B/Panama (Yamagata-like) 2/4 HA-positive clones were isolated (titres 64 and 128 units/50 
µL) and, for B/Shandong/7/97 (Victoria-like), haemagglutination could only be detected in 
the first well (i.e. titre 1). A higher rate of HA-positive results (5/7) was observed when the 
epidemic viruses were grown at 38°C, with the exception of B/Beijing/184/93 and 
B/Johannesburg (both Yamagata-like). At least one replicate with low HA yields (4-32 
units/50 µL) was isolated for B/Yamanashi/166/98 (Yamagata-like), B/Panama (Yamagata-
like), B/Brisbane/32/2002 (Victoria-like) and B/Shandong/7/97 (Victoria-like). Highest yields 
at 38°C were obtained for B/Victoria/505/2000 (titres of 64 and 128) for 2/4 clones. The 
growth of an epidemic strain at either selective temperature could result in the selection of 
reassortant viruses with internal genes derived from the epidemic strain. These results indicate 
a need to check each epidemic strain for growth at selective temperatures prior to the 
attempted preparation of reassortants, as use of temperature-adaptation as a selection or 
screening tool is negated if epidemic strains also possess that ability. As discussed in Chapter 
3 (Section 3.5), temperature sensitivity (ts) for influenza A viruses is characterised by highly 
restricted growth at 39°C while, for influenza B viruses, the restrictive temperature is 37°C 
(Murphy and Coelingh, 2002). The temperature-sensitive block occurs late in the 
multiplication cycle and causes a decrease in infectivity by reducing the M protein content of 
viral progeny (Giesendorf et al., 1986; Kendal et al., 1977). Studies have shown that, while 
the level of mRNA synthesis level in ts influenza A viruses is not affected at non-permissive 
temperatures, vRNA synthesis is greatly reduced and this has been associated with an amino 
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acid change at position 226 in the PA subunit (Kawaguchi, Naito, and Nagata, 2005; Krug, 
Ueda, and Palese, 1975). 
 
The design of primers suitable for the amplification of all strains (B/Lee, C25, H38, 
B/Johannesburg and B/Panama) used in the reassortment experiments presented some 
challenges because 1) primers that would amplify only one segment were preferred, 2) there 
were few homologous regions in the B/Lee and B/Panama genomes that were optimal for 
primer binding, and 3) for B/Johannesburg, only sequence data for a fragment of the HA gene 
were available (GenBank accession number AY223883). Seventeen primer pairs were 
designed during the development of the final 8 primer pair set that could be used to amplify 
PCR products for all five strains (Table 4.3). Near full-length amplification of the HA, M and 
NS gene segments was achieved but, for NA, PB1, PB2, PA and NP, only small fragments of 
approximately 300-800 bp could be amplified. Except for NP, RE digests produced fragments 
of the expected size. For reasons unknown, NP PCR product digestion using BstXI did not 
cleave B/Lee, C25 or H38 at the published restriction site (position bp 1010). BstXI cleaves 
the recognition sequence 5’ CCANNNNN↓NTGG 3’ (Promega Corporation datasheet). The 
initial digestion conditions used were those recommended by the manufacturer, an approach 
that had been successful with all the other PCR products. The digestions were repeated four 
times with varying amounts of enzyme and DNA, using the same PCR product preparation 
and purification protocols used for the other gene segments. One possibility was that the 
original B/Lee parent contained a mutation at the recognition site which differed from the 
published sequence in GenBank. A new primer pair for the NP segment, which amplified a 
larger fragment and included a RE site for ScaI specific for B/Lee, was necessary in order to 
overcome the problem. Digestion of the larger NP fragment with ScaI was successful in 
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cleaving B/Lee, C25 and H38. Digestion based on RE sites specific for the B/Panama HA, PA 
and NS PCR products (Table 4.3) also cleaved the same genes of B/Johannesburg. 
 
All reassortants produced using Protocol 1 possessed the NA of the donor strain (Table 4.5), 
which suggests that either the antiserum to the donor strain had not neutralised all progeny 
virus with donor strain surface antigens, or that a higher B/Johannesburg:donor ratio was 
required to produce reassortants containing the genes for both surface antigens of the 
epidemic strain. The protocol was, therefore, changed to include a longer period for 
neutralisation of the donor strains and a higher B/Johannesburg:donor strain co-infection ratio 
(Protocol 2). One of 24 (4.2%) reassortant clones prepared by Reassorting Protocol 2 
possessed both Johannesburg-derived surface antigens (Table 4.7). This reassortant (CJ4) also 
contained PA, NP and NS derived from B/Johannesburg and M, PB1 and PB2 from C25. All 
CJ reassortants possessed HA, PA and NS derived from B/Johannesburg and PB2 from C25. 
The HA, PB1, PA and NS of all HJ reassortants were derived from B/Johannesburg, while the 
NA, M and PB2 were from H38. A comparison of the CJ and HJ reassortants showed that all 
Protocol 2 progeny had NS and PA of Johannesburg origin, and most also had Johannesburg-
derived NP and PB1 (22/24 and 21/24). PB2 from all reassortant clones and M and NA from 
the great majority (23/24 for both segments) were derived from the donor strains. PB2 is one 
of three gene segments for which amino acid substitutions have been identified as being 
associated with the efficient growth of influenza B viruses at 25°C (Chen et al., 2006). 
 
Although the higher infectivity ratio of B/Johannesburg:donor strains used in Protocol 2 
produced reassortants with an over-representation of B/Johannesburg segments, the number 
with B/Johannesburg-derived NA remained low (Tables 4.6 and 4.7). It had been assumed 
that passage in the presence of antiserum would provide selection pressure against progeny 
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possessing donor strain NA, especially if an excess of B/Johannesburg was used in the co-
infection mixture. However the reassortant data do not support this. More consistent selection 
pressure against the donor strain NA may have been achieved using antisera raised against 
purified surface antigens rather than whole allantoic virus. Another possibility is that 
influenza B NA may be a relatively poor antigen and/or may be more subject to steric 
hindrance by HA than occurs with influenza A viruses. 
 
Published reports detailing the gene composition of reassortant clones for the preparation of 
vaccine seed viruses are limited, especially for influenza B strains, and most data provided are 
restricted to the gene composition of only selected 6:2 reassortants. However, there are a few 
early reports that provide some data on a selection of influenza A reassortants. All four 
selected clones from an A/Ann Arbor/6/60-ca reassortment with A/Washington/897/80 
possessed both epidemic strain surface antigens, only one of which had the required 6:2 gene 
constellation (Maassab and DeBorde, 1985). Of 40 clones selected and screened from a 
number of reassortments using A/Ann Arbor/6/60-ca and 10 other epidemic A strains, 61% 
(24/60) possessed the required 6:2 gene constellation (Kendal et al., 1981). Of six reassortant 
clones prepared using the A/Leningrad/134/57-ca or A/Leningrad/9/46-ca donor strains with 
four different epidemic A strains, all had surface antigens derived from the epidemic strain 
and four possessed the required 6:2 gene constellation (Kendal et al., 1981). The proportion of 
reassortants with epidemic strain NA obtained using Protocol 2 was much lower than the 
published reports for influenza A cold-adapted donor strains. 
 
Some influenza B reassortment data on the gene composition of potential vaccine strains has 
been published. A reassortant vaccine candidate prepared from the epidemic strain B/Ann 
Arbor/1/86 and B/Leningrad/14/55-ca was found to have epidemic strain HA, NA and NS 
138 
gene segments, while the vaccine candidate reassortant prepared from coinfection with 
epidemic strain B/Ann Arbor/1/86 with B/Ann Arbor/1/66-ca had the desired 6:2 gene 
constellation. Preparation of these reassortants included passage in the presence of antiserum 
but the gene composition of other screened reassortants was not provided (Alexandrova et al., 
1990; Obrosova-Serova et al., 1990). Two reassortants, prepared as potential vaccine 
candidates using B/Leningrad/14/1755-ca and B/England/2608/76, both possessed epidemic 
strain HA, NA, NP and NS (Medvedeva et al., 1983). Studies of different methods for the 
selection of influenza B reassortants have also been published. One reassortant prepared from 
B/Ann Arbor/1/66-SE4 (ca) and B/Bangkok/163/90, screened by RE digestion of PCR 
products, had the desired 6:2 gene constellation (Sakamoto et al., 1996). RE digestion of PCR 
products was also used to screen 12 selected clones prepared by co-infection of 
B/Shandong/7/97 and B/Beijing/184/93; all had B/Beijing-derived HA but NA from 
B/Shandong (Vodeiko et al., 2003). Fluorescent single-strand conformation polymorphism 
analysis (SSCP) has been used to screen 11 progeny prepared from B/Ann Arbor/1/66-ca and 
B/Harbin/7/94. Two were reassortants with both epidemic strain surface antigens (one with an 
additional B/Harbin M gene), four were identical to the ca donor and two were identical to the 
parental epidemic strain. The remaining three varied in gene composition but all had both 
surface antigens derived from the ca donor (Cha et al., 1997). A modified non-fluorescent 
SSCP method was used to screen reassortants prepared from B/Shandong/7/97 and 
B/Beijing184/93. Of the 10 reassortants described, four had both surface antigens derived 
from B/Beijing, although the NA possessed additional mutations. Another three reassortants 
possessed NS, M or NP derived from both parental strains (Lugovtsev et al., 2005). Ivshina et 
al (2004) described the use of an oligonucleotide microarray method to screen 24 reassortants 
prepared from B/Shandong/7/97 and B/Beijing/184/93. Full details were given for four of the 
reassortants, all of which possessed B/Beijing HA and B/Shandong NA. Fifteen reassortants 
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were found to have one gene segment (PB2, PB1, PA, NP NA or NA) derived from both 
parental strains (Ivshina et al., 2004). Although most published studies provide the genome 
composition of only a few selected reassortants, it has been generally observed that the 
proportion of influenza B reassortants with the desired 6:2 gene constellation is relatively low 
especially with respect to the NA gene. These problems could, in theory, be overcome by the 
application of reverse genetics to the selection of vaccine reassortants, which will be 
discussed in Chapter 6. 
 
Low rates of reassortment were achieved in the attempted preparation of B/Panama 
reassortants by Protocol 2. The progeny from 22 clones, (5/5 HP and 12/17 CP) were identical 
to B/Panama (77%). Of the five CP reassortants, one was a 7:1 and four were 3:5 reassortants. 
The latter had C25 donor strain HA but B/Panama NA. The presence of C25 HA was 
unexpected, as the C25 antiserum had high HI activity and there was little cross-reactivity 
with B/Panama (Table 4.1). B/Panama was shown to grow in eggs at both 25 and 38°C (Table 
4.2) and there was, therefore, little selection against the internal gene segments of B/Panama, 
although passage in the presence of antiserum should have removed progeny with donor HA 
and NA. All 4 CP reassortants possessed B/Panama NA, indicating that some selection had 
occurred. The reason for the failure of the antiserum to remove all reassortant progeny with 
donor strain HA is unclear, but may be related in some way to the ability of B/Panama to 
grow at the selective temperatures. The preparation of reassortant progeny possessing donor 
strain HA and epidemic strain NA after co-infection passage in the presence of antiserum has 
been described (Ivshina et al., 2004; Vodeiko et al., 2003). 
 
A high epidemic:donor strain co-infection ratio was used in Protocol 2, a modification that 
increased the proportion of reassortant clones with epidemic strain NA in the Johannesburg 
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experiments (Table 4.7). However, these conditions may not have been optimal for co-
infection with B/Panama and the experiment was repeated using a higher concentration of 
both donor strains (3-5 log10 pfu/mL) in the co-infection step (Protocol 2b). This modification 
increased the number of reassortants produced, with only two of the progeny (CP2/9 and 
CP2/12) being identical to B/Panama. Some CP reassorting patterns can be identified: all HA 
was derived from B/Panama, as were the majority of PB1 (12/14), PA (12/14), PB2 (13/14), 
NS (13/14) and M (9/14) segments. Most CP reassortants possessed C25 NA (12/14) and NP 
(11/14). All HP progeny were reassortants having H38 HA, NA, M, PB1, PB2, and PA gene 
segments (Table 4.14). All NS and the majority of NP (9/12) segments were derived from 
B/Panama. Again, the presence of donor HA was unexpected, as the H38 antiserum had high 
HI activity and there was little cross-reactivity with B/Panama (Table 4.1). A comparison of 
all protocol 2b reassortant progeny showed that the majority possessed B/Panama NS (25/26). 
 
The presence of donor strain HA in some reassortant Panama progeny was unexpected. The 
one common feature of the reassortants with donor HA was that they occurred only during 
reassortment with B/Panama which, unlike B/Johannesburg, was able to grow in eggs at the 
selective temperatures. Both C25 and H38 HA were detected in B/Panama reassortant 
progeny, with C25 HA only being obtained in the first B/Panama experiment while the HP 
reassortants with H38 HA were found only during the second B/Panama experiment. The two 
experiments differed only in the titre of donor strain used for co-infection. Donor HA was 
detected in 16/48 (33.3%) of B/Panama progeny, and 16/87 (18.4%) of all four co-infection 
experiments. 
 
Yields of infectious virus for the epidemic parental strains and the selected progeny (CJ4, 
CP1, HP1 and CP2) when assayed by three methods showed two statistically significant 
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differences. The TCID50 of CP2 was significantly lower than that of B/Panama (P= 0.01) 
while the EID50 of CJ4 was significantly higher than that of B/Johannesburg (P= 0.04). CJ4, 
CP1 and CP2 had a four-fold higher HA titre than their respective epidemic parent strain, 
while the HA titre for HP1 was the same as that for B/Panama. Comparison of the infectious 
titre:HA ratios showed that the ratio for CP2 was only 270 while that of all other strains was 
103 -104. While the CP2 HA titre was high, a much lower amount of infectious virus was 
present, indicating the presence of a higher proportion of defective interfering (DI) particles. 
The presence of DI particles could also explain the significantly lower infectious titre of CP2 
compared with that of the B/Panama parent. The reduced capacity to produce infectious 
progeny has been observed previously with the Russian ca donor strain B/USSR/60/69, when 
grown in continuous cell culture at higher multiplicities of infection (Audsley and Tannock, 
2005). 
 
 
 ___________________________________________________________________________ 
CHAPTER FIVE: 
GROWTH OF INFLUENZA B VIRUSES IN CELL CULTURE 
___________________________________________________________________________ 
Yields of several influenza B epidemic strains and potential donor strains were measured after 
growth in MDCK cells prepared in serum-free (SF) and animal- and human-derived protein-
free (AHPF) media. Attempts to condition MDCK cells by passage in a modified version of a 
previously published medium (SF1; Taub et al., 1979) or a commercial medium designed for 
Vero cells were unsuccessful. Two recent commercial media formulations were also tested for 
the ability to support the growth of MDCK cultures. One, EX-CELL MDCK, supported the 
growth of MDCK cells with or without conditioning, although cells that had been conditioned 
were more robust after resuscitation from LN2. 
 
Optimal multiplicities of infection (MOIs) were determined for B/Panama, B/Johannesburg 
and C25 in MDCK cultures grown in SC medium. Maximum yields for B/Panama and 
B/Johannesburg were obtained using an MOI of 0.01 (yields of 6.89 log10 pfu mL-1 at 24 h 
and 7.15 at 48h). The maximum yield for C25 was 6.91 log10 pfu mL-1 at 24h using an MOI 
of 2.0 although, for 0.01, the yield at 48h was only slightly less (6.63). A series of 
experiments were then undertaken to determine the maximum virus yields in MDCK cells 
grown in SC medium, followed by a further experiment using C25, B/Panama, 
B/Johannesburg, CJ4, CP1 and HP1 after preparation in AHPF medium (EX-CELL 
MDCK). Cell culture yields were compared with the yields obtained in eggs. Yields from 
5/6 viruses grown in MDCK cells prepared in AHPF medium were higher than in cells 
prepared in SC medium and approached those obtained in eggs. 
 
___________________________________________________________________________ 
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5.1 INTRODUCTION 
Most inactivated vaccines are prepared from viruses grown in the allantoic cavity of 
embryonated chicken eggs. Yields of viruses are usually high, but the use of eggs provides 
limited flexibility to increase supplies for expanded vaccine manufacture. Other unforeseen 
problems may occur due to the presence of diseases in layer flocks or to sterility problems 
that may occur during the processing of infected allantoic fluids. In addition, the growth of 
influenza viruses in embryonated eggs selects variants with amino acid changes in the HA 
close to the receptor-binding pocket. The use of egg-adapted viruses usually results in higher 
yields due to the increased capacity of variants to bind and internalise during the early stages 
of infection. However, egg-grown viruses when used in vaccines or for serological 
surveillance may not be representative of the viruses present in original clinical samples. 
 
Cell cultures provide an alternative substrate to eggs. Primary cell cultures can support the 
growth of influenza viruses but present a number of drawbacks due to 1) the availability and 
cost of source organs required for their preparation, 2) batch variation between cultures and 3) 
their potential for contamination with adventitious agents. Some continuous lines of epithelial 
origin do support the growth of influenza viruses in the presence of added trypsin to levels 
approximating those achieved by primary epithelial cells (Govorkova et al., 1995; Tobita et 
al., 1975). Growth in continuous cell cultures avoids many of these problems and does not 
select antigenically distinct virus variants. It also provides greater flexibility to the production 
process, as cell cultures prepared from continuous lines can be rapidly resuscitated and 
expanded from a frozen cell bank and grown to high volumes. 
 
Influenza viruses have been successfully grown in the MDCK and Vero cell lines, which have 
been used to prepare experimental vaccines. Acceptable viral yields can be obtained on both 
cell lines and the vaccines appear to be safe and immunogenic (Brands, Palache, and van 
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Scharrenburg, 1996; Bruhl et al., 2001; Govorkova et al., 1999; Halperin, Nestruck, and 
Eastwood, 1998; Palache et al., 1999). An inactivated MDCK-grown vaccine produced by 
Solvay Pharmaceuticals and an inactivated Vero-grown vaccine by Baxter International Inc 
have been licensed for human use in the Netherlands. MDCK cultures were chosen as the 
substrate for the cell culture in the experiments described in this chapter as they support the 
growth of influenza viruses to higher titres than Vero cells (Audsley and Tannock, 2005; 
Govorkova et al., 1999; Meguro et al., 1979). 
 
In the following experiments the growth of C25 and H38 potential donor strains, the B/Lee, 
B/Panama and B/Johannesburg epidemic strains and the CJ4, CP1, HP1 and CP2 selected 
progeny in MDCK cells were investigated and compared with their yields obtained in eggs. 
The use of serum-free media for the growth of MDCK cells was also studied, and the yields 
of C25, B/Panama, B/Johannesburg, CJ4, CP1 and HP1 were evaluated in a serum-free 
medium. 
 
5.2 THE GROWTH OF MDCK CULTURES IN SF MEDIA 
Serum, usually foetal calf serum (FCS), has been regarded as a critical supplement for cell 
culture medium. However, the potential introduction of contaminating agents through the use 
of animal sera has raised regulatory issues concerning the safety of human vaccines prepared 
in cell cultures. The use of SF media would improve the acceptability of such vaccines, 
although many SF media still contain animal or human-derived proteins. Animal- and human-
derived proteins can now be replaced by synthetic, recombinant or plant proteins. The use of 
chemically defined protein-free media minimises batch variability and contamination risks but 
development is complicated and usually depends on specific requirements for particular cell 
lines (Merten, 2002).  
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The serum-free experiments to be described were planned on the basis that the media used 
would not only be SF, but also be free of any human- or animal-derived proteins. Initially 
three types of commercially-available SF media were reported as being suitable for the 
growth of MDCK cells – Epi-Serf, MDSS2N and Ultra-MDCK (Brands, Palache, and van 
Scharrenburg, 1996; Kessler et al., 1999; Merten, Petres, and Couve, 1995; Tree et al., 2001). 
MDSS2N, is an SF and animal- and human-derived protein-free (AHPF) medium produced 
by Axcell Technologies, but was not available in Australia at the time this study was 
commenced. Ultra-MDCK was SF but contained bovine transferrin (Biowhittaker technical 
product notes). Epi-Serf was labelled as SF but included animal-derived proteins such as 
BSA, cholesterol, insulin and transferrin (Bruce Lamb, Gibco-LT Australia, personal 
communication). 
 
Another Gibco–LT product, VP-SFM, was AHPF but had only been used for the growth of 
Vero, COS-7, MDBK, BHK-21 and HEp2 cells. Attempts were undertaken to condition 
MDCK cells by stepwise growth in VP-SFM using mixtures of MEM with 5% FCS:VP-SFM. 
The MDCK cells were then serially subcultured in mixtures consisting of 1:1, 1:3, 1:9 and 
1:19 of VP-SFM:MEM. No growth in VP-SFM alone was achieved, and four further attempts 
in which extra subcultures using 1:9 and 1:19 mixtures were also unsuccessful. Cell growth 
slowed as the proportion of VP-SFM increased, and each time the second passage in 100% 
VP-SFM was attempted the cells attached but did not proliferate and lifted from the culture 
flask surface. All tested SF media was supplemented with 4mM L-glutamine, and 
trypsin/EDTA activity was inhibited by the addition of soybean trypsin inhibitor (0.25% (w/v) 
in PBS). 
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An SF medium designed specifically for the growth of MDCK cells and used to study the 
hormonal regulation of kidney function in an environment where all hormone concentrations 
were known, was described by Taub et al (Taub et al., 1979). As VP-SFM was unsuitable for 
the growth of MDCK cells, attempts at developing a medium that was both SF and AHPF, 
using the Taub formulation as its basis, were undertaken. The five added factors used in the 
Taub medium (Table 5.1) were either replaced with a synthetic, recombinant- or plant-derived 
protein, or substituted with a recombinant protein of similar function. This new formulation 
was designated J-SF1. During the course of this work, a new commercially available SF and 
AHPF medium was released in Australia. OPTI-PRO SFM (Gibco-LT), a medium 
containing no components of animal or human origin and reported to be suitable for cell 
growth of the kidney-derived cell lines MDBK, MDCK, Vero and PK-15 (Gibco Invitrogen 
technical product sheet). Five attempts were undertaken to adapt MDCK cultures by stepwise 
growth in J-SF1 and three in OPTI-PRO SFM. The cells grew well in mixtures containing 
up to 90% of either medium. However, with both, cell growth slowed down and after 3-4 
passages in either medium; cells attached but did not proliferate. At this stage a new SF and 
AHPF medium designed for the growth of MDCK cultures, EX-CELL MDCK, was 
released commercially by JRH Biosciences. Technical data indicated that MDCK cultures 
could be subcultured directly without adaptation. Direct subculturing of MDCK cultures with 
100% EX-CELL-MDCK was successful, although between the 5th and 6th passages a slight 
increase in doubling time was noted. The EX-CELL-adapted MDCK cultures were expanded 
then frozen in SF cell-freezing medium and aliquots were kept in LN2 for long-term storage. 
After resuscitation, these cells did not grow to form monolayers. Adaptation of MDCK 
cultures to EX-CELL MDCK was then undertaken, and frozen aliquots of adapted cultures 
formed monolayers two days after resuscitation from LN2. Attempts to grow the EX-CELL 
adapted MDCK cultures in J-SF1 were unsuccessful. 
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Table 5.1 Comparison of Taub1 and J-SF1 media 
Taub et al medium J-SF1 medium 
DMEM/Hams F12 (1:1) DMEM/Hams F12 (1:1) 
Prostaglandin E1, 25ng mL-1 1epidermal growth factor, 10 ng mL-1  
Hydrocortisone, 50nM 2Hydrocortisone, 50nM 
Transferrin, 5µg mL-1 ammonium iron (III) sulphate dodecahydrate, 0.5 µg mL-1 
Insulin, 5µ g mL-1 1Insulin, 5 µg mL-1 
Triiodothyronine, 5pM - 
 
1
 (Taub et al., 1979) 
2
 Recombinant protein 
3
 Plant-derived source 
 
 
5.3 VIRAL GROWTH IN MDCK CELLS USING SC MEDIUM 
5.3.1 Establishment of optimal multiplicities of infection (MOIs) for virus growth 
Serial passage of undiluted preparations of allantoic-grown influenza viruses in eggs 
decreases the proportion of infectious virus in the total yield (von Magnus, 1954). Non-
infectious particles produced at high MOIs interfere with the multiplication of infectious 
virus. Non-infectious particles, known as defective-interfering (DI) particles, can be produced 
in cell culture and are a feature of the growth of many viruses (Nayak, Chambers, and 
Akkina, 1985). Yields of B/Panama, B/Johannesburg and C25 were investigated in MDCK 
cultures infected at a range of MOIs to determine conditions for maximising yields of 
infectious virus. 
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The MOI for each virus was the plaque titre:viable cell ratio for each set of experiments 
which was determined at the time of infection. Confluent 6-well cultures were inoculated with 
virus at different MOIs. After adsorption at RT for 30 min, unadsorbed virus was removed by 
washing each monolayer with PBS and 3mL of maintenance medium were added to each 
well. The plates were incubated for 3 days at 34°C in a 5% CO2 incubator. Samples for total 
virus (cells plus maintenance medium) were taken at intervals to 72h. Cells from samples 
were suspended in maintenance medium by aspiration and stored at -80°C until assayed by the 
plaque technique (Section 2.13.3.1). The procedure was repeated for each virus at MOIs of 
0.01, 0.1, 1.0 and 2.0. The infectious titre for each sample was determined in triplicate by 
plaque assay. Maximum yields obtained for B/Panama and B/Johannesburg were obtained 
using an MOI of 0.01 (yields of 6.89 log10 pfu mL-1 at 24 h and 7.15 at 48h respectively; 
Figures 5.1 and 5.2). The maximum yield for C25 was 6.91 log10 pfu mL-1 at 24h using an 
MOI of 2.0, although at 0.01 the yield at 48h was similar (6.63; Figure 5.3). 
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Figure 5.1 Yields of B/Panama/45/90 over a range of MOIs 
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Figure 5.2 Yields of B/Johannesburg/5/99 over a range of MOIs 
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Figure 5.3 Yields of B/Lee/40-C25 over a range of MOIs 
 
150 
5.3.2 Virus yields in MDCK cultures grown in serum-containing (SC) medium 
The growth of B/Lee/40, C25, H38, B/Panama, B/Johannesburg, CJ4, CP1, HP1 and CP2 
were investigated in MDCK cultures using serum-containing (SC) medium. MEM with 5% 
FCS was used as the growth medium in all SC experiments (Section 2.4.1) and an MOI of 
0.01, as determined in Section 5.3.1. Confluent 6-well cell cultures were inoculated with each 
virus and, after adsorption at RT for 30 min, the inoculum was removed, the cultures washed 
with PBS and 3mL of maintenance medium added to each well. Maintenance medium 
consisted of MEM without FCS, but supplemented with trypsin (1 µg mL-1) to allow 
proteolytic cleavage of HA for the production of infectious virus (Section 2.4.1). The plates 
were incubated at 34°C in a 5% CO2 incubator and samples for total virus (cells plus 
maintenance medium) were taken at intervals to 72h. Cells from samples were suspended by 
aspiration with the same maintenance medium and stored at -80°C until assayed by the plaque 
technique. This procedure was repeated for each virus and the infectious titres of all samples 
were determined in triplicate by plaque assays. The mean yields are shown in Table 5.2. 
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Table 5.2 Mean yields for two growth experiments using MDCK monolayers grown in 
(SC) medium 
 
Yield (log10 pfu mL-1) at:1 Virus 
24h 48h 72h 
B/Lee/40 4.86 5.27 5.21 
B/Lee/40-C25 6.51 6.62 5.89 
B/Lee/40-H38 5.53 5.74 5.42 
B/Panama/45/90 5.72 5.61 5.46 
B/Johannesburg/5/99 4.01 5.98 5.92 
CJ4 6.45 6.26 5.85 
CP1 5.84 5.59 5.51 
HP1 5.46 5.31 4.97 
CP2 4.41 4.44 4.19 
1
 Each figure represents the mean of two experiments, each sample was assayed in triplicate 
 
 
 
5.4 VIRAL GROWTH IN MDCK CELLS USING SF MEDIUM 
5.4.1 Virus yields in MDCK cultures grown in serum-free (SF) medium 
The growth of C25, B/Panama, B/Johannesburg, CJ4, CP1, and HP1 was investigated in 
MDCK cultures using EX-CELL MDCK medium, again using an MOI of 0.01. Confluent 6-
well cultures were inoculated with each virus and, after adsorption at RT for 30 min, the 
inoculum was removed, the cultures were washed with PBS and 3mL of EX-CELL MDCK 
maintenance medium were added to each well. EX-CELL MDCK maintenance medium was 
152 
supplemented with trypsin (1 µg mL-1) to optimise yields of infectious virus. The plates were 
incubated for 3 days at 34°C in a 5% CO2 incubator and samples for total virus (cells plus 
medium) were taken at intervals to 72h. Cells from samples were suspended by aspiration in 
the same maintenance medium and stored at -80°C until assayed by the plaque technique. 
Again, the procedure was repeated for each virus and the infectious titre for each sample 
determined in triplicate by plaque assays. Mean yields are shown in Table 5.3. 
 
 
Table 5.3 Mean yields for two growth experiments using MDCK monolayers cultured in 
animal- and human-derived protein free (AHPF) medium 
 
Yield (log10 pfu mL-1) at:1 Virus 
24h 48h 72h 
B/Panama/45/90 6.70 7.10 6.50 
B/Johannesburg/5/99 4.61 7.11 7.34 
C25 4.85 5.92 6.25 
CJ4 7.37 7.36 6.37 
CP1 6.91 6.63 5.86 
HP1 6.64 6.59 6.17 
1
 Each figure represents the mean of two experiments; each sample was assayed in triplicate 
 
5.5 COMPARISON OF VIRUS YIELDS OBTAINED IN VARIOUS GROWTH 
SUBSTRATES 
 
A summary of the infectious titres of B/Lee/40, C25, H38, B/Panama, B/Johannesburg, CJ4, 
CP1, HP1 and CP2 obtained in SC and SF MDCK cultures and eggs is shown in Table 5.4. 
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Yields in eggs were at least one log10 higher than those obtained in MDCK monolayers 
prepared in SC medium. Yields of viruses grown in MDCK monolayers prepared and 
maintained (with added trypsin) in AHPF medium, with the exception of C25, were higher 
than those obtained in MDCK monolayers prepared in SC medium. 
 
Table 5.4 Comparison of maximum virus yields obtained in cell culture and eggs 
 
Yield (log10 pfu mL-1) at: Virus 
Eggs Serum-containing 
(SC) cell culture 
Serum- and animal-
protein free (AHPF) 
cell culture 
B/Lee/40 7.51 5.27 ND1 
B/Lee/40-C25 8.01 6.62 6.25 
B/Lee/40-H38 8.07 5.74 ND 
B/Panama/45/90 7.24 5.72 7.1 
B/Johannesburg/5/99 7.49 5.98 7.34 
CJ4 7.92 6.45 7.36 
CP1 7.62 5.84 6.91 
HP1 7.42 5.46 6.64 
CP2 6.83 4.44 ND 
1
 ND: not done 
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5.5 DISCUSSION 
Although the introduction of SF media represented an important step in improving the safety 
of human vaccines prepared in cell culture, many SF formulations contain other components 
of animal origin, which introduces theoretical risks from contamination from viruses or the 
agent(s) of TSE. The use of synthetic, recombinant or plant proteins in media that are 
completely free of animal- or human-derived proteins (AHPF media) greatly reduces that risk 
and are more acceptable to regulatory authorities. Of three commercially available SF media 
that were first described as being suitable for the growth of MDCK cultures, Epi-Serf and 
Ultra-MDCK contained animal-derived proteins and MDSSN2 was not available in Australia 
at the time this work commenced. Attempts at adaptation of MDCK cultures to growth in the 
commercial AHPF medium VP-SFM, designed for the growth of Vero cells, were 
unsuccessful. 
 
Reformulation of the medium described by Taub et al (1979) to remove all animal-derived 
components required a number of changes. As a first step two components of animal origin 
were replaced with plant-derived hydrocortisone and recombinant insulin, both of which were 
commercially available. Triiodothyronine was used at a very low concentration (5pM) and its 
omission from the formulation was shown to inhibit cell growth by less than 20% (Taub et al., 
1979). It was not included in the J-SF1 medium. Prostaglandin E1 (PGE1) and transferrin 
were the most critical of the five factors in the Taub SF medium (Taub et al., 1979). 
Transferrin supplies iron in a biologically active form and is involved in the removal of toxic 
compounds (Keenan and Clynes, 1996). Soluble iron has been reported to be a stimulator of 
cultured cells, and simple iron compounds can be used to replace transferrin for the growth 
and subculture of MDCK cells grown in serum-free medium (Keenan and Clynes, 1996; 
Kovar, 1990). One of the iron compounds described, ammonium iron (III) sulphate 
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dodecahydrate, was selected to replace the transferrin used in the Taub formulation. A 
replacement for PGE1 presented a challenge, as suitable quantities of synthetic PGE1 were 
not available in Australia for small-scale evaluation at the time. Recombinant epidermal 
growth factor was selected as a potential replacement for PGE1, which was used in the Taub 
medium to specifically stimulate the growth of kidney epithelial cells (Taub et al., 1979). 
 
Testing of J-SF1 and the commercial product OPTI-PRO SFM showed that neither was 
suitable for the growth of MDCK cells. AHPF media is usually specific for the cell type and 
its formulation can be a difficult and time-consuming process (Merten, 2002). The 
replacement of transferrin and PGE1 with ammonium iron (III) sulphate and recombinant 
PGF, together with the exclusion of triiodothyronine, produced a formulation that did not 
support the growth of MDCK cells. A recombinant transferrin product has since been released 
by Novozymes Biopharmaceuticals, DeltaFerrin™, and could be used to replace bovine 
transferrin. However, as the AHPF medium EX-CELL MDCK became available and proved 
suitable for the growth and maintenance of MDCK cultures, further refinement of the J-SF1 
medium was considered unnecessary. 
 
The maximum yield of C25 was achieved using an MOI of 2.0 - much higher than the figure 
of 0.01 for both B/Panama and B/Johannesburg (Figures 5.1-5.3). The C25 data also showed 
that with an MOI of 0.01, the maximum C25 titre was not significantly different from that 
achieved with 2.0. Maximum yields of all nine viruses infected at the same MOI were 1.5 -2 
log10 pfu mL-1 lower in MDCK cultures grown in SC medium than in eggs (Table 5.4). 
Similar findings for egg-adapted viruses have been reported previously (Audsley and 
Tannock, 2005). Of the six viruses that were also tested in MDCK cultures grown in AHPF 
medium, only the yield for C25 was lower following their preparation in SC medium, 
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although the difference was small (6.25 versus 6.62 log10 pfu mL-1). The  selected reassortant 
and temperature-adapted viruses (CJ4, CP1 and HP1) all grew to titres approximately 10-fold 
higher in MDCK cultures prepared in AHPF- rather than SC-medium; AHPF yields were 0.6 
– 0.8 log10 pfu mL-1 lower than those obtained in eggs. The two epidemic strains, 
B/Johannesburg and B/Panama, grew to titres approximately 1.3 log10 pfu mL-1 higher in 
MDCK cultures prepared in AHPF- rather than SC-medium and, interestingly, the yields of 
both in cultures prepared in AHPF medium were very similar to those obtained in eggs (Table 
5.4). An AHPF medium, designed and optimised specifically for the growth of a particular 
cell line, such as EX-CELL MDCK, may provide better conditions for cell and virus growth 
than a general medium, such as SC MEM. The rate of early cell death and the amount of 
cellular precursor mRNAs, as well as available free nucleotides and amino acids can all 
impact on the dynamics of viral replication in MDCK cells (Sidorenko and Reichl, 2004). In 
addition, studies with MDCK cells have shown that cell metabolism can affect viral 
replication (Genzel et al., 2004). SC and AHPF media contain different concentrations of 
amino acids, mineral salts and other constituents. Other factors, such as the concentrations of 
ammonium chlorideand  lactate, changes in pH and the depletion of both essential and non-
essential amino acids can impact on virus yield (Genzel, Fischer, and Reichl, 2006; Genzel et 
al., 2006). However, why the C25 yield alone did not improve in cultures grown in AHPF 
medium remains unclear. CP1 and HP1 were temperature-adapted viruses, with all gene 
segments being derived from the B/Panama parental strain, and a similar yield following 
preparation in EX-CELL MDCK medium to that observed for B/Panama was expected. 
Similarly, as CJ4 had five gene segments derived from B/Johannesburg, a similar yield was 
expected. 
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While the yields of B/Panama and B/Johannesburg were similar in both eggs and AHPF-
grown MDCK cells, yields from all viruses used in this study, with the exception of C25, 
were up to 10-fold higher in eggs. With further adjustments to the medium and improvements 
to cell cultivation (for example, the use of microcarriers or bioreactors), yields should be 
further improved. 
 
 
 ________________________________________________________________ 
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Influenza remains a disease of major public health significance and is the only human 
respiratory viral infection for which a vaccine is available. Currently, annually updated 
vaccines are the most effective measures for protection against influenza. Influenza A vaccine 
seeds used for the preparation of inactivated vaccines are usually prepared by reassortment of 
current epidemic strains with donor strains of high growth potential. Reassortant viruses 
contain the surface glycoproteins of specified epidemic strains and the internal genes of a 
high-yielding egg-adapted strain, generally A/PR/8/34. Reassortment of influenza B viruses 
for the preparation of seeds for inactivated vaccines is not usually attempted due to a lack of 
suitable donor strains. 
 
In this study, two potential influenza B donor strains were developed from B/Lee/40, a virus 
that predates the emergence of the current the major influenza B virus lineages. Adaptation to 
growth at 38°C was undertaken, in addition to the conventional approach of adaptation to 
growth at 25°C (cold adaptation). Both approaches were successful, although fewer viable 
progeny were isolated from plaques in CEK cultures at 38°C and a higher number of clones 
were required for screening at that temperature – the highest that could be used to maintain 
plaque formation. Restricted growth above 38°C may be associated with the lower shut-off 
temperature of growth (37°C) for influenza B strains compared with influenza A strains 
(39°C; Murphy and Coelingh, 2002). Potential donor strains selected at temperatures of 25°C 
(C25) and 38°C (H38) consistently produced HAs with titres of 320 units/50µL when grown 
in eggs at the permissive temperature (34°C). As it is usual for donor strains to be neutralised 
after reassortment, it was important to demonstrate that the temperature adaptation did not 
bring about changes to donor surface antigens. Previous studies have identified mutations in 
several genes associated with cold-adaptation and possible attenuation that are present in the 
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internal gene segments of cold-adapted influenza B donor strains (Chen et al., 2006; 
Hoffmann et al., 2005). The haemagglutinins of B/Lee/40, C25 and H38 were shown to be 
antigenically similar (Table 4.1). Partial nucleotide sequencing revealed that the HA gene of 
C25 differed from the parental B/Lee/40 in one residue (Thr → Ile) at aa position 409 of 
HA0. 
 
Difficulties were experienced in the preparation of reassortants that possessed both surface 
antigens derived from the epidemic parent after co-infection. None of the reassortants 
obtained had the desired 6:2 gene constellation. Of 24 reassortants prepared by co-infection 
with B/Johannesburg, only one had both B/Johannesburg HA and NA, and only three of its 
internal gene segments were derived from the C25 donor. While the majority (71/87) of viral 
progeny from the reassortant experiments possessed the epidemic strain HA, only 25 screened 
progeny had the epidemic strain NA. Of the latter, five were reassortants and the remainder 
were identical to the epidemic strain. The use of hyperimmune antisera prepared against 
purified surface antigens, rather than allantoic-grown virus, may have provided greater 
selection pressure against the donor strain NA and further studies are needed to resolve this 
question. It is also possible that influenza B NAs may also be inherently weak immunogens. 
However, one B/Johannesburg:C25 reassortant (CJ4) possessed both the HA and NA of the 
epidemic strain and had an HA titre four-fold higher than that of B/Johannesburg. 
 
In the first of two reassorting experiments with B/Panama using a high epidemic:donor strain 
co-infection ratio, 17/22 progeny clones were identical to the B/Panama epidemic strain. The 
epidemic:donor strain ratio was reduced in the 2nd experiment and only two of the progeny 
were identical to B/Panama. B/Panama was able to grow at both selective temperatures (Table 
4.2), so that there was no pressure against the selection of progeny with B/Panama internal 
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antigens and most progeny were identical to B/Panama, especially when the ratio of 
epidemic:donor strain was high. Interestingly, the HA titres of the cold-adapted B/Panama-
like progeny, CP1 and CP2, were four-fold higher than those of the B/Panama parent, 
indicating that passage at 25°C resulted in increased HA yields. However, no increase in HA 
titre was observed for the progeny of the B/Panama-like HP1, which grew efficiently at 38°C. 
For influenza B viruses, the ability to grow at 25°C may be a reasonably quick and simple 
method to increase HA titre after 1-2 egg-passages at that temperature. This increase in yield 
may be associated with mutations that have been previously identified in the PB2, PA, M1 
and NP genes of ca-influenza B viruses that are involved with temperature-sensitivity, 
attenuation and cold-adaptation (Chen et al., 2006; Hoffmann et al., 2005). Yields of 
influenza B viruses that do not grow at 25°C, such as B/Johannesburg, can be improved using 
the reassortment process, but this needs to be tested using other influenza B strains. 
 
Reverse genetics is, at least in theory, a safer (in the case of highly pathogenic viruses) and 
more attractive alternative to the preparation of high-yielding reassortant influenza B viruses 
containing both the HA and NA of the epidemic strain. It would involve generating c-DNA 
copies of the two surface antigen genes of the epidemic strain and the six internal genes of 
suitable strain that could confer high growth potential. The c-DNA copies can then be 
introduced separately into plasmids, and reassortants prepared by transfection of Vero cells 
with all plasmids. The rescued virus may be suitable for use as seed virus. Such a procedure 
represents a significant advance in rational vaccine design, and has been used for the 
production of avian pandemic vaccines (WHO, 2003). Problems associated with the use of 
reverse genetics include the negotiation of patent rights for certain procedures that are held by 
a number of parties, who have provided ready access to the technology but have indicated 
their intention to claim future royalties from vaccine manufacturers. Reassortant viruses 
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prepared by reverse genetics may also be classified as genetically modified organisms in 
some jurisdictions, and may be submitted to extra regulatory hurdles and safety testing. 
Another potential issue is the lack of heterogeneity implicit in reverse genetics, as the c-DNA 
copies of the surface antigens are derived from a single clone of one virus. Classical 
reassortment usually produces a population of viruses with minor variations in their HA 
sequence, which may have a role in antigen recognition and/or growth characteristics and can 
be easily determined by further selection. Reverse genetics produces a specific clone of the 
HA gene of one virus which may not be optimal for use as a vaccine seed. In order to 
overcome this, a number of parallel transfections may be required which would greatly 
increase the work load required in the relatively short time available for seed preparation. 
 
MDCK cultures were chosen as the substrate for the cell culture experiments because they 
support the growth of influenza viruses to higher titres than Vero cells, the only accredited 
cell line for human vaccines that also supports the growth of influenza viruses. Maximum 
yields of the viruses tested in this study were 1.5 -2 log10 pfu mL-1 lower in MDCK cultures 
grown in SC medium than in eggs. Of the six viruses that were also tested in MDCK cultures 
grown in AHPF medium, only the C25 yield was lower than that obtained following growth 
in SC medium. CJ4, CP1, HP1, B/Johannesburg and B/Panama all grew to titres 
approximately 10-fold higher in MDCK cultures prepared in AHPF- rather than SC-medium. 
Titres of B/Johannesburg and B/Panama in cultures prepared in AHPF medium were very 
similar to those obtained in eggs. 
 
Ultimately, the complete removal of any animal-derived components from media 
formulations is the most effective method for minimising risk from the transmission of TSEs 
and other diseases in human vaccines. It is now possible to do this with the development of 
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AHPF media, such as EX-CELL MDCK. Trypsin must be added to media used in the 
maintenance of MDCK cells for influenza growth to improve yield because they lack 
endogenous proteases necessary for the proteolytic cleavage of HA to produce infectious 
virus. Traditionally, trypsin used in cell culture has been of either porcine or bovine origin. 
Recently, sources of recombinant trypsin have become commercially available, allowing the 
entire process of influenza virus production in MDCK cells to be completely free of animal-
derived components. 
 
Reassortment of influenza B viruses to improve yields for the preparation of vaccines can be 
accomplished but is labour-intensive and the results are variable. The potential of cold 
passaging to increase the yield of influenza B viruses requires further investigation, but 
presents a possible simple and rapid alternative for those viruses that can grow at 25°C. The 
yields of influenza B viruses in AHPF-grown MDCK cultures can reach those obtained in 
eggs, and could be increased with further optimisation of the medium and culture system 
used. 
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